Compositions and methods for treating systemic lupus erythematosus
Administering anti-FcRn antibodies like nipocalimab subcutaneously targets FcRn to manage SLE by reducing pathogenic autoantibodies, improving clinical responses, and allowing for reduced glucocorticoid use.
Patent Information
- Application Number
- PCT/IB2026/054537
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-01-05
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for systemic lupus erythematosus (SLE) are inadequate in effectively managing the disease and reducing the reliance on glucocorticoids, as they do not adequately address the pathogenic autoantibodies causing tissue damage.
Administering an anti-FcRn antibody, such as nipocalimab, subcutaneously at 460 mg or 518 mg weekly to target the neonatal Fc receptor (FcRn), thereby modulating the half-life of IgG antibodies and reducing pathogenic autoantibodies.
The anti-FcRn antibody therapy significantly improves clinical responses in SLE patients, allowing for a reduction in oral glucocorticoid dosage and achieving therapeutic targets like SRI-4 response and IgG lowering, thereby enhancing treatment efficacy.
Smart Images

Figure IMGF000078_0001_TABLE 
Figure IMGF000079_0001_TABLE 
Figure IMGF000080_0001_TABLE
Abstract
Description
COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUSFIELD
[0001] The present application is related to, among other things, treating patients with systemic lupus erythematosus.CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U. S. Provisional Application No. 63 / 801,526, filed on May 7, 2025, and U. S. Provisional Application No. 63 / 954,049, filed on January 5, 2026, the disclosures of each of which are hereby incorporated by reference in their entireties.SEQUENCE LISTING
[0003] The instant application contains a sequence listing which is being submitted herewith electronically in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on May 4, 2026, is named 103693007823_SequenceListing_ST26.xml and is 24,674 bytes in size.BACKGROUND
[0004] Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. SLE may affect all organ systems in the body through the loss of immunological tolerance against selfantigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. Genetic factors play a role in the etiopathogenesis of SLE and the most common genetic predisposition is located at the major histocompatibility (MHC) locus. The disease is observed with a ~9-fold greater prevalence in women, and there is suggestion of an association with genes on the X-chromosome, although exact genes have not been identified. While SLE is more common in women of childbearing age, it has been reported in the pediatric and elderly population.DESCRIPTION OF DRAWINGS-1- 103693.007823\4927-3677-6616.1
[0005] The following description of the illustrative examples may be better understood when read in conjunction with the appended drawings. It is understood that potential examples of the disclosed systems and methods are not limited to those depicted.
[0006] FIG. 1 is a schematic overview of the Phase 2 study described in Example 1.
[0007] FIG. 2A is a graph showing the proportion of participants in nipocalimab 15 mg / kg group, nipocalimab 5 mg / kg group, and placebo group achieving SRI-4 response at Week 52.
[0008] FIG. 2B is a graph showing the proportion of participants in nipocalimab 15 mg / kg group, nipocalimab 5 mg / kg group, and placebo group achieving SRI-5 response at Week 52.
[0009] FIG. 2C is a graph showing the proportion of participants in nipocalimab 15 mg / kg group, nipocalimab 5 mg / kg group, and placebo group achieving SRI-6 response at Week 52.
[0010] FIG. 3 is a graph showing proportion of participants in nipocalimab 15 mg / kg group, nipocalimab 5 mg / kg group, and placebo group achieving <7.5 mg / day oral GCs over time.
[0011] FIG. 4A is a graph showing proportion of participants achieving 7.5 mg / day oral GC taper target and SRI-4.
[0012] FIG. 4B is a graph showing proportion of participants achieving 7.5 mg / day oral GC taper target and BICLA.
[0013] FIG. 4C is a graph showing proportion of participants achieving 7.5 mg / day oral GC taper target and CLASI-50.
[0014] FIG. 4D is a graph showing proportion of participants achieving 7.5 mg / day oral GC taper target and Joint-50.
[0015] FIG. 4E is a graph showing the proportion of participants within the IFN-high subgroup achieving 7.5 mg / day oral GC taper target and SRI-4.
[0016] FIG. 4F is a graph showing the proportion of participants within the modified aAB-high subgroup achieving 7.5 mg / day oral GC taper target and SRI-4.-2- 103693.007823\4927-3677-6616.1
[0017] FIG. 5 is a graph showing proportion of participants in nipocalimab 15 mg / kg group, nipocalimab 5 mg / kg group, and placebo group achieving LLDAS response over time.
[0018] FIG. 6 is a graph showing proportion of participants achieving SRI-4 response at Week 52 in IFN-high subgroup (left) and IFN-low subgroup (right).
[0019] FIG. 7 is a graph showing proportion of participants receiving >10 mg / day baseline oral GC who achieved taper target and SRI-4 in IFN-high subgroup (left) and IFN-low subgroup (right).
[0020] FIG. 8 is a graph showing proportion of participants achieving SRI-4 response at Week 52 in aAB-high subgroup.
[0021] FIG. 9 is a graph showing proportion of participants achieving SRI-4 in enriched aAB-high subgroup.
[0022] FIG. 10 is a schematic overview of the Phase 3 study described in Example 2.
[0023] FIG. 11 shows a drug product according to one example that comprises a syringe containing a therapeutic agent of this disclosure.
[0024] FIG. 12 shows a drug product according to one example that comprises a syringe supported in a housing, the syringe containing a therapeutic agent of this disclosure.
[0025] FIG. 13 shows a drug product according to one example that comprises an auto injector having a cartridge containing a therapeutic agent of this disclosure.
[0026] FIG. 14 shows a drug product according to one example that comprises an autoinjector having a syringe containing a therapeutic agent of this disclosure.
[0027] FIG. 15 shows a perspective view drug product according to one example that comprises an on-body delivery system having a container that contains a therapeutic agent of this disclosure.
[0028] FIG. 16 shows a perspective view of the drug product of FIG. 15 with the container removed.-3- 103693.007823\4927-3677-6616.1
[0029] FIG. 17 shows a side view of the drug product of FIG. 15.
[0030] FIG. 18 shows a simplified schematic of the drug product of FIG. 15 according to one example.
[0031] FIG. 19 shows a simplified schematic of the drug product of FIG. 15 according to another example.
[0032] FIG. 20 is a schematic overview of the Phase 3 study described in Example 3.
[0033] FIG. 21 is a graph showing the proportion of participants achieving SRI-4 response at Week 52 in the modified aAB-high subgroup.
[0034] FIG. 22 is a graph showing simulated % IgG lowering over time with the 15 mg / kg IV q2w and 460 mg SC qw Nipocalimab dose regimens. Lines and shaded regions represent medians and 90% prediction intervals of simulated % IgG lowering, respectively.
[0035] FIG. 23 is a graph showing exposure-response modeling of SRI-4 composite response at week 52 and model-predicted average IgG reduction. Top panel: Error bars are the 95% CI of observed response rate in the respective IgG reduction (%) quartile groups. Grey shaded areas of the logistic regression plot represent the 95% CI of the predicted response rate. Short vertical lines at the lower and upper part of the plotting area represent the IgG reduction (%) metric in participants negative and positive for response, respectively. Bottom panel:Boxplot of IgG reduction (%) for different dosing regimens included in the E-R analysis of SRI-4 composite response.
[0036] FIG. 24 are graphs showing model-based predictions for total cholesterol, LDL, and albumin following Nipocalimab 15 mg / kg IV q2w and 460 mg SC qw.
[0037] FIG. 25 is a graph showing the proportion of participants achieving SRI-4 response at Week 52 among all patients.
[0038] FIG. 26 includes graphs showing the proportion of participants achieving LLDAS response at Week 52 among all patients, patients in modified aAB-high subgroup, patients in aAB-high subgroup, and IFN-high subgroup.-4- 103693.007823\4927-3677-6616.1
[0039] FIG. 27 is a graph showing median change of total IgG (%) from baseline through Week 52.
[0040] FIG. 28 is a graph showing median change of CIC (%) from baseline through Week 52.
[0041] FIG. 29 is a graph showing median change of anti-dsDNA (%) from baseline through Week 52.
[0042] FIG. 30 is a graph showing median change of C3 (%) from baseline through Week 52.SUMMARY
[0043] Provided herein are methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering an anti-FcRn agent to the subject.
[0044] Provided herein are methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 3, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.
[0045] Provided herein are methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:-5- 103693.007823\4927-3677-6616.1(a) a light chain, which comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 3, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.
[0046] Provided herein are methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 460 mg.
[0047] Provided herein are methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 518 mg.
[0048] Provided herein are pharmaceutical products comprising: a therapeutic agent, comprising from about 400 mg to about 600 mg of nipocalimab; and a subcutaneous injection device that comprises: a container configured to contain the therapeutic agent; a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously; and a driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.DETAILED DESCRIPTION
[0049] The present disclosure provides methods of treating systemic lupus erythematosus (SLE) and related symptoms or pathologies associated with the same with an agent against human neonatal Fc receptor (FcRn). As used herein, the terms “systemic lupus erythematosus”, “SLE”, and “disseminated lupus erythematosus” are used interchangeably.
[0050] As used herein, the terms “seropositive” and “positive” are used interchangeably in the context of determining the presence of antibodies in a biological sample. As used herein, the-6- 103693.007823\4927-3677-6616.1terms “seronegative” and “negative” are used interchangeably in the context of determining the absence of antibodies in a biological sample.
[0051] As used herein, the term “FcRn” refers a neonatal Fc receptor that binds to the Fc region of an IgG antibody, e.g., an IgGl antibody. An exemplary FcRn is human FcRn having UniProt ID No. P55899, which is hereby incorporated by reference in its entirety. Without being bound to any particular theory, human FcRn is believed to be responsible for maintaining the half-life of IgG by binding and trafficking constitutively internalized IgG back to the cell surface for the recycling of IgG.
[0052] In some embodiments, the anti-FcRn agent is an anti-FcRn antibody.
[0053] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), scFVs, nanobodies, VHH, and antibody fragments so long as they exhibit FcRn antigen-binding activity.
[0054] Additionally, antibody or antibody molecule, as that term is used herein, refers to a polypeptide, e.g., an immunoglobulin chain or fragment thereof, comprising at least one functional immunoglobulin variable domain sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In some embodiments, an antibody molecule comprises an antigen binding or functional fragment of a full-length antibody, or a full-length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes. In some embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment (e.g., a functional fragment) comprises a portion of an antibody, e.g., Fab, Fab', F(ab')2, F(ab)2, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules -7- 103693.007823\4927-3677-6616.1in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab’, and F(ab’)2 fragments, and single chain variable fragments (scFvs).
[0055] Immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FRs) joined by three hypervariable regions, also called complementarity determining regions (CDRs). The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).
[0056] The term “antibody molecule” also encompasses whole or antigen binding fragments of domain, or single domain, antibodies, which can also be referred to as “sdAb” or “VHH.” Domain antibodies comprise either VH or VL that can act as stand-alone, antibody fragments. Additionally, domain antibodies include heavy-chain-only antibodies (HCAbs). Domain antibodies also include a CH2 domain of an IgG as the base scaffold into which CDR loops are grafted. It can also be generally defined as a polypeptide or protein comprising an amino acid sequence that is comprised of four framework regions interrupted by three complementarity determining regions. This is represented as FR1- CDR1 -FR2-CDR2-FR3-CDR3-FR4. sdAbs can be produced in camelids such as llamas, but can also be synthetically generated using techniques that are well known in the art. The numbering of the amino acid residues of a sdAb or polypeptide is according to the general numbering for VH domains given by Kabat et al.(“Sequence of proteins of immunological interest,” US Public Health Services, NIH Bethesda, MD, Publication No. 91, which is hereby incorporated by reference). According to this numbering, FR1 of a sdAb comprises the amino acid residues at positions 1-30, CDR1 of a sdAb comprises the amino acid residues at positions 31-36, FR2 of a sdAb comprises the amino acids-8- 103693.007823\4927-3677-6616.1at positions 36-49, CDR2 of a sdAb comprises the amino acid residues at positions 50-65, FR3 of a sdAb comprises the amino acid residues at positions 66- 94, CDR3 of a sdAb comprises the amino acid residues at positions 95-102, and FR4 of a sdAb comprises the amino acid residues at positions 103-113. Domain antibodies are also described in International Publication Nos.W02004 / 041862 and WO2016 / 065323, both of which are hereby incorporated by reference in their entireties.
[0057] In some embodiments, as provided for herein, antibody molecules can be monospecific (e.g., monovalent or bivalent), bispecific (e.g., bivalent, trivalent, tetravalent, pentavalent, or hexavalent), trispecific (e.g., trivalent, tetravalent, pentavalent, hexavalent), or with higher orders of specificity (e.g., tetraspecific) and / or higher orders of valency beyond hexavalency. An antibody molecule can comprise a functional fragment of a light chain variable region and a functional fragment of a heavy chain variable region, or heavy and light chains may be fused together into a single polypeptide.
[0058] As used herein, the terms “variable region” and “variable domain” refer to the portions of the light and heavy chains of an antibody that include amino acid sequences of complementary determining regions (e.g., CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDR H3) and framework regions. According to the methods used in this disclosure, the amino acid positions assigned to CDRs and FRs are defined according to Kabat (“Sequences of Proteins of Immunological Interest”, 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a CDR (defined further herein) or FR (defined further herein) of the variable region. For example, a heavy chain variable region may include a single inserted residue (i.e., residue 52a according to Kabat) after residue 52 of CDRH2 and inserted residues (i.e., residues 82a, 82b, 82c, etc. according to Kabat) after residue 82 of heavy chain FR. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.
[0059] As used herein, the terms “complementary determining regions” and “CDRs” refer to the regions of an antibody variable domain or variable region which are hypervariable in-9- 103693.007823\4927-3677-6616.1sequence and / or form structurally defined loops. A CDR is also known as a hypervariable region. The light chain and heavy chain variable regions each has three CDRs. The light chain variable region contains CDR LI, CDR L2, and CDR L3. The heavy chain variable region contains CDR Hl, CDR H2, and CDR H3. Each CDR may include amino acid residues from a complementarity determining region as defined by Kabat, i.e., about residues 24-34 (CDR LI), 50-56 (CDRL2) and 89-97 (CDR L3) in the light chain variable region and about residues 31-35 (CDR Hl), 50-65 (CDR H2) and 95-102 (CDR H3) in the heavy chain variable region.
[0060] In some embodiments, the anti-FcRn antibody comprises a heavy chain or light chain. In some embodiments, the anti-FcRn antibody comprises a heavy chain and a light chain in a scFv format. In some embodiments, the heavy and light chain are linked with a peptide linker, such a glycine / serine or glycine / alanine linker.
[0061] In some embodiments, the anti-FcRn antibody is nipocalimab, efgartigimod, rozanolixizumab, batoclimab, IMVT-1402, orilanolimab, SYNT001, SYNT002, ABY-039, or DX-2507.
[0062] In some embodiments, the anti-FcRn antibody is nipocalimab, which can also be referred to as M281. Nipocalimab is an antibody that binds to FcRn and is described, for example, in US Patent No. 10,676,526, PCT Publication No. W02020 / 023310, and PCT Publication No. W02020 / 018910, all of which are hereby incorporated by reference in their entireties.
[0063] In some embodiments, the anti-FcRn antibody is M281 (nipocalimab). In some embodiments, nipocalimab comprises or consists of: a light chain comprising or consisting of the sequence:QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSE RPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVET TTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1);-10- 103693.007823\4927-3677-6616.1and a heavy chain comprising or consisting of the sequence:EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGAS GSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVI< FNWYVDGVEVHNAI< TI< PREEQYASTYRVVSVLTVLHQDWLNGI< EYI< CI< VSN KALPAPIEKHSKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPG (SEQ ID NO: 2).
[0064] In some embodiments, the anti-FcRn antibody has: (a) a light chain sequence that is at least 95%, 96%, 97% 98%, or 99% identical to SEQ ID NO: 1, wherein the CDRL1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), the CDRL2 comprises the sequence GDSERPS (SEQ ID NO: 4), the CDRL3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 5); and (b) a heavy chain sequence that is at least 95%, 96%, 97% 98%, or 99% identical to SEQ ID NO: 2, wherein the CDRH1 comprises the sequence TYAMG (SEQ ID NO: 6), the CDRH2 comprises the sequence SIGASGSQTRYADSVKG (SEQ ID NO: 7), and the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 8).
[0065] In some embodiments, the anti-FcRn antibody has: (a) a light chain sequence that is at least 95%, 96%, 97% 98%, or 99% identical to SEQ ID NO: 1, wherein the CDR LI comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), the CDRL2 comprises the sequence GDSERPS (SEQ ID NO: 4), the CDRL3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 5); and (b) a heavy chain sequence that is at least 95%, 96%, 97% 98%, or 99% identical to SEQ ID NO: 2, wherein the CDR Hl comprises the sequence TYAMG (SEQ ID NO: 6), the CDRH2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 23), and the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 8).
[0066] In some embodiments, the anti-FcRn antibody is an anti-FcRn antibody comprising a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the -11- 103693.007823\4927-3677-6616.1amino acid sequence of SEQ ID NO: 5; and a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 8.
[0067] In some embodiments, the anti-FcRn antibody is an anti-FcRn antibody comprising a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 8.
[0068] In some embodiments, the anti-FcRn antibody comprises a light chain variable region comprising the amino acid sequence that is at least 95%, 97%, 99%, or 100% identical to: QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGV SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL (SEQ ID NO: 9). In some embodiments, the light chain variable region contains a CDR LI having the sequence of SEQ ID NO: 3, a CDR L2 having the sequence of SEQ ID NO: 4, a CDR L3 having the sequence of SEQ ID NO: 5.
[0069] In some embodiments, the anti-FcRn antibody comprises a heavy chain variable region comprising the amino acid sequence that is at least 95%, 97%, 99%, or 100% identical to: EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQT RYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS(SEQ ID NO: 10). In some embodiments, the heavy chain variable region contains a CDR Hl having the sequence of SEQ ID NO: 6, a CDR H2 having the sequence of SEQ ID NO: 7, and a CDR H3 having the sequence of SEQ ID NO: 8.
[0070] In some embodiments, the anti-FcRn antibody comprises a heavy chain variable region comprising the amino acid sequence that is at least 95%, 97%, 99%, or 100% identical to: EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQT RYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS-12- 103693.007823\4927-3677-6616.1(SEQ ID NO: 10). In some embodiments, the heavy chain variable region contains a CDRH1 having the sequence of SEQ ID NO: 6, a CDR H2 having the sequence of SEQ ID NO: 23, and a CDR H3 having the sequence of SEQ ID NO: 8.
[0071] In some embodiments, the anti-FcRn antibody comprises a light chain of the anti-FcRn antibody that comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9; and a heavy chain of the anti-FcRn antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10.
[0072] In some embodiments, the anti-FcRn antibody comprises a light chain of the anti-FcRn antibody comprising the amino acid sequence of SEQ ID NO: 1; and a heavy chain of the anti-FcRn antibody comprising the amino acid sequence of SEQ ID NO: 2.
[0073] In some embodiments, the anti-FcRn agent is nipocalimab.
[0074] In some embodiments, some of the heavy chains of nipocalimab may comprise an additional Lysine (K) residue at the C-terminus of SEQ ID NO: 2.
[0075] The term “nipocalimab” as used herein is intended to encompass biosimilar anti-FcRn antibodies that are equivalent to the nipocalimab protein developed and marketed by Johnson and Johnson. For example, a biosimilar of nipocalimab may be acceptable to the European Medicines Agency (EMA) and / or the United States Food and Drug Administration (FDA) when it has essentially the same pharmacological effects as the reference product nipocalimab. For example, a biosimilar of nipocalimab may comprise or consist of the same heavy and light chains sequences as nipocalimab, with the exception of a C-terminal modification. For example, the C-terminal amino acid or acids of the heavy chain may be absent, e.g. compared to SEQ ID NO: 2. The present disclosure extends to the use of antibody that uses the International Nonproprietary Name (INN) “nipocalimab”.
[0076] In some embodiments, the antibodies may further comprise amino acid substitutions, additions, and / or deletions outside of the CDRs (i.e., in framework regions (FRs)). An amino acid substitution, addition, and / or deletion can be a substitution, addition, and / or deletion of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more). An amino acid substitution, addition,-13- 103693.007823\4927-3677-6616.1and / or deletion can be a substitution, addition, and / or deletion of eight or fewer, seven or fewer, six or fewer, five or fewer, four or fewer, three or fewer, or two or fewer single amino acids.
[0077] In some embodiments, the antibodies described herein may include amino acid substitutions, additions, and / or deletions in the constant regions (e.g., Fc region) of the antibody that, e.g., lead to decreased effector function, e.g., decreased complement-dependent cytolysis (CDC), antibody-dependent cell-mediated cytolysis (ADCC), and / or antibody-dependent cell-mediated phagocytosis (ADCP), and / or decreased B-cell killing. The constant regions are not involved directly in binding an antibody to its target, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity. In some embodiments, the antibodies described herein are characterized by decreased binding (i.e., absence of binding) to human complement factor Clq and / or human Fc receptor on natural killer (NK) cells. In other embodiments, the antibodies are characterized by decreased binding (i.e., absence of binding) to human FcyRI, FcyRIIA, and / or FcyRIIIA. In some embodiments, the antibodies described herein contain asparagine (N) at position 297 (numbering according to the EU System). In some embodiments, an anti-FcRn antibody described herein is aglycosylated at position 297 (numbering according to the EU System). In some cases, an anti-FcRn antibody described herein does not have an N at position 297 (EU numbering) in any one of SEQ ID NO: 2, such that the antibody is aglycosylated at that position. The resulting effectorless antibody shows very little binding to complement or Fc receptors (i.e., complement Clq binding), indicating low CDC potential. In some embodiments, the Fc region is an effectorless Fc region.
[0078] In some embodiments, the heavy chain of the anti-FcRn antibody comprises a sequence having no more than 5, 4, 3, 2 or 1 single amino acid substitutions relative to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the light chain of the anti-FcRn antibody comprises a sequence having no more than 5, 4, 3, 2 or 1 single amino acid substitutions relative to the sequence of SEQ ID NO: 1.
[0079] As used herein, the term “percent (%) identity” refers to the percentage of amino acid (or nucleic acid) residues of a candidate sequence, e.g., an anti-FcRn antibody of the disclosure, that are identical to the amino acid (or nucleic acid) residues of a reference sequence, e.g., a wild-type anti-FcRn antibody, after aligning the sequences and introducing gaps, if-14- 103693.007823\4927-3677-6616.1necessary, to achieve the maximum percent identity (i.e., gaps can be introduced in one or both of the candidate and reference sequences for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). Alignment for purposes of determining percent identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, the percent amino acid (or nucleic acid) sequence identity of a given candidate sequence to, with, or against a given reference sequence (which can alternatively be phrased as a given candidate sequence that has or includes a certain percent amino acid (or nucleic acid) sequence identity to, with, or against a given reference sequence) is calculated as follows:100 x (fraction of A / B)where A is the number of amino acid (or nucleic acid) residues scored as identical in the alignment of the candidate sequence and the reference sequence, and where B is the total number of amino acid (or nucleic acid) residues in the reference sequence. In some embodiments where the length of the candidate sequence does not equal to the length of the reference sequence, the percent amino acid (or nucleic acid) sequence identity of the candidate sequence to the reference sequence would not equal to the percent amino acid (or nucleic acid) sequence identity of the reference sequence to the candidate sequence.
[0080] In some embodiments, a reference sequence aligned for comparison with a candidate sequence may show that the candidate sequence exhibits from 50% to 100% identity across the full length of the candidate sequence or a selected portion of contiguous amino acid (or nucleic acid) residues of the candidate sequence. The length of the candidate sequence aligned for comparison purpose is at least 30%, e.g., at least 40%, e.g., at least 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid (or nucleic acid) residue as the corresponding position in the reference sequence, then the molecules are identical at that position. A position may be altered by a substitution, deletion, or insertion. A substitution, deletion, or insertion may comprise a-15- 103693.007823\4927-3677-6616.1certain number of amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more). When describing a substitution, deletion, or insertion of no more than n amino acids, this is meant that the substitution, deletion, or insertion comprises, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or n amino acids. The number or substitutions, deletions, or insertions can comprise a percent of the total sequence (e.g., 1%, 5%, 10%, 15%, 20%, or more) where the number of substitutions, deletions, or insertions alters 5%, 10%, 15%, 20% or more, of the amino acids in the total sequence.
[0081] In some embodiments, the Fc domain of the antibody is not fucosylated. In some embodiments, the Fc domain of the antibody is not glycosylated. In some embodiments, the antibody lacks effector function. In some embodiments, the antibody is an IgGl antibody.
[0082] In some embodiments, the anti-FcRn antibody is efgartigimod (also known as ARGX-113), a modified human IgGl -derived Fc fragment that binds FcRn. In some embodiments, efgartigimod is described in U. S. Patent No. 10,316,073, which is incorporated herein by reference in its entirety. In some embodiments, efgartigimod comprises or consists of a first subunit comprising or consisting of the sequence:DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKFN WYVDGVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CT< VSNI< AL PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYT QKSLSLSPGK (SEQ ID NO: 11);and a second subunit comprising or consisting of the sequence:DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKFN WYVDGVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CT< VSNI< AL PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYT QKSLSLSPGK (SEQ ID NO: 12).-16- 103693.007823\4927-3677-6616.1
[0083] In some embodiments, the anti-FcRn antibody is rozanolixizumab (also known as UCB7665), a humanized anti-FcRn antibody. In some embodiments, rozanolixizumab is described in U. S. Patent No. 10,233,243, which is incorporated herein by reference in its entirety. In some embodiments, rozanolixizumab comprises or consists of a light chain comprising or consisting of the sequence:DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYL VSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO: 13);and a heavy chain comprising or consisting of the sequence:EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDS DGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYW GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSQEDPEVQFN WYVDGVEVHNAI< TI< PREEQFNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSNI< GL PSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYT QKSLSLSLGK (SEQ ID NO: 14).
[0084] In some embodiments, the anti-FcRn antibody is batoclimab (also known as IMVT-1401, RVT1401, HL161BKN, and HBM9161), a fully human, anti-FcRn antibody. In some embodiments, batoclimab is described in U. S. Patent No. 10,544,226, which is incorporated herein by reference in its entirety. In some embodiments, batoclimab comprises or consists of a light chain comprising or consisting of the sequence:SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRP SGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWFGGGTKLTVLG QPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETT-17- 103693.007823\4927-3677-6616.1TPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 15);and a heavy chain comprising or consisting of the sequence:QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYS GNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPE VI< FNWYVDGVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPG (SEQ ID NO: 16).
[0085] In some embodiments, the anti-FcRn antibody is IMVT-1402 (also known as HL161ANS), a fully human, anti-FcRn antibody. In some embodiments, IMVT-1402 is disclosed in WO2023 / 235679, which is incorporated herein by reference in its entirety.
[0086] In some embodiments, the anti-FcRn antibody is orilanolimab (also known as ALXN1830 and SYNT001), a humanized anti-FcRn antibody. In some embodiments, orilanolimab is described in U. S. Patent No. 10,626,175, which is incorporated herein by reference in its entirety. In some embodiments, orilanolimab comprises or consists of a light chain variable region comprising or consisting of the sequence:DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLE TGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK(SEQ ID NO: 17);and a heavy chain variable region comprising or consisting of the sequence:QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPR SGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIW GTGTTVTVSS (SEQ ID NO: 18).-18- 103693.007823\4927-3677-6616.1
[0087] In some embodiments, the anti-FcRn antibody is SYNT002, a humanized anti-FcRn antibody. In some embodiments, SYNT002 is described in U. S. Patent No. 10,822,417, which is incorporated herein by reference in its entirety. In some embodiments, SYNT002 comprises or consists of a light chain variable region comprising or consisting of the sequence:DIVMTQSPDSLSASVGDRVTITCKASQSVSNDVAWYQQKPGQPPKLLIYYASNR YTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYFCQQDYSSLTFGQGTKLEIK (SEQ ID NO: 19);and a heavy chain variable region comprising or consisting of the sequence:EVQLVESGGGLVKPGGSLKLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISS GSSTIYYADTVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCARAESTTTVGD YWGQGTSVTVSS (SEQ ID NO: 20).
[0088] In some embodiments, the anti-FcRn antibody is ABY-039 (also known as Affibody AB), a bivalent antibody-mimetic targeting FcRn. In some embodiments, ABY-039 is described in U. S. Patent No. 10,323,066, which is incorporated herein by reference in its entirety.
[0089] In some embodiments, the anti-FcRn antibody is DX-2507, a fully human anti-FcRn monoclonal antibody. In some embodiments, DX-2507 is described in U. S. Patent No.9,862,768, which is incorporated herein by reference in its entirety. In some embodiments, DX-2507 comprises or consists of a light chain comprising or consisting of the sequence:QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMITGDSQ RPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCASTAGSGITVFGTGTKVTVL GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVE TTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(SEQ ID NO: 21);and a heavy chain comprising or consisting of the sequence:EVQLLESGGGLVQPGGSLRLSCAASGFTFSEYAMGWVRQAPGKGLEWVSSIGSS GGQTI< YADSVI< GRFTISRDNSI< NTLYLQMNSLRAEDTAVYYCARLAIGDSYWG-19- 103693.007823\4927-3677-6616.1QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVI< FNWYVDGVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSN KALPAPIEKTISKAKGQPREPQVYTLPPSArqEEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYI< TTPPVLDSDGSFFLYSI< LTVDI< SRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG (SEQ ID NO: 22).
[0090] In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered to the subject suffering from systemic lupus erythematosus. In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered to the subject suffering from systemic lupus erythematosus every week, every two weeks, every three weeks, or monthly.
[0091] In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered at a dose from about 5 mg / kg to about 45 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose from about 5 mg / kg to about 15 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose from about 15 mg / kg to about 45 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose from about 30 mg / kg to about 45 mg / kg, based on the weight of the subject.
[0092] In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered at a dose of about 5 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose of about 15 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose of about 30 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered at a dose of about 45 mg / kg, based on the weight of the subject.
[0093] The anti-FcRn agent (e.g., nipocalimab) may be administered by any means. In some embodiments, the anti-FcRn agent is administered intravenously or subcutaneously.
[0094] In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered intravenously. In some embodiments, the anti-FcRn agent is administered every two weeks-20- 103693.007823\4927-3677-6616.1intravenously at 10-30 mg / kg, based on the weight of the subject. In some embodiments, the anti-FcRn agent is administered every two weeks intravenously at 15 mg / kg based on the weight of the subject.
[0095] In some embodiments, the nipocalimab is administered every two weeks intravenously at 10-30 mg / kg based on the weight of the subject.
[0096] In some embodiments, the nipocalimab is administered every two weeks intravenously at 15 mg / kg based on the weight of the subject.
[0097] In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered subcutaneously. In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered subcutaneously to the subject every week. In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered subcutaneously to the subject every two weeks.
[0098] The anti-FcRn agent (e.g., nipocalimab) may be administered at 200-1000mg. The anti-FcRn agent (e.g., nipocalimab) may be administered at 200-600 mg, 300-700 mg, 400-800 mg, 500-900 mg, or 600-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered at 200-400 mg, 300-500 mg, 400-600 mg, 500-700 mg, 600-800 mg, 700-900 mg, or 800-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered at 200-300 mg, 300-400 mg, 400-500 mg, 500-600 mg, 600-700 mg, 700-800 mg, 800-900 mg, or 900-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered at 230, 460, 518, 690, or 920 mg. In some embodiments, the anti-FcRn agent is administered every week subcutaneously at 200-1000 mg. In some embodiments, the anti-FcRn agent is administered every week subcutaneously at 200-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered every week subcutaneously at 200-600 mg, 300-700 mg, 400-800 mg, 500-900 mg, or 600-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered every week subcutaneously at 200-400 mg, 300-500 mg, 400-600 mg, 500-700 mg, 600-800 mg, 700-900 mg, or 800-1000 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered every week subcutaneously at 200-300 mg, 300-400 mg, 400-500 mg, 500-600 mg, 600-700 mg, 700-800 mg, 800-900 mg, or 900-1000 mg. In some embodiments, the anti-FcRn agent is administered every week subcutaneously at 230, 460, 518, 690, or 920 mg. Administration of the anti-FcRn agent (e.g., nipocalimab) at 460 mg may be preferred. In some embodiments, the anti-FcRn agent is administered every week -21- 103693.007823\4927-3677-6616.1subcutaneously at 460 mg. It also may be preferred to administer 518 mg of the anti-FcRn agent (e.g., nipocalimab). In some embodiments, the anti-FcRn agent is administered every week subcutaneously at 518 mg.
[0099] In some embodiments, the anti-FcRn agent is administered subcutaneously via an autoinjector. Administration the anti-FcRn agent (e.g., nipocalimab) every week subcutaneously via an autoinjector may be preferred. In some embodiments, the anti-FcRn agent (e.g., nipocalimab) is administered subcutaneously every week via an autoinjector.
[0100] The anti-FcRn agent (e.g., nipocalimab) may be administered every week subcutaneously at 460 mg or 518 mg. The anti-FcRn agent (e.g., nipocalimab) may be administered every week subcutaneously at 460 mg or 518 mg via an autoinjector. In one particular embodiment, administration of the anti-FcRn agent (e.g., nipocalimab) subcutaneously at 460 mg may be preferred. Administration of the anti-FcRn agent (e.g., nipocalimab) every week subcutaneously at 460 mg may be preferred. Administration of the anti-FcRn agent (e.g., nipocalimab) every week subcutaneously at 460 mg via an autoinjector may be preferred. In another particular embodiment, administration of the anti-FcRn agent (e.g., nipocalimab) subcutaneously at 518 mg may be preferred. Administration of the anti-FcRn agent (e.g., nipocalimab) every week subcutaneously at 518 mg may be preferred. Administration of the anti-FcRn agent (e.g., nipocalimab) every week subcutaneously at 518 mg via an auto injector may be preferred.
[0101] In some embodiments, the nipocalimab is administered every week subcutaneously at 200-1000 mg.
[0102] In some embodiments, the nipocalimab is administered every week subcutaneously at 400-600 mg.
[0103] In some embodiments, the nipocalimab is administered every week subcutaneously at 460 mg or 518 mg.
[0104] In some embodiments, the nipocalimab is administered via an autoinjector.-22- 103693.007823\4927-3677-6616.1
[0105] In some embodiments, the subject has a SLEDAI-2K score over 4, 5, or 6 before initiation of said administering.
[0106] In some embodiments, the subject has a BILAG-2004 index score equal to or over 1 BILAG A score before initiation of said administering.
[0107] In some embodiments, the subject has a BILAG-2004 index score equal to or over 2 BILAG B score before initiation of said administering.
[0108] In some embodiments, the subject has a CLASI activity score equal to or over 6 before initiation of said administering.
[0109] In some embodiments, the subject has at least 4 active joints before initiation of said administering.
[0110] In some embodiments, by administering the anti-FcRn agent (e.g., nipocalimab) to a subject suffering from systemic lupus erythematosus, the subject has a reduction in autoantibodies in the blood. In some embodiments, the autoantibodies are selected from the group consisting of: anti-La antibodies, anti-Smith antibodies, antinuclear antibodies (ANA), anti-dsDNA antibodies, anti-nRNP (ribonucleoproteins) antibodies, anti-RO60 (SSA) autoantibodies, and anti-RO52 autoantibodies.
[0111] In some embodiments, the subject is seropositive for antinuclear antibodies (ANA). Any suitable testing system known in the art may be used to determine the positivity of ANA. For example, subjects that are ANA seropositive may have an ANA titer ≥1:80 using ZEUS IFA™ test system).
[0112] In some embodiments, the subject is seropositive for anti-dsDNA antibodies before initiation of said administering. Any suitable testing system known in the art may be used to determine the positivity of anti-dsDNA antibodies. For example, subjects that are anti-dsDNA antibodies seropositive may have an anti-dsDNA antibody level ≥75 IU / ml using QUANTA Lite test system or ≥15 IU / ml using Phadia (EliA) dsDNA test system.-23- 103693.007823\4927-3677-6616.1
[0113] In some embodiments, the subject is seropositive for anti-Smith antibodies before initiation of said administering. Any suitable testing system known in the art may be used to determine the positivity of anti-Smith antibodies. For example, subjects that are anti-Smith antibody seropositive may have an anti-Smith antibody level >120 AU / ml using AtheNA ANA-II Plus test system or >20 CU using QUANTA Flash Sm test system.
[0114] In some embodiments, the subject is seropositive for antinuclear antibodies (ANA) and at least one of:1) is seropositive for anti-RO52 and / or anti-RO60 antibodies;2) is seropositive for anti-La antibodies;3) is seropositive for anti-RNP antibodies; and4) has historical evidence of seropositive anti-dsDNA antibodies, before initiation of said administering.
[0115] Any suitable testing system known in the art may be used to determine the positivity of anti-Ro52 antibodies. For example, subjects that are anti-Ro52 antibody seropositive may have an anti-Ro52 antibody level >120 AU / ml using AtheNA ANA-II Plus test system or >20 CU using QUANTA Flash Ro52 test system.
[0116] Any suitable testing system known in the art may be used to determine the positivity of anti-Ro60 antibodies. For example, subjects that are anti-Ro60 antibody seropositive may have an anti-Ro60 antibody level >120 AU / ml using AtheNA ANA-II Plus test system or >20 CU using QUANTA Flash Ro60 test system.
[0117] Any suitable testing system known in the art may be used to determine the positivity of anti-La antibodies. For example, subjects that are anti-La antibody seropositive may have an anti-La antibody level >20 CU using QUANTA Flash SSB test system.
[0118] Any suitable testing system known in the art may be used to determine the positivity of anti-RnP antibodies. For example, subjects that are anti-RnP antibody seropositive may have-24- 103693.007823\4927-3677-6616.1an anti-RnP antibody level >120 AU / ml using AtheNA ANA-II Plus test system or >20 CU using QUANTA Flash RnP test system.
[0119] In some embodiments, the subject is seropositive for antinuclear antibodies (ANA) and has low C3 and / or C4 levels.
[0120] In some embodiments, the subject is seropositive for anti-RO52 antibodies (level >20 CU on e.g., QUANTA Flash Ro52 test system) and anti-RO60 antibodies (level >20 CU on e.g., QUANTA Flash Ro60 test system, and is seronegative for anti-La antibodies (level <20 CU on e.g., QUANTA Flash SSB test system).
[0121] In some embodiments, the modified aAB-high group subjects exhibit at least one of the following:seropositive for anti-dsDNA antibodies (i.e., >75 lU / mL evaluated with QUANTA Lite test system);seropositive for anti-Smith antibodies (i.e., >20 CU evaluated with QUANTA Flash® Sm Werfen);seropositive for ANA (i.e., >1:80 on ZEUS IFA test system) and at least one of the following:o seropositive for anti-Ro60 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro60);o seropositive for anti-Ro52 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro52);o seropositive for anti-RNP antibodies (i.e., >120 AU / ml using AtheNA ANA-II Plus test system);o historical evidence of being seropositive for anti-dsDNA antibodies.
[0122] In some embodiments, the enriched aAB-high group subjects exhibit at least one of the following:-25- 103693.007823\4927-3677-6616.1seropositive for anti-dsDNA antibodies (i.e., >75 lU / mL evaluated with QUANTA Lite test system), seropositive for anti-Ro60 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro60), and seropositive for anti-Ro52 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro52), but seronegative for anti -La antibodies (i.e., <20 CU evaluated with QUANTA Flash SSB);seropositive for anti-Smith antibodies (i.e., >20 CU evaluated with QUANTA Flash® Sm Werfen), seropositive for anti-Ro60 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro60), and seropositive for anti-Ro52 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro52), but seronegative for anti-La antibodies (i.e., <20 CU evaluated with QUANTA Flash SSB);seropositive for ANA (i.e., >1:80 on ZEUS IFA test system), seropositive for anti-Ro60 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro60), and seropositive for anti- Ro52 antibodies (i.e., >20 CU evaluated with QUANTA Flash Ro52), but seronegative for anti-La antibodies (i.e., <20 CU evaluated with QUANTA Flash SSB).
[0123] As used herein, the phrase “does not significantly increase” when used in reference to levels (measurements) of albumin means that any increase is less than 20% as compared to the level(s) prior (baseline) to the administration of the antibody or compositions provided for herein. In some embodiments, the administering of the anti-FcRn agent (e.g., nipocalimab) to a subject suffering from systemic lupus erythematosus does not significantly increase the level of albumin in the subject compared with baseline. In some embodiments, the increase is less than 20%. In some embodiments, the increase is no greater than about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1%. As used herein, a less than 10% increase may be categorized as “not significantly increase.”
[0124] The phrase “does not significantly increase” when used in reference to levels (measurements) of serum total cholesterol means that there is no increase in lipid-lowering therapy.-26- 103693.007823\4927-3677-6616.1
[0125] As used herein, the term “change” in reference to a baseline refers to a subject having an improvement as compared to that subject’s conditions, scores, symptoms, and the like prior to being treated with the anti-FcRn antibodies as provided for herein.
[0126] ‘Baseline” refers to a subject prior to being treated with a therapeutic, such as the anti-FcRn antibodies, including those provided for herein.
[0127] In some embodiments, nipocalimab is administered to a subject with a baseline IgG level of >8 g / L, >9 g / L, >10 g / L, >11 g / L, >12 g / L, >13 g / L, >14 g / L, or >15 g / L. In some embodiments, nipocalimab is administered to a subject with a baseline IgG level of >10 g / L. In some embodiments, nipocalimab is administered to a subject with a baseline IgG level of >11 g / L. In some embodiments, nipocalimab is administered to a subject with a baseline IgG level of >12 g / L. In some embodiments, nipocalimab is administered to a subject with a baseline IgG level of >13 g / L.
[0128] As used herein, the phrase “does not significantly decrease” when used in reference to levels (measurements) of albumin or serum total cholesterol means that any decrease is less than 10% as compared to the level(s) prior (baseline) to the administration of the antibody or compositions provided for herein. In some embodiments, the administering of the anti-FcRn agent (e.g., nipocalimab) to a subject suffering from systemic lupus erythematosus, the administration does not significantly decrease level of albumin in the subject compared with baseline. In some embodiments, the decrease is less than 10%, or 5%. In some embodiments, the decrease is no greater than about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1%. As used herein, a less than 10% reduction may be categorized as “not significantly decrease”.
[0129] As used herein “combined expression value” refers to a value or mathematical representation of the level of expression of a combination of test genes, such as a combination of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L.
[0130] Level of gene expression" or "expression level" refers to the level (e.g., amount) of one or more products (e.g. RNA, protein) encoded by a given gene in a sample or reference standard. The expression level can be relative or absolute.-27- 103693.007823\4927-3677-6616.1
[0131] Gene expression" refers to translation of information encoded in a gene into a gene product (e.g., RNA, protein). Expressed genes include genes that are transcribed into RNA (e.g., mRNA) that is subsequently translated into protein as well as genes that are transcribed into noncoding functional RNAs that are not translated into protein (e.g., miRNA, tRNA, rRNA, ribozymes etc.).
[0132] Threshold value” refers to a value obtained for the combined expression of genes, for example DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L, that differentiates subjects having elevated IFN-I signature vs. subjects having baseline IFN-I signature with high accuracy. Threshold value may be expressed by various ways depending on the methods of analyzing gene expression. The threshold value may for example be obtained from a population of subjects that are substantially healthy (e.g. subjects who display a baseline IFN-I signature). The threshold value may be stored as a value(s) on a computer or PDA device to permit comparison with a value obtained from a subject using the methods described herein. The threshold value may also be obtained from the same subject e.g., at an earlier time point prior to onset of an IFN-I mediated disease, or prior to initiation of treatment with an IFN-I inhibitor. One of skill in the art can determine an appropriate reference sample for use with the methods described herein.
[0133] “Type I interferon” or “IFN-I” refers to all native subtypes of human interferon-a (IFNa) and one subtype of interferon-b (IFNb ), interferon-e (IFNe), interferon-w (IFNω) and interferon-k (IFNK) which bind to a common heterodimeric interferon receptor IFNAR comprising of IFNAR1 and IFNAR2. The amino acid sequences of the various IFN-I proteins, IFNAR1 and IFNAR2 are well known are retrievable from example UNIPROT or Genbank.
[0134] “Type I interferon signature”, “IFN-I signature”, or “type I interferon (IFN-I) gene signature” refers to the upregulation of a subset of genes that are modulated by IFN-I. Various IFN-I signatures are known, ranging from a handful to several hundred genes and including the gene set described herein. These signatures may be utilized for example as pharmacodynamic markers to assess target engagement of IFN-I inhibitors.-28- 103693.007823\4927-3677-6616.1
[0135] ‘Interferon gene signature (IGS) score”, “IGS score”, or “IFN-I gene signature score” refer to a value that can be measured using various sets of genes that are regulated by IFN.
[0136] In some embodiments, systemic lupus erythematosus patients may be defined by an interferon gene signature (IGS) score derived from WB with a 10 gene signature. In some embodiments, the genes in the gene signature include, but are not limited to, DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1, and SAMD9L.
[0137] In some embodiments, the present disclosure provides determining that the subject has an elevated IGS score by providing a biological sample from the subject; assaying gene expression of the gene signature in the biological sample; determining a combined expression value of the gene signature in the biological sample; and determining that the subject has the elevated IGS score when the combined expression value is equal to or higher than a threshold value.
[0138] In some embodiments, the present disclosure provides determining that the subject has an elevated IGS score by providing a biological sample from the subject; assaying gene expression of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in the biological sample; determining a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in the biological sample; and determining that the subject has the elevated IGS score when the combined expression value is equal to or higher than a threshold value. IGS scores are also described in International Publication No. W02020 / 084591, which is hereby incorporated by reference in its entirety.
[0139] ‘DHX58” refers to human DExH-box helicase 58 gene that produces a transcript comprising the polynucleotide sequence of NM_024119.
[0140] ‘EIF2AK2” refers to human eukaryotic translation initiation factor 2 alpha kinase 2 gene that that produces a transcript comprising the polynucleotide sequence of NM 001135651.-29- 103693.007823\4927-3677-6616.1
[0141] ‘HERC5” refers to human HECT and RLD domain containing E3 ubiquitin protein ligase 5) gene that produces a transript comprising the polynucleotide sequence of NM_016323.3
[0142] ‘IFI44” refers to interferon induced protein 44 gene that produces a transcript comprising the polynucleotide sequence of NM_006417.4.
[0143] ‘IFI44L” refers to interferon induced protein 44 like gene that produces a transcript comprising the polynucleotide sequence of NM_006820.3.
[0144] ‘IFI6” refers to interferon alpha inducible protein 6 gene that produces a transcript comprising the polynucleotide sequence of NM_022873.2.
[0145] ‘IRF7” refers to interferon regulatory factor 7 gene that produces a transcript comprising the polynucleotide sequence of NM_004031.3.
[0146] ‘PARP9” refers to poly(ADP-ribose) polymerase family member 9 that produces a transcript comprising the polynucleotide sequence of NM_001146102.1.
[0147] ‘PLSCR1” refers to phospholipid scramblase 1 gene that produces a transcript comprising the polynucleotide sequence of NM_021105.2.
[0148] SAMD9L” refers to sterile alpha motif domain containing 9 like gene that produces a transcript comprising the polynucleotide sequence of NM_152703.4.
[0149] In some embodiments, the subject has a positive type I interferon (IFN-I) gene signature.
[0150] As disclosed herein, IFN gene signatures score may be determined using a POISE 10-gene set disclosed in U. S. Patent No. 12,009,079, which is incorporated herein by reference. In brief, gene expression data from healthy individuals and SLE patients are used to compute the IFN POISE Enrichment score using GSVA (Hanzelmann, S., Castelo, R., & Guinney, J. (2013). **GSVA: gene set variation analysis for microarray and RNA-seq data.** *BMC Bioinformatics*, 14, 7. [DOI: 10.1186 / 1471-2105-14-7](https: / / doi.org / 10.1186 / 1471-2105-14--30- 103693.007823\4927-3677-6616.17)). The score distribution is bimodal, with the lower distribution including both healthy individuals and SLE patients, while the higher distribution consist solely of SLE patients.
[0151] To determine the cutoff between these distributions, the ' cutoff package (Version: 0.1.0) (Choisy, M. (2015). **cutoff: Identify a cutoff value from bimodal data (Version 0.1.0).** Retrieved from [GitHub Repository](https: / / github.com / choisy / cutoff) is used. This package estimates a finite mixture model through the Expectation-Maximization algorithm; here, two normal distributions were assumed. The algorithm determines the optimal cutoff at -0.33, which also represent the maximum healthy value. The parameters for the ' cutoff function are set to nb = 50, distr = 2, and typel = 0.05.
[0152] In another embodiment, the IFN gene signature score also may be determined using DxTerity test. DxTerity Modular Immune Profile (MIP) test by DxTerity Diagnostics, Rancho Dominguez, CA USA. MIP test is a chemical ligation-dependent probe amplification and gene expression test with relative quantitative analysis by capillary electrophoresis. Modules analyzed are: DxTerity IFN Module (IFN-I), B Cell Module, Energy Module, IFN Beta Module, IFN Gamma Module, mRNA Translation Module, Neutrophil Module, pDC Module, Plasmablasts Module, T Cell Module. Sample testing and analysis would be performed directly on PAXgene RNA Stabilized Blood. The DxTerity MIP test measures the RNA expression levels of 51 immune response genes relative to the expression levels of 3 housekeeping normalizer genes (ACTB, GAPDH and TFRC). Normalized expression values of each respective response gene were calculated per the following function: Normalized ExpressionGene i = Log2(HeightGene i) - Mean (Log2(Normalized Gene Height). A 4-gene Type I Interferon (IFN-I) signature score would be calculated by averaging the normalized expression values of HERC5, IFI27, IFIT1, and RSAD2 in the MIP panel. The IFN signature score cutoff of -0.5 between IFN high and low is determined based on measurement of 281 healthy human blood samples and placing the cut-off at 2 standard deviations (95th percentile) above the mean healthy IFN score (-0.5). This cut-off falls within the trough of the observed bimodal distribution of IFN scores for this and other cohorts of SLE samples.
[0153] In some embodiments, the subject has a positive IFN-I gene signature when a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7,-31- 103693.007823\4927-3677-6616.1PARP9, PLSCR1 and SAMD9L in a biological sample from the subject is equal to or higher than a threshold value.
[0154] In some embodiments, the biological sample is a blood sample or a tissue sample.
[0155] In some embodiments, the gene expression is assayed using quantitative Polymerase Chain Reaction (qPCR), RNA sequencing, or microarray.
[0156] In some embodiments, gene expression is measured at the mRNA level.
[0157] In some embodiments, the combined expression value is a sum of normalized threshold cycle (CT) values (SUMΔCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L.
[0158] In some embodiments, the threshold value is SUMΔCT of genes DHX58, EIF2AK2,HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.
[0159] In some embodiments, the threshold value is SUMΔCT of 57.474.
[0160] In some embodiments, the combined expression value is a sum of log2 fold changes of normalized differential expression between the biological sample and a biological sample obtained from one or more healthy subjects of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L ((SUMlog2(2A’ddCT)).
[0161] In some embodiments, the threshold value is SUMlog2(2^-ddCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.
[0162] In some embodiments, the threshold value is SUMlog2(2^-ddCT) of 8.725.
[0163] In some embodiments, the combined expression value is a POISE Score of Formula I:POISE Score = 70- 143.7251664- SUMlog2(2A’ddCT)| (Formula I)-32- 103693.007823\4927-3677-6616.1
[0164] In some embodiments, the threshold value is the POISE Score of between 30 and 40.
[0165] In some embodiments, the threshold value is the POISE score of 35.
[0166] In some embodiments, the subject has a positive IFN-I gene signature based on immune profile test of a blood sample from the subject.
[0167] In some embodiments, the subject has a positive IFN-I gene signature based on immune profile test when a combined expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 is equal to or higher than a threshold value.
[0168] In some embodiments, the threshold value is based on the expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 of one or more healthy subjects.
[0169] The immune profile test may be a DxTerity Modular Immune Profile (MIP) test by DxTerity Diagnostics, Rancho Dominguez, CA USA. MIP test is a chemical ligation-dependent probe amplification and gene expression test with relative quantitative analysis by capillary electrophoresis. Modules analyzed can be: DxTerity IFN Module (IFN-I), B Cell Module, Energy Module, IFN Beta Module, IFN Gamma Module, mRNA Translation Module, Neutrophil Module, pDC Module, Plasmablasts Module, T Cell Module. Sample testing and analysis can be performed directly on PAXgene RNA Stabilized Blood as described by Kim et al. The DxTerity MIP test measures the RNA expression levels of 51 immune response genes relative to the expression levels of 3 housekeeping normalizer genes (ACTB, GAPDH and TFRC).
[0170] Normalized expression values of each respective response gene can be calculated per the following function: Normalized ExpressionGene i = Log2(HeightGene i) - Mean (Log2(Normalized Gene Height). A 4-gene Type I Interferon (IFN-I) signature score can be calculated by averaging the normalized expression values of HERC5, IFI27, IFIT1, and RSAD2 in the MIP panel.
[0171] Without wishing to be bound by theory, an IFN-I signature score cutoff of -0.5 between IFN high and low was determined based on measurement of 281 healthy human blood samples and placing the cut-off at 2 standard deviations (95th percentile) above the mean healthy-33- 103693.007823\4927-3677-6616.1IFN-I score (-0.5). This cut-off falls within the trough of an observed bimodal distribution of IFN-I scores for cohorts of SLE samples.
[0172] In some embodiments, the baseline level of total IgG is measured by an immunoassay, and wherein the sample is the patient’s serum or plasma.
[0173] In some embodiments, the reference level of total IgG is about 8 g / L, about 9 g / L, about 10 g / L, about 11 g / L, about 12 g / L, about 13 g / L, about 14 g / L, about 15 g / L, or about 16 g / L. In some embodiments, the reference level of total IgG is within a range from about 10 g / L to about 16 g / L. In some embodiments, the reference level of total IgG is about 12 g / L when measured by an immunoassay.
[0174] In some embodiments, the sample used in measuring the baseline level of IGS score is the patient’s whole blood (WB) or peripheral blood mononuclear cells (PBMCs). In some embodiments, the reference level of the IGS score is about -0.6, about -0.55, about -0.50, about -0.45, about -0.40, about -0.35, or about -0.30 when measured by an 88 gene signature. In some embodiments, the IGS score can be measured using various sets of genes that are regulated by IFN. In some embodiments, an “88 gene signature” is used in the examples disclosed herein. In some embodiments, the reference level of the IGS score is within a range from about -0.55 to about -0.35 when measured by an 88 gene signature. In some embodiments, the reference level of the IGS score is about -0.45 when measured by an 88 gene signature.
[0175] In some embodiments, systemic lupus erythematosus patients may be defined by an interferon gene signature (IGS) score derived from WB with a 10 gene signature. In some embodiments, the genes in the gene signature include, but are not limited to, DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1, and SAMD9L. In some embodiments, the present disclosure provides determining that the subject has an elevated IGS score by providing a biological sample from the subject; assaying gene expression of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in the biological sample; determining a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in the biological sample; and determining that the subject has the elevated IGS score when the combined expression value is equal to or-34- 103693.007823\4927-3677-6616.1higher than a threshold value. IGS scores are also described in International Publication No. W02020 / 084591, which is hereby incorporated by reference in its entirety.
[0176] In some embodiments, the sample is whole blood (WB), plasma, or serum.
[0177] In some embodiments, the subject receives glucocorticoid at a first dose before initiation of said administering, and the method provides a clinical benefit as indicated by the subject receives glucocorticoid at a second dose that is lower than the first dose within 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52 weeks or more weeks of initiation of said administering.
[0178] In some embodiments, the first dose is 20 mg per day or higher.
[0179] In some embodiments, the second dose is 7.5 mg per day or lower.
[0180] In some embodiments, the first dose is 30 mg per day or higher.
[0181] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by a decrease in SLE Disease Activity Index 2K (SLEDAI-2K) in the subject by more than 4, 5, 6, 7, 8 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0182] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by the subject achieving SLEDAI-2K Responder Index (SRI)-4 within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0183] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by a decrease in CLASI-activity score in the subject by more than 40%, 50%, 60%, 70%, 80% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.-35- 103693.007823\4927-3677-6616.1
[0184] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by a CLASI-activity score of >=6, 8, 10, 12 at baseline.
[0185] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by a reduction in active joint counts in the subject by more than 50%, 60%, 70% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0186] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by the subject achieving Lupus Low Disease Activity State (LLDAS) within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0187] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by an improvement in Bodily Pain Score SF-36 score in the subject by more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0188] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit in the subject as measured by an improvement of 1-3 points in Lupus Symptoms from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0189] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by a decrease in FACIT Fatigue score in the subject by more than 3, 4, 5, 6 or points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0190] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus provides a clinical benefit as measured by-36- 103693.007823\4927-3677-6616.1the subject achieving no moderate or severe British Isles Lupus Activity Group (BILAG) flare within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
[0191] In some embodiments, the subject has a reduction in autoantibodies in the blood.
[0192] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus does not significantly decrease level of albumin in the subject compared with baseline.
[0193] In some embodiments, the administering of the anti-FcRn agent (e.g. nipocalimab) to a subject suffering from systemic lupus erythematosus does not significantly increase the level of serum total cholesterol in the subject compared with baseline.
[0194] The present disclosure provides methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 3, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.
[0195] The present disclosure provides methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and-37- 103693.007823\4927-3677-6616.1(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.
[0196] The present disclosure provides methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 460 mg.
[0197] The present disclosure provides methods of treating systemic lupus erythematosus in a subject in need thereof, the methods comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 518 mg.Pharmaceutical Product
[0198] Throughout this description, like reference labels depict like features. For succinctness, descriptions of like features might not be repeated. It will be understood that any description of a feature in relation to a figure applies equally to like features in other figures.
[0199] In various examples of this disclosure, a pharmaceutical product comprises a therapeutic agent and a subcutaneous injection device. The therapeutic agent comprises a weekly dose as discussed above. The injection device comprises a container configured to contain the therapeutic agent. The container can be a syringe barrel, a vial, a cartridge, a bladder, or any other suitable container. The injection device comprises a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously. The discharge nozzle can be a needle, catheter, other suitable discharge nozzle for delivering the therapeutic agent to a subject subcutaneously.
[0200] In some embodiments, the present disclosure provides pharmaceutical products comprising: a therapeutic agent comprising: a dose from about 400 mg to about 600 mg of nipocalimab; and a subcutaneous injection device, comprising: a container configured to contain the therapeutic agent; a discharge nozzle sized to deliver the therapeutic agent to a subject-38- 103693.007823\4927-3677-6616.1subcutaneously; and a driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.
[0201] In some embodiments, the therapeutic agent comprises 200 mg / mL to 250 mg / mL nipocalimab. In some embodiments, the therapeutic agent comprises from about 400 mg to about 500 mg of nipocalimab. In some embodiments, the therapeutic agent comprises about 460 mg of nipocalimab.
[0202] In some embodiments, the therapeutic agent comprises has a volume from 1.4mL to 2.5mL.
[0203] In some embodiments, the injection device is configured to deliver about 2.09mL ± 0.25mL of the therapeutic agent to the subject.
[0204] In some embodiments, the subcutaneous injection device is an on-body delivery device.
[0205] In some embodiments, the driver has a drive force that drives the therapeutic agent out of the discharge nozzle at a rate from 0.09mL / minute to 2.0mL / minute.
[0206] In some embodiments, the subcutaneous injection device is configured to deliver the therapeutic agent to the subject in no more than 30 seconds, such as no more than 25 seconds, such as no more than 20 seconds, such as no more than 15 seconds, such as no more than 10 seconds.
[0207] In some embodiments, the subcutaneous injection device is an autoinjector.
[0208] In some embodiments, the subcutaneous injection device comprises a skin-contacting surface that contacts skin of the subject during an injection, and the discharge nozzle is a needle that (i) extends beyond the skin-contacting by about 6.5mm ± 1mm when the drug is delivered to the subject, and / or (ii) has a needle gage from 23Gto 27G, or both (i) and (ii).
[0209] In some embodiments, the container is a cartridge having a septum; the subcutaneous injection device pierces the septum to fluidly couple the cartridge to the discharge nozzle; and the subcutaneous injection device delivers the therapeutic agent out of the discharge nozzle such-39- 103693.007823\4927-3677-6616.1that no particulate matter generated during piercing of the septum is discharged from the discharge nozzle that has a particle diameter >150 pm.
[0210] In some embodiments, the pharmaceutical product is disposed in the container.
[0211] In some embodiments, the pharmaceutical product is a kit comprising a separate container that is separate from the subcutaneous injection device, and the separate container contains the therapeutic agent.
[0212] The injection device comprises a driver configured to drive the therapeutic agent from the container and out of the discharge nozzle. The driver comprises one or more plungers, one or more springs, one or more motors, one or more compressed gas canisters, one or more hydraulic actuator, one or more pneumatic actuators, one or more other suitable drivers for driving the therapeutic agent from the container, or any combination thereof. In examples in which the driver comprises one or more springs, each spring can be a helical spring, a compression spring, an extension spring, a torsion spring, a constant force spring, a leaf spring, a gas spring, any other suitable spring, or any combination thereof. In some examples, the pharmaceutical product can be a kit comprising the subcutaneous injection device and the therapeutic agent disposed in a container that is separate from the subcutaneous injection device. In some examples, the pharmaceutical product can be a kit comprising the therapeutic agent, the subcutaneous injection device, and at least one other subcutaneous injection device, where a dose of the therapeutic agent is divided between the subcutaneous injection device and the at least one other subcutaneous injection device.
[0213] Referring to FIG. 11, a pharmaceutical product 100 is shown according to one example in which the subcutaneous pharmaceutical injection device 102 is a syringe. The pharmaceutical injection device 102 comprises a container 110 in the form of a syringe barrel. The container 110 has a proximal end 110a and a distal end 110b. The proximal end 110a can define an opening to receive a driver 114 therein. The distal end 110b can be offset from the proximal end 110a along a central axis along a distal direction. The container 110 contains the therapeutic agent 116 therein.-40- 103693.007823\4927-3677-6616.1
[0214] The injection device 102 comprises a discharge nozzle 112 which can be in the form of a subcutaneous injection needle or catheter. The injection needle can be a 25 gage, 26 gage, or 27 gage needle. For instance, the injection device 102 can comprise an abutment surface that is configured to abut a subject’s skin while the therapeutic agent is delivered to the subject, and the discharge nozzle 112 can extend from the abutment surface by a distance in a range from 4.5mm to 8.5mm, such as in a range from 5mm to 8mm, such as in a range from 5.5mm to 7.5mm, such as in a range from 6mm to 7mm, such as by a distance of 6.5mm. In one example, the abutment surface can be at the distal end 110b of the container 110. In other examples, the injection device can comprise a housing that houses the container 110, and the abutment surface can be defined by the housing. For instance, the injection device can comprise the Becton Dickinson® UltraSafe®, the West Pharmaceutical® SelfDose®, or the grip accessory of FIG. 12, and the housing can be a housing of such devices.
[0215] Referring briefly to FIG. 12, an alternative injection device 100' comprises a housing 130 that houses the container 110. The housing 130 has a proximal end 130a and a distal end 130b. The proximal end 130a can define an opening that receives the container 110 into the housing 130 to support the container 110 therein, although the opening could alternatively extend into a different surface of the housing 130 such as into a side of the housing 130. The distal end 130b defines an abutment surface that is configured to abut a subject’s skin while the therapeutic agent 116 is delivered to the subject. The housing 130 supports the container 110 such that the discharge nozzle 112 extends from the abutment surface by a distance in a range from 4.5mm to 8.5mm, such as in a range from 5mm to 8mm, such as in a range from 5.5mm to 7.5mm, such as in a range from 6mm to 7mm, such as by a distance of 6.5mm.
[0216] Referring back to FIG. 11, the injection device 102 comprises a driver 114 in the form of a plunger. The driver 114 comprises a plunger rod 114a that extends into the proximal end 110a of the container 110. The driver 114 comprises a gasket 114b disposed in the syringe barrel 110 at a distal end of the plunger rod 114a. The gasket 114b forms a seal with an interior surface of the container 110 that prevents the therapeutic agent 116 from escaping past the gasket 114b along a proximal direction, opposite the distal direction. The driver 114 can be operated by a user applying a manual force to a proximal end of the driver 114 to move the driver 114 in the-41- 103693.007823\4927-3677-6616.1distal direction to drive the therapeutic agent 116 from the container 110 and out of the discharge nozzle 112.
[0217] Optionally, the injection device 102 can comprise a cap 118. Fluid flow between the discharge nozzle 112 and the container 110 can be enabled by removing a cap 118 from the discharge nozzle 112. In operation, a user such as the subject or a healthcare provider can remove the cap 118 from the discharge nozzle 112, insert the discharge nozzle 112 into a subcutaneous layer of the subject, and actuate the diver 114 to drive the contents of the injection device 110 from the container 110 and out of the discharge nozzle 112.
[0218] In the example shown in FIG. 11, the injection device 102 is a pre-filled syringe that is preloaded with the therapeutic agent 116 prior to delivery of the pharmaceutical product 100 to a subject or healthcare provider. In other examples, the pharmaceutical product 100 can be in the form of a kit that comprises the injection device 102, and a separate container (not shown) that is separate from the injection device 102, wherein the separate container contains the therapeutic agent 116 disposed therein. The separate container can be any suitable container such as (without limitation) a vial, cartridge, syringe, or bag. In such examples, a health care provider or the subject can introduce a volume of the therapeutic agent 116 into the container 110 by inserting the discharge nozzle 112 into the separate container containing the therapeutic agent 116, and withdrawing the driver 114 along the proximal direction to draw the therapeutic agent 116 from container, through the discharge nozzle 112, and into the container 110. In yet still other examples, the pharmaceutical product 100 can be in the form of a kit that comprises the therapeutic agent 116, the injection device 102, and at least one other injection device 102, where a dose of the therapeutic agent 116 is divided between the injection device 102 and the at least one other injection device 102 prior to delivery to the subject or healthcare provider, or is divided by the subject or healthcare provider.
[0219] In some examples, the therapeutic agent 116 can comprise a weekly dose from about 400 mg to about 600 mg of nipocalimab, such as about 460 mg of nipocalimab. The therapeutic agent 116 can comprise a formulation having a concentration of about 230 mg / ml. The weekly dose of the therapeutic agent 116 has a volume from 1.4mL to 2.5mL, such as a volume of about 2.09mL ± 0.25mL. The container 110 can define a volume of at least 2.0mL, such as at least-42- 103693.007823\4927-3677-6616.12.1mL, such as at least 2.2mL, such as at least 2.5 mL that contains the dose of the therapeutic agent 116. The injection device 102 is configured to deliver at least 1.4mL of the therapeutic agent 116 to the subject. In some examples, the injection device 102 is configured to deliver 2.09mL ± 0.025mL to the subject.
[0220] Referring to FIG. 13, a pharmaceutical product 200 is shown according to one example in which the subcutaneous pharmaceutical injection device 202 is an autoinjector. The pharmaceutical product 200 comprises the injection device 202 and a therapeutic agent 116. The pharmaceutical injection device 202 comprises a container 210 in the form of a cartridge that contains the therapeutic agent 116. In alternative examples, the pharmaceutical product 200 can comprise a container 210 in the form of a syringe barrel 110 as shown in FIG. 14 in which corresponding features are labeled using the same reference labels. The container 110 has a proximal end 210a and a distal end 210b. The proximal end 210a defines an opening to receive a driver 214 therein. The distal end 210b can be offset from the proximal end 210a along a central axis along a distal direction. The container 210 contains the therapeutic agent 116 therein. The distal end 210b of the container 210 comprises a head 211 with a septum disposed therein that prevents the therapeutic agent 116 from escaping in the distal direction until the septum is pierced by a piercing nozzle. The container 210 can comprise a gasket 222 disposed in the cartridge 210. The gasket 222 forms a seal with an interior surface of the container 210 that prevents the therapeutic agent 116 from escaping past the gasket 222 along a proximal direction, opposite the distal direction.
[0221] The injection device 202 comprises a discharge nozzle 112 which can be in the form of a subcutaneous injection needle or catheter. The injection needle can be a 25 gage, 26 gage, or 27 gage needle. For instance, the injection device 202 can comprise an abutment surface that is configured to abut a subject’s skin while the therapeutic agent is delivered to the subject, and the discharge nozzle 112 can extend from the abutment surface by a distance in a range from 4.5mm to 8.5mm, such as in a range from 5mm to 8mm, such as in a range from 5.5mm to 7.5mm, such as in a range from 6mm to 7mm, such as by a distance of 6.5mm, when the abutment surface is pressed against the skin. In one example, the abutment surface can be at the distal end 230 of a housing 230 of the injection device 202.-43- 103693.007823\4927-3677-6616.1
[0222] The injection device 202 comprises a septum-piercing nozzle 212 that is configured to move so as to pierce the septum of the cartridge 210, thereby placing the discharge nozzle 112 in fluid communication with the therapeutic agent 116. For example, pressing a sleeve 234 of the injection device 202 against a subject’s skin can cause the septum-piercing nozzle 212 to move proximally to pierce the septum. The septum-piercing nozzle 212 can be a needle. In some examples, the septum-piercing nozzle 212 and the discharge nozzle 112 can be opposing ends of a double-sided needle. In other examples, as shown in FIG. 14, the injection device 202' can be devoid of a septum-piercing nozzle, and instead, the discharge nozzle 112 can extend from the container 110.
[0223] The injection device 202 comprises a driver 213. The driver 213 comprises a plunger 214 that extends into the proximal end 210a of the container 210. The driver 213 comprises a motive force device 227 that is configured to apply a motive force to the plunger 214 to move the plunger 214 in the distal direction to drive the therapeutic agent 216 from the container 210 and out of the discharge nozzle 112. The motive force device 227 comprises a spring, although the motive force device could alternatively comprise a motor, a compressed gas canister, a hydraulic actuator, a pneumatic actuator, any other suitable motive force device, or any combination thereof.
[0224] The injection device 202 comprises a latch 251 that is configured to transition between a latched position in which the driver 213 is prevented causing the plunger 214 to move, and an unlatched position in which the plunger 214 is permitted to move. The injection device 202 can comprise an actuator that is configured to transition the latch 251 between the latched position and the unlatched position. The actuator can be any suitable actuator. In one example, the actuator can be a button that is depressed by a user. In another example, the actuator can be a sleeve 241 of the housing 230.
[0225] The housing 230 houses the container 116 and the driver 213 therein. The housing 230 comprises a main body 232 and the sleeve 234 that is retractable relative to the main body 232. In particular, pressing the sleeve 234 against the skin of the subject can cause the sleeve 234 to retract relative to the main body 232. As discussed above, in some examples, the sleeve 234 can be an actuator that causes the latch 251 to transition between the latched position and the-44- 103693.007823\4927-3677-6616.1unlatched position when the sleeve 234 is retracted. In some examples, the sleeve 234 can be a needle guard that is configured to transition between an initial position in which a distal end of the discharge nozzle 112 is contained within the sleeve 234, and a retracted position in which the distal end of the discharge nozzle 112 extends from sleeve 234. The sleeve 234 can be transitioned between the initial and retracted positions by pressing the sleeve 234 against the subject’s skin. As the sleeve 234 transitions to the retracted position, the discharge nozzle 112 is inserted into the subject’s skin.
[0226] A distal end of the housing 230 can define the abutment surface. For instance, a distal end of the sleeve 234 can define the abutment surface such that, when the sleeve 234 is in the retracted position, the discharge nozzle 112 extends from the abutment surface by a distance in the range discussed above. The sleeve 234 can be configured to transition from the retracted potion to an extended position in which the distal end of the discharge nozzle 112 is contained within the sleeve 234 after the injection device 202 is removed from the subject’s skin. For example, the injection device 202 can comprise a return spring 242 that is configured to bias the sleeve 234 towards the extended position. The injection device 202 can comprise a latch that is configured lock the sleeve 234 in the extended position so as to guard against inadvertent needle sticks.
[0227] In alternative examples, the sleeve 234 does not serve as a needle guard, and instead, the container 210 can be configured to move within the housing 230 relative to the main body 232 between an initial position in which a distal end of the discharge nozzle 112 is contained within the housing 230, and a retracted position in which the distal end of the discharge nozzle 112 extends from the housing 230. In such examples, the sleeve 234 can retract a sufficient amount to transition the latch 251 between the latched position and the unlatched position, without exposing the full length of the discharge nozzle 112.
[0228] In some examples, the therapeutic agent 116 can comprise a weekly dose from about 400 mg to about 600 mg of nipocalimab, such as about 460 mg of nipocalimab. The weekly dose of the therapeutic agent 116 has a volume from 1.4mL to 2.5mL, such as a volume of about 2.09mL ± 0.25mL. The injection device 202 is configured to deliver at least 1.4mL of the therapeutic agent 116 to the subject. The container 110 can define a volume of at least 2.0mL,-45- 103693.007823\4927-3677-6616.1such as at least 2.1mL, such as at least 2.2mL, such as at least 2.5mL that contains the weekly dose of the therapeutic agent 116. To deliver the weekly dose, the driver has a drive force that drives the therapeutic agent out of the discharge nozzle and into air at a rate from 0.09mL / second to 0.3mL / second.
[0229] The injection device 200 can be configured to deliver the therapeutic agent 116 out of the discharge nozzle 112 such that no particulate matter generated during piercing of the septum is discharged from the discharge nozzle 112 that has a particle diameter >150 pm. For instance, in some examples, the injection device 202 can comprise a filter in a flow path that extends from the container 210 (or 110) to a distal end of the discharge nozzle 112.
[0230] While the foregoing description relates to one example of an autoinjector, the present invention is not limited to such an autoinjector. The skilled person would understand that various other modifications to the described autoinjector may be used with the present invention. For example, the autoinjector may be gas powered, electrically powered, or powered by a torsion spring.
[0231] Turning to FIGs. 15 to 17, a pharmaceutical product 300 is shown according to one example in which the subcutaneous pharmaceutical injection device 302 is a patch pump or on-body delivery system (OBDS). The pharmaceutical product 300 comprises the injection device 302, a container 210, and a therapeutic agent 116. The injection device 302 has a housing 303 that can support, such as house, a container 210 that contains the therapeutic agent 116. The container 210 can be a cartridge as shown. Alternatively, the container 210 can be a syringe, a vial, an expandable bladder, or any other suitable container for containing the therapeutic agent 116. The housing 303 can support, such as house, other components of the injection device 302, such as a driver, a discharge nozzle 112, a septum piercing mechanism, control circuitry, a nozzle insertion mechanism, or any combination thereof. The driver is configured to drive the therapeutic agent 116 from the container 210 and out of the discharge nozzle 112. The driver can comprise one or more plungers, one or more springs, one or more motors, one or more compressed gas canisters, one or more hydraulic drivers, one or more pneumatic actuators, one or more other suitable drivers for driving the therapeutic agent from the container, or any combination thereof.-46- 103693.007823\4927-3677-6616.1
[0232] The housing 303 can be configured to support, such as house, at least a portion up to an entirety of the container 210 therein. The housing 303 can be configured to receive, and in some cases removably receive, the drug container 210. Thus, the container 210 can be insertable into and / or removable from the housing 303. The housing 303 can define an opening 306 therein that is configured to receive the container 210 at least partially or fully into the housing 303. In some examples, the housing 303 can comprise a closure 308, such as a cap or a door, that is configured to close at least a portion of the opening 306 to maintain the container 210 in the opening 306. The opening 306 can be configured such that the drug container 210 is received into the opening 306 along an insertion direction I. The insertion direction I can be transverse to a longitudinal axis of the drug container 210 as shown or can be aligned with the longitudinal axis of the drug container 210. In other examples, the housing 303 can be devoid of the opening 306 and closure 308, and the container 210 can be sealed within the housing 303.
[0233] The drug delivery device housing 303 can have a bottom 303a and an opposing top 303b that are opposite from one another along a first direction DI. The injection device 302 is configured such that the bottom 303a faces the skin of the subject when the injection device 302 is attached to the subject. The housing 303 can have a first side 303c and a second side 303d opposite from one another along a second direction D2. The first and second sides 303 c and 303d can extend between the bottom 303a and the top 303b. The housing 303 can have a first end 303e and a second end 303f that are opposite one another along a third direction D3. The first and second ends 303e and 303f can extend between the first and second sides 303 c and 303 d and between the bottom 303 a and bottom 303b. The opening 306 can extend into the top 303b. In alternative examples, the opening can extend into another suitable surface or surfaces, such as one or more of the bottom 303 a, the first side 303 c, the second side 303 d, the first end 303e, and the second end 303f.
[0234] The injection device 202 comprises a discharge nozzle 112 which can be in the form of a subcutaneous injection needle or catheter. The injection needle can be a 25 gage, 26 gage, or 27 gage needle. For instance, the discharge nozzle 112 can extend from the bottom 303a of the housing 303 by a distance in a range from 4.5mm to 8.5mm, such as in a range from 5mm to 8mm, such as in a range from 5.5mm to 7.5mm, such as in a range from 6mm to 7mm, such as by a distance of 6.5mm, when the abutment surface is pressed against the skin.-47- 103693.007823\4927-3677-6616.1
[0235] The injection device 302 comprises a fastener 304 configured to attach the housing 303 to a subject’s body. The fastener 304 can be any suitable fastener for attaching to a subject’s body, such as (without limitation) an adhesive, including a tape with adhesive, a strap, or other suitable fastener. The fastener 304 can be supported by the bottom 303a of the housing 303.
[0236] Turning now to FIG. 18, a simplified schematic of the drug product 300 of FIGs. 13 to 15 is shown according to one example. The delivery device 302 comprises a driver 313 configured to drive the therapeutic agent 116 from the container 210 out of the discharge nozzle 112. The driver 313 can be any suitable driver for expelling the therapeutic agent 116 from the drug container 200. The driver 313 can comprise a plunger 314 that is configured to move the gasket 222 of the container 210 to drive the therapeutic agent 116 from the container 210. The driver 313 can comprise a motive force device 315 that is configured to cause the plunger 314 to move the gasket 222. The motive force device 315 can be any suitable device for moving the plunger 314. For example, the motive force device 315 can be (without limitation) a motor, a spring, a hydraulic actuator, a pneumatic actuator, a compressed gas canister, any other suitable motive force device, or any combination thereof. In the example of FIG. 18, the motive force device 315 is a motor that is controlled by control circuitry 328.
[0237] The injection device 302 can comprise a septum piercing needle 312 that is configured to pierce the septum of the container 210. At least one of the septum piercing needle 312 and the container 210 can be configured to move towards the other to cause the piercing needle 312 to pierce the septum. The injection device 302 can comprise a septum piercing mechanism 318 that is configured to cause the least one of the septum piercing needle 312 and the container 210 to move towards the other to cause the piercing needle 312 to pierce the septum. The septum piercing mechanism 318 can comprise any suitable driver for piercing the septum such as (without limitation) a motor, a spring, a hydraulic actuator, a pneumatic actuator, a compressed gas canister, any other suitable driver, or any combination thereof. Piercing the septum places the septum piercing needle 312 in fluid communication with the therapeutic agent 116 contained within the container 210. The injection device 302 can be configured to deliver the therapeutic agent 116 out of the discharge nozzle 112 such that no particulate matter generated during piercing of the septum is discharged from the discharge nozzle 112 that has a particle diameter >150 pm. For instance, in some examples, the injection device 302 can comprise a-48- 103693.007823\4927-3677-6616.1filter in a flow path that extends from the container 210 to a distal end of the discharge nozzle 112, such as between the septum piercing needle 312 and the distal end of the discharge nozzle 112.
[0238] The injection device 302 can comprise a conduit 320, such as tubing, that fluidly connects the septum piercing needle 312 to the discharge nozzle 112. Thus, piercing the septum can place the discharge nozzle 112 in fluid communication with the therapeutic agent 116 contained within the container 210 via the septum piercing needle 312 and the conduit 320.
[0239] The injection device 302 can comprise a nozzle insertion mechanism 322 that is configured to cause the discharge nozzle 112 to be inserted into a subject, such as into a subject’s skin. The nozzle insertion mechanism 322 can be configured to cause the discharge nozzle 112 to extend out of the housing 303 (labeled in FIGs. 15 to 17) of the injection device 302 and into the subject. In some examples, the nozzle insertion mechanism 322 can be configured to cause the discharge nozzle 112 to retract back into the housing after injection. The nozzle insertion mechanism 322 can comprise any suitable driver for inserting the discharge nozzle 112 into the subject’s skin, such as (without limitation) a motor, a spring, a hydraulic actuator, a pneumatic actuator, a compressed gas canister, any other suitable motive force device, or any combination thereof. Additionally, or alternatively, the injection device 302 can comprise a needle guard (not shown) that extends over the discharge nozzle 112 after injection. Retracting and / or covering the discharge nozzle 112 after injection can prevent inadvertent needle sticks and / or limit human contact with biological materials remaining on the discharge nozzle 112.
[0240] The injection device 302 can comprise control circuitry 328 that is configured to control various features of the injection device 302. For example, the control circuitry 328 can be configured to control operation of the driver 313. The control circuitry 328 can be configured to cause the driver 313 to begin driving the therapeutic agent 116 from the container 210. The control circuitry 328 can be configured to control the flow rate in which the therapeutic agent 116 is driven from the container 210. The control circuitry 328 can be configured to cause the driver 313 to stop driving the therapeutic agent 116 when an injection is complete and / or when an error is detected during the injection. The control circuitry 328 can also be configured to-49- 103693.007823\4927-3677-6616.1control operation of the nozzle insertion mechanism 322 to cause the discharge nozzle 112 to be inserted into the subject before injection and / or removed from the subject after injection.
[0241] The injection device 302 can comprise a user interface 324 that is configured to be engaged by a user such as a health care provider or subject to operate the injection device 302. The user interface 324 can comprise an input device that is configured to receive commands and / or instructions from the user. For example, the input device can be a button, a touchscreen, or other input device that is engaged by the user to begin an injection. As another example, the input device can be an audio input device.
[0242] The user interface 324 can be configured to provide information to a user of the injection device 302. The user can be, for example, a subject, or a subject’s care giver or health care professional assisting the subject in using the injection device 302. The user interface 324 can have a variety of configurations, and the injection device 302 can include a single type of user interface or can include more than one type of user interface. For example, the user interface 324 can include one or more lights, e.g., a light emitting diode (LED) or other type of light, configured to illuminate to provide various information. Examples of the information indicated by the user interface 324 include power (on / off) status, error state (e.g., low power supply, improper nozzle advancement into the subject, incompatible type of container 210 loaded into the injection device 302, etc.), drug delivery status (e.g., indication that drug delivery is currently occurring), drug delivery progress information, an orientation of the injection device 302 relative to gravity, an indication of a dose of the therapeutic agent 116 to be provided in each delivery of the therapeutic agent 116 to the subject, and any other suitable type of information.
[0243] As another example, the user interface 324 can include a display configured to show information thereon, such as by using text and / or graphics. The display can include a display screen having any of a variety of configurations, such as a cathode ray tube (CRT), a liquid crystal display (LCD), a touchscreen, etc. As yet another example, the user interface 324 can include a vibration mechanism configured to vibrate with the vibration being configured to be felt by the subject wearing the injection device 302. As still another example, the user interface 324 can include a speaker configured to provide an audio signal. As another example, the user-50- 103693.007823\4927-3677-6616.1interface 324 can include a mechanical level configured to indicate an orientation of the injection device 302 relative to gravity.
[0244] In some examples, the therapeutic agent 116 can comprise a weekly dose from about 400 mg to about 600 mg of nipocalimab, such as about 460 mg of nipocalimab. The therapeutic agent 116 can comprise a formulation having a concentration of about 230 mg / ml. The weekly dose of the therapeutic agent 116 has a volume from 1.4mL to 2.5mL, such as a volume of about 2.09mL ± 0.25mL. The container 210 can define a volume of at least 2.0mL, such as at least 2.1mL, such as at least 2.2mL, such as at least 2.5 mL that contains the dose of the therapeutic agent 116. The injection device 302 is configured to deliver at least 1.4mL of the therapeutic agent 116 to the subject. In some examples, the injection device 102 is configured to deliver 2.09mL ± 0.025mL to the subject.
[0245] Referring now to FIG. 19, a simplified schematic of the drug product 300 of FIGs.15 to 17 is shown according to another example. In this example, the container 210 is shown as a cartridge, although in alternative examples, the container could be another suitable container such as a vial. Unlike the example drug injection device 302 of FIG. 18 in which the driver 313 acts on the gasket 222 of the container 210, the example drug injection device 302 of FIG. 19 has a pump 450 that is configured to drive the therapeutic agent 116 from the container 210. The injection device 300 can comprise a conduit 430, such as tubing, that fluidly couples the pump 450 to the container 210, e.g., via the septum piercing needle 312. The pump 450 can be configured to apply a suction to the container 210 to draw the therapeutic agent 116 from the container 210 into a pump chamber 434 of the pump 450, and then drive the therapeutic agent 116 from the pump chamber 434 to the discharge nozzle 112.
[0246] The pump 450 can be any suitable pump. In this specific example, the pump 450 is shown as a piston pump. The pump 450 comprises the pump chamber 434, a driver 413, an inlet valve 432, and an outlet valve 436. The driver 413 comprises a plunger 414 and a motive force device 415. The motive force device 415 can be (without limitation) a motor, a spring, a hydraulic actuator, a pneumatic actuator, a compressed gas canister, any other suitable motive force device, or any combination thereof. In the example of FIG. 19, the motive force device 415 is a motor that is controlled by control circuitry 328.-51- 103693.007823\4927-3677-6616.1
[0247] The pump 450 is configured such that the motive force device 415 moves the plunger 414 in a reciprocating manner. In a first pumping phase, the control circuitry 328 is configured to drive the plunger 414 (e.g., slidably move the plunger 414 within the pump chamber 434) to draw the therapeutic agent 116 from the container 210 into the conduit 430, then through an inlet valve 432 and into the pump chamber 434. The inlet valve 432 is configured to be opened and closed such that when the inlet valve 324 is open there is fluid communication between the container 210 and the pump chamber 434, and when the inlet valve 432 is closed there is no fluid communication between the container 210 and the pump chamber 434. During the first pumping phase, the control circuitry 328 is configured to cause the inlet valve 432 to open, cause an outlet valve 436 to close, and drive the plunger 434 to draw the therapeutic agent 116 from the container 210 into the pump chamber 434. For instance, the control circuitry 328 is configured to set the inlet valve 432 and the outlet valve 436 such that the therapeutic agent 116 can flow only between the container 210 and the pump chamber 434. Thus, as the plunger 414 is drawn back, the therapeutic agent 116 is drawn into pump chamber 434. The control circuitry 328 causing the inlet valve 432 to open and the outlet valve 436 to close can be active control or can be passive control in which the valves 432, 436 are mechanical valves that automatically open / close due to the driving of the plunger 414.
[0248] In some instances, the control circuitry 328 is configured to drive the plunger 414 to draw the therapeutic agent 116 into the pump chamber 434 in a single motion of the plunger 414. For example, the plunger 414 is pulled back in a single motion to draw a volume of the therapeutic agent 116 into the pump chamber 434 during the first pumping phase. In other instances, the control circuitry 328 is configured to drive the plunger 414 to draw the therapeutic agent 116 into the pump chamber 434 in a plurality of discrete motions of the plunger 414. For example, the plunger 414 is incrementally pulled back into the pump chamber 434 in a plurality of discrete motions thereby drawing the therapeutic agent 116 into the pump chamber 434 in a plurality of discrete dosages. For instance, the plunger 414 can be pulled halfway into the pump chamber 434 in one motion and then the rest of the way into the pump chamber 434 in a second, separate motion.
[0249] In a second pumping phase, the control circuitry 328 is configured to drive the plunger 414 to deliver the therapeutic agent 116 from the pump chamber 434 through the outlet-52- 103693.007823\4927-3677-6616.1valve 436 to an outlet fluid path 438 and then to the discharge nozzle 112 for delivery into the subject. The outlet valve 436 is configured to be opened and closed such that when the outlet valve 436 is open, there is fluid communication between the pump chamber 434 and the discharge nozzle 112, and when the outlet valve 436 is closed, there is no fluid communication between the pump chamber 434 and the discharge nozzle 112. During the second pumping phase, the control circuitry 328 is configured to cause the inlet valve 432 to close, cause the outlet valve 436 to open, and drive the plunger 414 to deliver the therapeutic agent 116 from the pump chamber 434 to the discharge nozzle 112. For instance, the control circuitry 326 can be configured to set the inlet valve 432 and the outlet valve 436 such that the therapeutic agent 116 can flow only between the pump chamber 434 and the discharge nozzle 112. Thus, as the plunger 414 is pushed into the pump chamber 434, the therapeutic agent 116 is pushed out of the pump chamber 434. Similar to that discussed above, the control circuitry 328 causing the inlet valve 432 to close and the outlet valve 436 to open can be active control or can be passive control in which the valves 432, 436 are mechanical valves that automatically open / close due to the driving of the plunger 414.
[0250] In some examples, the control circuitry 328 is configured to drive the plunger 414 to drive the therapeutic agent 116 from the pump chamber 434 in a single motion. For instance, the plunger 414 is pushed into the pump chamber 434 in a single motion to drive a volume of the therapeutic agent 116 from the pump chamber 434 to the discharge nozzle 112. Alternatively, the control circuitry 36 can be configured to drive the plunger 34 to drive the therapeutic agent 116 from the pump chamber 28 in one or more discrete expansion motions of the plunger 414. For instance, the plunger 414 can be pushed halfway into of the pump chamber 434 in one motion and then the rest of the way into the pump chamber 434 in a second, separate motion.
[0251] The injection device 302 can be configured to deliver the therapeutic agent 116 out of the discharge nozzle 112 such that no particulate matter generated during piercing of the septum is discharged from the discharge nozzle 112 that has a particle diameter >150 pm. For instance, in some examples, the injection device 302 can comprise a filter in a flow path that extends from the container 210 to a distal end of the discharge nozzle 112, such as between the septum piercing needle 312 and the pump 450 or between the pump 450 and the discharge nozzle 112.-53- 103693.007823\4927-3677-6616.1
[0252] In some examples, the therapeutic agent 116 can comprise a weekly dose from about 400 mg to about 600 mg of nipocalimab, such as about 460 mg of nipocalimab. The therapeutic agent 116 can comprise a formulation having a concentration of about 230 mg / ml. The weekly dose of the therapeutic agent 116 has a volume from 1.4mL to 2.5mL, such as a volume of about 2.09mL ± 0.25mL. The container 210 can define a volume of at least 2.0mL, such as at least 2.1mL, such as at least 2.2mL, such as at least 2.5 mL that contains the dose of the therapeutic agent 116. The injection device 302 is configured to deliver at least 1.4mL of the therapeutic agent 116 to the subject. In some examples, the injection device 302 is configured to deliver 2.09mL ± 0.025mL to the subject.
[0253] The present disclosure provides a pharmaceutical product, comprising:a therapeutic agent, comprising from about 400 mg to about 600 mg of nipocalimab; anda subcutaneous injection device, comprising:a container configured to contain the therapeutic agent;a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously; anda driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.
[0254] In some embodiments, the therapeutic agent has a volume from about 1.4 mL to 2.5 mL.
[0255] In some embodiments, the therapeutic agent has a volume of about 2.09mL ± 0.25mL.
[0256] In some embodiments, the subcutaneous injection device is an autoinjector.
[0257] In some embodiments, the driver has a drive force that drives the therapeutic agent out of the discharge nozzle and into air at a rate from 0.09mL / second to 0.3mL / second.-54- 103693.007823\4927-3677-6616.1
[0258] In some embodiments, the subcutaneous injection device comprises a skin-contacting surface that contacts skin of the subject during an injection, and the discharge nozzle is a needle that (i) extends beyond the skin-contacting by about 6.5mm + 1mm when the drug is delivered to the subject, and / or (ii) has a needle gage from 23Gto 27G, or both (i) and (ii).
[0259] In some embodiments, the pharmaceutical product is disposed in the container.
[0260] In some embodiments, the therapeutic agent comprises 200 mg / mL to 250 mg / mL nipocalimab.
[0261] In some embodiments, the therapeutic agent comprises from about 400 mg to about 500 mg of nipocalimab.
[0262] In some embodiments, the therapeutic agent comprises about 460 mg of nipocalimab.
[0263] It should be noted that the illustrations and descriptions of the examples and embodiments shown in the figures are for exemplary purposes only and should not be construed limiting the disclosure. One skilled in the art will appreciate that the present disclosure contemplates various embodiments. Additionally, it should be understood that the concepts described above with the above-described examples and embodiments may be employed alone or in combination with any of the other examples and embodiments described above. It should further be appreciated that the various alternative examples and embodiments described above with respect to one illustrated embodiment can apply to all examples and embodiments as described herein, unless otherwise indicated.
[0264] Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and / or steps. Thus, such conditional language is not generally intended to imply that features, elements, and / or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features,-55- 103693.007823\4927-3677-6616.1elements and / or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.
[0265] While certain example embodiments have been described, these embodiments have been presented by way of example only and are not intended to limit the scope of the inventions disclosed herein. Thus, nothing in the foregoing description is intended to imply that any particular feature, characteristic, step, module, or block is necessary or indispensable. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms; furthermore, various omissions, substitutions, and changes in the form of the methods and systems described herein may be made without departing from the spirit of the inventions disclosed herein. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of certain of the inventions disclosed herein.
[0266] It will be understood that reference herein to “a” or “one” to describe a feature such as a component or step does not foreclose additional features or multiples of the feature. For instance, reference to a device having or defining “one” of a feature does not preclude the device from having or defining more than one of the feature, as long as the device has or defines at least one of the feature. Similarly, reference herein to “one of’ a plurality of features does not foreclose the invention from including two or more, up to all, of the features. For instance, reference to a device having or defining “one of a protrusion and a recess” does not foreclose the device from having both the protrusion and the recess.Embodiments:Embodiments Section I:1. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn agent to the subject.-56- 103693.007823\4927-3677-6616.12. The method of embodiment 1, wherein the anti-FcRn agent is administered every week, every two weeks, every three weeks, or monthly.3. The method of embodiment 1 or 2, wherein the anti-FcRn agent is nipocalimab, rozanolixizumab, batoclimab, IMVT-1402, efgartigimod, SYNT001, SYNT002, ABY-039, or DX-2507.4. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered at a dose from about 5 mg / kg to about 45 mg / kg, about 5 mg / kg to about 15 mg / kg, about 15 mg / kg to about 45 mg / kg, or about 30 mg / kg to about 45 mg / kg based on the weight of the subject.5. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered at a dose of about 5 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 45 mg / kg based on the weight of the subject.6. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered intravenously or subcutaneously.7A. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is an anti-FcRn antibody comprising:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8.7B. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is an anti-FcRn antibody comprising:-57- 103693.007823\4927-3677-6616.1(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8.8. The method of embodiment 7, wherein (a) the light chain of the anti-FcRn antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9; and (b) the heavy chain of the anti-FcRn antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10.9. The method of embodiment 7 or embodiment 8, wherein (a) the light chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 1; and (b) the heavy chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 2.10. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is nipocalimab.11. The method of any one of the preceding embodiments, wherein nipocalimab is administered every two weeks intravenously at 10-30 mg / kg based on the weight of the subject.12. The method of any one of the preceding embodiments, wherein nipocalimab is administered every two weeks intravenously at 15 mg / kg based on the weight of the subject.13. The method of any one of embodiments 1-9, wherein nipocalimab is administered every week subcutaneously at 200-1000 mg.14. The method of any one of embodiments 1-9 or 13, wherein nipocalimab is administered every week subcutaneously at 400-600 mg.15. The method of any one of embodiments 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 460 mg or 518 mg.-58- 103693.007823\4927-3677-6616.116. The method of any one of embodiments 1-9 or 13-15, wherein nipocalimab is administered via an autoinjector.17. The method of any one of the preceding embodiments, wherein the subject has a SLEDAI-2K score over 4, 5, or 6 before initiation of said administering.18. The method of any one of the preceding embodiments, wherein the subject has a BILAG-2004 index score equal to or over 1 BILAG A score before initiation of said administering.19. The method of any one of the preceding embodiments, wherein the subject has a BILAG-2004 index score equal to or over 2 BILAG B score before initiation of said administering.20. The method of any one of the preceding embodiments, wherein the subject has a CLASI activity score equal to or over 6 before initiation of said administering.21. The method of any one of the preceding embodiments, wherein the subject has at least 4 active joints before initiation of said administering.22. The method of embodiments 20 or 21, wherein the subject is seropositive for antinuclear antibodies (ANA).23. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-dsDNA antibodies before initiation of said administering.24. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-Smith antibodies before initiation of said administering.25. The method of any one of the preceding embodiments, wherein the subject is seropositive for antinuclear antibodies (ANA) and at least one of: 1) is seropositive for anti-RO52 and / or anti-RO60 antibodies; 2) is seropositive for anti-La antibodies; 3) is seropositive for anti-RNP antibodies; and 4) has historical evidence of being seropositive for anti-dsDNA antibodies, before initiation of said administering.26. The method of any one of the preceding embodiments, wherein the subject is seropositive for antinuclear antibodies (ANA) and has low C3 and / or C4 levels.-59- 103693.007823\4927-3677-6616.127. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-RO52 antibodies and anti-RO60 antibodies, and is seronegative for anti-La antibodies.28. The method of any one of the preceding embodiments, wherein the subject has a seropositive type I interferon (IFN-I) gene signature.29. The method of embodiment 28, wherein the subject has a positive IFN-I gene signature when a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in a biological sample from the subject is equal to or higher than a threshold value.30. The method of embodiment 28, wherein the biological sample is a blood sample or a tissue sample.31. The method of embodiment 29 or embodiment 30, wherein the gene expression is assayed using quantitative Polymerase Chain Reaction (qPCR), RNA sequencing, or microarray.32. The method of any one of embodiments 29-31, wherein gene expression is measured at the mRNA level.33. The method of any one of embodiments 29-32, wherein the combined expression value is a sum of normalized threshold cycle (CT) values (SUMΔCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L.34. The method of embodiment 33, wherein the threshold value is SUMΔCT of genes DHX58, EIF2AK2,HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.35. The method of embodiment 33 or 34, wherein the threshold value is SUMΔCT of 57.474.36. The method of any one of embodiments 29-32, wherein the combined expression value is a sum of log2 fold changes of normalized differential expression between the biological sample and a biological sample obtained from one or more healthy subjects of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L ((SUMlog2(2-ddCT)).-60- 103693.007823\4927-3677-6616.137. The method of embodiment 36, wherein the threshold value is SUMlog2(2^-ddCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.38. The method of embodiment 36 or embodiment 37, wherein the threshold value is SUMlog2(2^-ddCT) of 8.725.39. The method of any one of embodiments 29-32, wherein the combined expression value is a POISE Score of Formula I:POISE Score = 70- 143.7251664- SUMlog2(2A’ddCT)| (Formula I)40. The method of embodiment 37, wherein the threshold value is the POISE Score of between 30 and 40.41. The method of embodiment 37 or embodiment 38, wherein the threshold value is the POISE score of 35.42. The method of embodiment 28, wherein the subject has a positive IFN-I gene signature based on immune profile test of a blood sample from the subject.43. The method of embodiment 42, wherein the subject has a positive IFN-I gene signature based on immune profile test when a combined expression value of the genes HERC5, IF127, IFIT1, and RSAD2 is equal to or higher than a threshold value.44. The method of embodiment 33, wherein the threshold value is based on the expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 of one or more healthy subjects.40. The method of any one of the preceding embodiments, wherein the subject receives glucocorticoid at a first dose before initiation of said administering, and the method provides a clinical benefit as indicated by the subject receives glucocorticoid at a second dose that is lower than the first dose within 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52 weeks or more weeks of initiation of said administering.41. The method of embodiment 40, wherein the first dose is 20 mg per day or higher.-61- 103693.007823\4927-3677-6616.142. The method of embodiment 25, wherein the second dose is 7.5 mg per day or lower.43. The method of embodiment 25, wherein the first dose is 30 mg per day or higher.44. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a decrease in SLE Disease Activity Index 2K (SLEDAI-2K) in the subject by more than 4, 5, 6, 7, 8 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.45. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving SLEDAI-2K Responder Index (SRI)-4 within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.46. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a decrease in CLASI-activity score in the subject by more than 40%, 50%, 60%, 70%, 80% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.47. The method of embodiment 46, wherein the subject has a CLASI-activity score of >=6, 8, 10, 12 at baseline.48. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a reduction in active joint counts in the subject by more than 50%, 60%, 70% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.49. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving Lupus Low Disease Activity State (LLDAS) within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.50. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by an improvement in Bodily Pain Score SF-36 score in the subject by more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.-62- 103693.007823\4927-3677-6616.151. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit in the subject as measured by an improvement of 1-3 points in Lupus Symptoms from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.52. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by an increase in FACIT Fatigue score in the subject by more than 3, 4, 5, 6 or points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.53. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving no moderate or severe British Isles Lupus Activity Group (BILAG) flare within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.54. The method of any one of the preceding embodiments, wherein the subject has a reduction in autoantibodies in the blood.55. The method of any one of the preceding embodiments, wherein the method does not significantly decrease level of albumin in the subject compared with baseline.56. The method of any one of the preceding embodiments, wherein the method does not significantly increase the level of serum total cholesterol in the subject compared with baseline.57A. A method of treating Systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;-63- 103693.007823\4927-3677-6616.1and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.57B. A method of treating Systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.58. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 460 mg.59. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 518 mg.60. A pharmaceutical product, comprising:a therapeutic agent, comprising from about 400 mg to about 600 mg of nipocalimab; and a subcutaneous injection device, comprising:a container configured to contain the therapeutic agent;a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously; anda driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.-64- 103693.007823\4927-3677-6616.161. The pharmaceutical product of embodiment 60, wherein the therapeutic agent has a volume from about 1.4 mL to 2.5 mL.62. The pharmaceutical product of embodiment 33, wherein the therapeutic agent has a volume of about 2.09mL ± 0.25mL.63. The pharmaceutical product of any one of embodiments 60-62, wherein the subcutaneous injection device is an autoinjector.64. The pharmaceutical product of any one of embodiments 60-63, wherein the driver has a drive force that drives the therapeutic agent out of the discharge nozzle and into air at a rate from 0.09mL / second to 0.3mL / second.65. The pharmaceutical product of any one of embodiments 60-64, wherein the subcutaneous injection device comprises a skin-contacting surface that contacts skin of the subject during an injection, and the discharge nozzle is a needle that (i) extends beyond the skin-contacting by about 6.5mm + 1mm when the drug is delivered to the subject, and / or (ii) has a needle gage from 23G to 27G, or both (i) and (ii).66. The pharmaceutical product of any one of embodiments 60-65, wherein the pharmaceutical product is disposed in the container.67. The pharmaceutical product of any one of embodiments 60-66, wherein the therapeutic agent comprises 200 mg / mL to 250 mg / mL nipocalimab.68. The pharmaceutical product of any one of embodiments 60-66, wherein the therapeutic agent comprises from about 400 mg to about 500 mg of nipocalimab.69. The pharmaceutical product of any one of embodiments 60-68, wherein the therapeutic agent comprises about 460 mg of nipocalimab.Embodiments Section II:1. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn agent to the subject.-65- 103693.007823\4927-3677-6616.12. The method of embodiment 1, wherein the anti-FcRn agent is administered every week, every two weeks, every three weeks, or monthly.3. The method of embodiment 1 or 2, wherein the anti-FcRn agent is nipocalimab, rozanolixizumab, batoclimab, IMVT-1402, efgartigimod, SYNT001, SYNT002, ABY-039, or DX-2507.4. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered at a dose from about 5 mg / kg to about 45 mg / kg, about 5 mg / kg to about 15 mg / kg, about 15 mg / kg to about 45 mg / kg, or about 30 mg / kg to about 45 mg / kg based on the weight of the subject.5. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered at a dose of about 5 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 45 mg / kg based on the weight of the subject.6. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is administered intravenously or subcutaneously.7A. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is an anti-FcRn antibody comprising:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8.7B. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is an anti-FcRn antibody comprising:-66- 103693.007823\4927-3677-6616.1(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8.8. The method of embodiment 7, wherein (a) the light chain of the anti-FcRn antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9; and (b) the heavy chain of the anti-FcRn antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10.9. The method of embodiment 7 or embodiment 8, wherein (a) the light chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 1; and (b) the heavy chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 2.10. The method of any one of the preceding embodiments, wherein the anti-FcRn agent is nipocalimab.11. The method of any one of the preceding embodiments, wherein nipocalimab is administered every two weeks intravenously at 10-30 mg / kg based on the weight of the subject.12. The method of any one of the preceding embodiments, wherein nipocalimab is administered every two weeks intravenously at 15 mg / kg based on the weight of the subject.13. The method of any one of embodiments 1-9, wherein nipocalimab is administered every week subcutaneously at 200-1000 mg.14. The method of any one of embodiments 1-9 or 13, wherein nipocalimab is administered every week subcutaneously at 400-600 mg.15. The method of any one of embodiments 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 460 mg or 518 mg.-67- 103693.007823\4927-3677-6616.116. The method of any one of embodiments 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 460 mg.17. The method of any one of embodiments 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 518 mg.18. The method of any one of embodiments 1-9 or 13-17, wherein nipocalimab is administered via an autoinjector.19. The method of any one of the preceding embodiments, wherein the subject has a SLEDAI-2K score over 4, 5, or 6 before initiation of said administering.20. The method of any one of the preceding embodiments, wherein the subject has a BILAG-2004 index score equal to or over 1 BILAG A score before initiation of said administering.21. The method of any one of the preceding embodiments, wherein the subject has a BILAG-2004 index score equal to or over 2 BILAG B score before initiation of said administering.22. The method of any one of the preceding embodiments, wherein the subject has a CLASI activity score equal to or over 6 before initiation of said administering.23. The method of any one of the preceding embodiments, wherein the subject has at least 4 active joints before initiation of said administering.24. The method of any one of the preceding embodiments, wherein the subject is seropositive for antinuclear antibodies (ANA) before initiation of said administering.25. The method of embodiments 22 or 23, wherein the subject is seropositive for antinuclear antibodies (ANA) before initiation of said administering.26. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-dsDNA antibodies before initiation of said administering.27. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-Smith antibodies before initiation of said administering.-68- 103693.007823\4927-3677-6616.128. The method of any one of the preceding embodiments, wherein the subject is seropositive for antinuclear antibodies (ANA) and at least one of: 1) is seropositive for anti-RO52 and / or anti-RO60 antibodies; 2) is seropositive for anti-La antibodies; 3) is seropositive for anti-RNP antibodies; and 4) has historical evidence of seropositive anti-dsDNA antibodies, before initiation of said administering.29. The method of any one of the preceding embodiments, wherein the subject meets at least one of the following criteria before initiation of said administering:a) seropositive for anti-dsDNA antibodies;b) seropositive for anti-Smith antibodies;c) seropositive for antinuclear antibodies (ANA)and at least one of:i) seropositive for anti-RO52 and / or anti-RO60 antibodies;ii) seropositive for anti-RNP antibodies; oriii) subject has historical evidence of seropositivity for anti-dsDNA antibodies.30. The method of any one of the preceding embodiments, wherein the subject is seropositive for antinuclear antibodies (ANA) and has low C3 and / or C4 levels, before initiation of said administering.31. The method of any one of the preceding embodiments, wherein the subject is seropositive for anti-RO52 antibodies and anti-RO60 antibodies, and is seronegative for anti-La antibodies, before initiation of said administering.32. The method of any one of the preceding embodiments, wherein the subject meets at least one of the following criteria before initiation of said administering:a) seropositive for anti-dsDNA antibodies, seropositive for anti -RO 52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies;-69- 103693.007823\4927-3677-6616.1b) seropositive for anti-Smith antibodies, seropositive for anti-RO52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies; orc) seropositive for ANA, seropositive for anti-RO52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies.33. The method of any one of the preceding embodiments, wherein the subject has a positive type I interferon (IFN-I) gene signature score, before initiation of said administering.34. The method of embodiment 33, wherein the subject has a positive IFN-I gene signature score when a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in a biological sample from the subject is equal to or higher than a threshold value.35. The method of embodiment 33, wherein the biological sample is a blood sample or a tissue sample.36. The method of embodiment 34 or embodiment 35, wherein the gene expression is assayed using quantitative Polymerase Chain Reaction (qPCR), RNA sequencing, or microarray.37. The method of any one of embodiments 34-36, wherein gene expression is measured at the mRNA level.38. The method of any one of embodiments 34-37, wherein the combined expression value is a sum of normalized threshold cycle (CT) values (SUMΔCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L.39. The method of embodiment 38, wherein the threshold value is SUMΔCT of genes DHX58, EIF2AK2,HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.40. The method of embodiment 38 or 39, wherein the threshold value is SUMΔCT of 57.474.41. The method of any one of embodiments 34-37, wherein the combined expression value is a sum of log2 fold changes of normalized differential expression between the biological sample-70- 103693.007823\4927-3677-6616.1and a biological sample obtained from one or more healthy subjects of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L ((SUMlog2(2-ddCT)).42. The method of embodiment 41, wherein the threshold value is SUMlog2(2^-ddCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.43. The method of embodiment 41 or embodiment 42, wherein the threshold value is SUMlog2(2^-ddCT) of 8.725.44. The method of any one of embodiments 34-37, wherein the combined expression value is a POISE Score of Formula I:POISE Score = 70- 143.7251664- SUMlog2(2A’ddCT)| (Formula I)45. The method of embodiment 42, wherein the threshold value is the POISE Score of between 30 and 40.46. The method of embodiment 42 or embodiment 43, wherein the threshold value is the POISE score of 35.47. The method of embodiment 33, wherein the subject has a positive IFN-I gene signature score based on immune profile test of a blood sample from the subject, before initiation of said administering.48. The method of embodiment 47, wherein the subject has a positive IFN-I gene signature score based on immune profile test when a combined expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 is equal to or higher than a threshold value.49. The method of embodiment 38, wherein the threshold value is based on the expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 of one or more healthy subjects.50. The method of any one of the preceding embodiments, wherein the subject receives glucocorticoid at a first dose before initiation of said administering, and the method provides a clinical benefit as indicated by the subject receives glucocorticoid at a second dose that is lower-71- 103693.007823\4927-3677-6616.1than the first dose within 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52 weeks or more weeks of initiation of said administering.51. The method of embodiment 50, wherein the first dose is 10 mg per day or higher.52. The method of embodiment 50, wherein the second dose is 5mg per day or lower.53. The method of embodiment 50, wherein the first dose is 20 mg per day or lower.54. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a decrease in SLE Disease Activity Index 2K (SLEDAI-2K) in the subject by more than 4, 5, 6, 7, 8 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.55. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving SLEDAI-2K Responder Index (SRI)-4 within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.56. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a decrease in CLASI-activity score in the subject by more than 40%, 50%, 60%, 70%, 80% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.57. The method of embodiment 56, wherein the subject has a CLASI-activity score of >=6, 8, 10, 12 at baseline.58. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by a reduction in active joint counts in the subject by more than 50%, 60%, 70% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.59. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving Lupus Low Disease Activity State (LLDAS) within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.-72- 103693.007823\4927-3677-6616.160. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by an improvement in Bodily Pain Score SF-36 score in the subject by more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.61. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit in the subject as measured by an improvement of 1-3 points in Lupus Symptoms from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.62. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by an increase in FACIT Fatigue score in the subject by more than 3, 4, 5, 6 or points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.63. The method of any one of the preceding embodiments, wherein the method provides a clinical benefit as measured by the subject achieving no moderate or severe British Isles Lupus Activity Group (BILAG) flare within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.64. The method of any one of the preceding embodiments, wherein the subject has a reduction in autoantibodies in the blood.65. The method of any one of the preceding embodiments, wherein the method does not significantly decrease level of albumin in the subject compared with baseline.66. The method of any one of the preceding embodiments, wherein the method does not significantly increase the level of serum total cholesterol in the subject compared with baseline.67A. A method of treating Systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:-73- 103693.007823\4927-3677-6616.1(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.67B. A method of treating Systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.68. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 460 mg.69. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 518 mg.-74- 103693.007823\4927-3677-6616.170. A pharmaceutical product, comprising:a therapeutic agent, comprising from about 400 mg to about 600 mg of nipocalimab; and a subcutaneous injection device, comprising:a container configured to contain the therapeutic agent;a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously; anda driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.71. The pharmaceutical product of embodiment 70, wherein the therapeutic agent has a volume from about 1.4 mL to 2.5 mL.72. The pharmaceutical product of embodiment 70, wherein the therapeutic agent has a volume of about 2.09mL ± 0.25mL.73. The pharmaceutical product of any one of embodiments 70-72, wherein the subcutaneous injection device is an autoinjector.74. The pharmaceutical product of any one of embodiments 70-73, wherein the driver has a drive force that drives the therapeutic agent out of the discharge nozzle and into air at a rate from 0.09mL / second to 0.3mL / second.75. The pharmaceutical product of any one of embodiments 70-74, wherein the subcutaneous injection device comprises a skin-contacting surface that contacts skin of the subject during an injection, and the discharge nozzle is a needle that (i) extends beyond the skin-contacting by about 6.5mm + 1mm when the drug is delivered to the subject, and / or (ii) has a needle gage from 23G to 27G, or both (i) and (ii).76. The pharmaceutical product of any one of embodiments 70-75, wherein the pharmaceutical product is disposed in the container.77. The pharmaceutical product of any one of embodiments 70-76, wherein the therapeutic agent comprises 200 mg / mL to 250 mg / mL nipocalimab.-75- 103693.007823\4927-3677-6616.178. The pharmaceutical product of any one of embodiments 70-76, wherein the therapeutic agent comprises from about 400 mg to about 500 mg of nipocalimab.79. The pharmaceutical product of any one of embodiments 70-78, wherein the therapeutic agent comprises about 460 mg of nipocalimab.-76- 103693.007823\4927-3677-6616.1EXAMPLESExample 1
[0267] This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of nipocalimab in adults 18 to 65 years old with autoantibody positive active SLE in addition to standard of care medication, including antimalarials, oral glucocorticoids (GCs) and protocol permitted non-biologic immunomodulators (mycophenolate mofetil, mycophenolic acid, azathioprine and methotrexate).
[0268] A total of 228 participants were randomly assigned into 3 treatment groups with a 1:1:1 ratio.Group 1: placebo IV every 2 weeks (q2w)Participants will receive placebo IV q2w from Week 0 through Week 50.Group 2: nipocalimab 5 mg / kg IV q2wParticipants will receive nipocalimab 5 mg / kg IV q2w from Week 0 through Week 50.Group 3: nipocalimab 15 mg / kg IV q2wParticipants will receive nipocalimab 15 mg / kg IV q2w from Week 0 through Week 50.
[0269] Of the 228 participants, 75 were randomized to Group 1 (the placebo group), 77 to Group 2 (the nipocalimab 5 mg / kg group), and 76 to Group 3 (the nipocalimab 15 mg / kg group). The total duration of the study was up to 64 weeks and included a <6-week screening period, a 52-week double-blind treatment period, and a 6-week follow-up period.
[0270] In addition, all participants received nipocalimab or placebo in addition to the standard-of-care of immunosuppressants and GCs.
[0271] With this standard-of-care regimen, participants would enter on GCs (not exceeding 20 mg / day prednisone or its equivalent) and participants treated with at least 10 mg / day-77- 103693.007823\4927-3677-6616.1prednisone or its equivalent oral GCs at baseline would be tapered starting at Week 6 to <7.5 mg / day prednisone equivalent by Week 16 to minimize confounding treatment effects of GCs on major efficacy endpoints. This mandatory taper is important to assess whether nipocalimab improves the ability to reduce GCs. See FIG. 1 for a schematic overview of the study.Table 1 A. Objectives and Endpoints-78- 103693.007823\4927-3677-6616.1-79- 103693.007823\4927-3677-6616.1-80- 103693.007823\4927-3677-6616.1-81- 103693.007823\4927-3677-6616.1-82- 103693.007823\4927-3677-6616.1-83- 103693.007823\4927-3677-6616.1EFFICACY EVALUATIONS
[0272] Clinician-reported outcomes and patient-reported outcomes (PROs) of efficacy include the following:• BILAG• SLEDAI-2K• Physician's Global Assessment (PGA) of disease activity• Joint count assessments• CLASI• Systemic Lupus International Collaborating Clinics (SLICC) / American College of Rheumatology (ACR) damage index• Efficacy composite scores: SRI-4, LuMOS, LLDAS, BICLA• PRO measures to assess: pain (Pain NRS), Lupus symptoms (Lupus Symptoms questionnaire), fatigue (FACIT-Fatigue), disease severity (PGIS), changes in disease activity (PGIC), health-related quality of life (LupusQoL, SF-36).Definitions of Efficacy Endpoints:• SLE Responder Index (SRI)-4 response is defined as:o ≥4-point reduction in SLEDAI-2K total scoreo no new development of significant disease activity in new organ systems (no new BILAG A or >1 new BILAG B)o no worsening in Physician's Global Assessment (PGA >10% increase from baseline)• Composite SRI-4 response is defined as:o Meeting SRI-4 response AND not meeting any TF criteria.• BICLA response is defined as BILAG 2004 disease activity index improvement without worsening (A scores at baseline improved to B, C, or D; B scores improved to C or D; no new A scores or no more than 1 new B); and no worsening in the-84- 103693.007823\4927-3677-6616.1SLEDAI-2K total score compared with Baseline Visit (defined as no increase in SLEDAI-2K total score); no worsening in PGA compared with Baseline Visit defined as ≤ 10% increase on a 0-3 visual analog scale (VAS), and no discontinuation of study intervention or use of rescue medication beyond protocol allowed threshold; no meeting treatment failure criteria.• LuMOS is defined as a ≥4-point reduction on the SLEDAI-2K, an increase in C4 levels, a decrease in anti-dsDNA titers, and changes in the BILAG scores for organ system manifestations (no worsening in renal components and improvements in mucocutaneous components).• LLDAS is defined as meeting the following criteria:o SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system [CNS], cardiopulmonary, vasculitis) and no reported fever, hemolytic anemia, or gastrointestinal activityo No new disease activity compared with the previous assessmento PGA ≤1 on a 0-3 VASo A current prednisone (or equivalent) dose of ≤7.5 mg dailyo Well-tolerated standard maintenance doses of permitted immunosuppressive drugs• Four (4) points improvement in SLEDAI-2K modified to exclude renal itemsA 4-point improvement from baseline in total SLEDAI-2K score modified to exclude renal items (i.e., urinary casts, hematuria, proteinuria, pyuria).• 50% reduction in active jointsParticipants with baseline arthritis who have at least a >50% reduction in active joints from baseline, i.e., an active joint must demonstrate tenderness and at least one additional sign of inflammation (e.g., observed swelling such as edema or effusion) on physical examination as determined by the joint assessor.• 50% reduction in CLASI scoreParticipants with baseline active mucocutaneous lupus manifestations who have at least a >50% reduction in CLASI score from baseline (CLASI activity and CLASI damage analyzed independently).Inclusion Criteria-85- 103693.007823\4927-3677-6616.1
[0273] Each potential participant must satisfy all of the following criteria to be enrolled in the study:Age1. 18 to 65 years of age (inclusive) at the time of consent. (In regions where the legal age of consent is older than 18 years and the participant is under the legal age, signed informed consent must be obtained from both the participant and his or her legally acceptable representative)Disease Characteristics2. Has a clinical diagnosis of SLE ≥6 months prior to the screening visit and according to Systemic Lupus International Collaborating Clinics (SLICC)-2012 classification criteria: at least 4 criteria fulfilled, with at least one clinical criterion AND one immunologic criterion.3. Has at least 1 BILAG A and / or 2 BILAG B scores observed during screening.4. Must have at least moderately active SLE, as defined as SLEDAI-2K score ≥6 at screening visit. Must also have SLEDAI 2K ≥4 for clinical features (i.e., SLEDAI- 2K score excluding headache and laboratory abnormalities) present at Week 0 prior to randomization.5. Has a CLASI activity score of at least 6 (excluding diffuse non-inflammatory alopecia) or at least 4 joints with pain and signs of inflammation (active joints) at screening or at Week 0, or both.6. At least 1 well-documented (subject file, referring physician letter, or laboratory result) unequivocally positive, test for autoantibodies in medical history including one of the following: antinuclear antibodies (ANA), and / or anti-dsDNA antibodies, and / or antiSmith antibodies.7. At least 1 unequivocally positive autoantibody test including ANA (≥1:80 evaluated on e.g., ZEUS IFA test system) and / or anti-dsDNA antibodies (level ≥75 IU / mL evaluated on e.g., QUANTA Lite test system) and / or anti-Smith antibodies (>120 AU / mL evaluated on e.g., AtheNA ANA-II Plus test system) detected during screening.8. Must be receiving one or more of the following protocol-permitted, systemic standard-of- care treatments:-86- 103693.007823\4927-3677-6616.1a) Oral GCs (average daily dose ≤20 mg of prednisone or equivalent) for ≥6 weeks and at a stable dose ≥4 weeks prior to first administration of study intervention. If currently not using oral GCs, must not have received them for ≥6 weeks prior to the first administration of study intervention.b) Antimalarials (≤250 mg / day chloroquine, ≤400 mg / day hydroxychloroquine, and / or ≤100 mg / day quinacrine) at a stable dose for ≥12 weeks prior to first administration of study intervention.c) If using one or more of the following immunomodulatory drugs, must be on a stable dose for ≥8 weeks prior to first administration of study intervention:- Mycophenolate mofetil (MMF) ≤2 g / day- Mycophenolic acid (MPA) ≤1.5 g / day- Azathioprine (AZA) / 6-mercaptopurine (6-MP) ≤2 mg / kg / day; up to 100 mg / day for participants weighing ≤50 kg- Oral methotrexate (MTX) ≤25 mg / week or SC or intramuscular (IM) MTX ≤20 mg / week with concomitant folic acid or folinic acidNo more than 2 immunomodulatory drugs listed above (MMF, MPA, AZA, 6-MP, MTX) is allowed. If the participant is using concomitantly 2 of the immunomodulatory drugs listed above (MMF, MPA, AZA, 6-MP, MTX), the suitability of the participant to participate in the study must be discussed with the medical monitor and / or sponsor before the participant is randomized.9. Regular or as needed treatment with the following agents with no changes in dose or frequency is permitted as follows:a) Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for ≥2 weeks prior to first administration of study intervention. b) Nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics for ≥2 weeks prior to first administration of study intervention.c) Permitted topical medications for cutaneous disease (Section 6.8.6) for ≥4 weeks prior to first administration of study intervention.
[0274] Sex and Contraceptive / Barrier Requirements-87- 103693.007823\4927-3677-6616.110. Male or female (according to their reproductive organs and functions assigned by chromosomal complement).11. A woman of childbearing potential must have a negative highly sensitive urine pregnancy test (β-human chorionic gonadotropin [β-hCG]) at screening and a negative urine (β-hCG) pregnancy test at Week 0 prior to administration of study intervention.12. A woman must be (as defined in Section 10.5, Contraceptive and Barrier Guidance): a) Not of childbearing potentialORb) Of childbearing potential, and:- Practicing a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study intervention and until 30 days after last dose - the end of relevant systemic exposure. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.- If using oral hormonal contraceptives for birth control and receiving MMF / MPA, a woman must, in addition to the oral hormonal contraceptive, utilize a barrier method of birth control (e.g., either an occlusive cap [diaphragm or cervical / vault caps] plus spermicidal foam / gel / film / cream / suppository if available in their locale) or their partner must agree to use a condom with spermicidal foam / gel / film / cream / suppository if available in their locale], during the study and for at least 30 days after receiving the last administration of study intervention. 13. A woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 30 days after the last administration of study intervention.14. A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for at least 90 days after receiving the last administration of study intervention. In addition, male participants with partners who are a woman of childbearing potential are to be highly encouraged to inform their partner to use highly effective contraception methods that result in low failure rate (less than 1% per year).-88- 103693.007823\4927-3677-6616.115. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last administration of study intervention.
[0275] Vaccination History16. It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) COVID-19 vaccination regimen at least 2 weeks prior to study-related visits or procedures. Study participants should follow applicable local vaccine labelling, guidelines, and standards- of-care for patients receiving immune-targeted therapy when determining an appropriate interval between vaccination and study enrolment.
[0276] General17. Must sign an ICF indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study. (In regions where the legal age of consent is older than 18 years and the participant is under the legal age, signed informed consent must be obtained from both the participant and his or her legally acceptable representative.)18. Must sign a separate ICF if he or she agrees to provide optional DNA samples for research where local regulations permit. Refusal to give consent for the optional DNA samples does not exclude a participant from participation in the study.19. Must be willing and able to adhere to all specified requirements, including but not limited to completion of the required assessments, adherence to the visit schedule, and compliance with the lifestyle restrictions as specified in this protocol.20. Must sign a separate ICF if he or she agrees to participate in optional skin biopsy substudy. Refusal to give consent for the optional substudy does not exclude a participant from participation in the study.21. Must be able to read and write. Visually impaired subjects may participate with the support of a legally acceptable representative.Exclusion Criteria-89- 103693.007823\4927-3677-6616.1
[0277] Any potential participant who meets any of the following criteria will be excluded from participating in the study:
[0278] Coexisting Medical Conditions or Past Medical History1. Current or history of, severe, progressive, or uncontrolled renal disease, with the exception of active LN. Have severe active LN as determined by sponsor (or designee) adjudication. Control of renal disease must be documented with at least 2 measurements of proteinuria or UPCR over the 6 months prior to screening.2. Has a history of severe, and / or uncontrolled hepatic (e.g., viral / alcoholic / autoimmune hepatitis / cirrhosis and / or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological, musculoskeletal disorder, hypertension, and / or any other medical or uncontrolled autoimmune disorder(s) (e.g., diabetes mellitus) that, might interfere with the participant's full participation in the study, and / or might jeopardize the safety of the participant or the validity of the study results. Note: Any condition for which, in the opinion of the investigator, adjudicator or sponsor, participation would not be in the best interest of the participant (e.g., compromise wellbeing) or that could prevent, limit, or confound the protocolspecified assessments.3. Anticipated to require dialysis within 6 months.4. Transplanted organ (with the exception of a corneal transplant performed >12 weeks before screening).5. Comorbidities (other than SLE, e.g., asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic GCs within the previous 12 months and likely to require multiple courses of GCs within 6 months.6. Has any unstable or progressive manifestation of SLE (including but not limited to lupus cerebritis, optic neuritis, transverse myelitis, psychosis, uncontrolled seizures, systemic vasculitis, end-stage renal disease, severe or rapidly progressive LN, pulmonary hemorrhage, myocarditis) that is likely to warrant escalation in therapy beyond permitted background medications.7. Confirmed or suspected inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis, RA / lupus overlap, psoriasis, Crohn’s disease, or active Lyme disease. Sponsor (or-90- 103693.007823\4927-3677-6616.1designee) adjudication will determine the final suitability of the potential participant with suspected inflammatory diseases to participate in the study before the participant is randomized.8. Has a history or suspected occurrence of drug-induced lupus.9. Has a history of catastrophic antiphospholipid syndrome (APS). Participants with a history of non-catastrophic APS must be adequately controlled with anticoagulation and / or anti-platelet therapy in accordance with local guidelines. Sponsor (or designee) adjudication will determine the final suitability of the potential participant with non- catastrophic APS to participate in the study before the participant is randomized.10. Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his / her SLE or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant.11. Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients (refer to the IB).12. Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis, to therapeutic proteins (e.g., mAbs).13. Had major surgery (e.g., requiring general anesthesia [although not all procedures requiring general anesthesia would necessarily be major]) within 3 months before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate.14. Is (anatomically or functionally) asplenic.15. Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening.16. History of moderate or severe substance or alcohol use disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria, except nicotine or caffeine, within 1 year before screening.17. Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and / or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months [defined as a minimum of 12 weeks] before the first study-91- 103693.007823\4927-3677-6616.1intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention administration).18. Screening laboratory tests• Estimated glomerular filtration rate (eGFR) <30 ml / min per 1.73 m2.• Has urinary protein level of >4 g / day or protein / creatinine ratio estimating >4 g / day equivalent proteinuria.• Absolute neutrophil count <1.0×109 / L.• Platelet count <75x109 / L.• Hemoglobin <8.0 g / dL.• Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) results that are ≥3×the upper limit of normal [ULN]).• Serum total IgG <6 g / L (<600 mg / dL).
[0279] Concurrent Nursing and Family Planning19. Is planning to father a child while enrolled in this study or donate sperm within 90 days after the last administration of study intervention.20. Is currently breastfeeding, pregnant, intends to become pregnant during the study, or is planning egg donation during the study or within 30 days after the last dose of study intervention.
[0280] Concomitant or previous medical therapies received21. Is currently taking IgGFc-related protein therapeutics, or Fc-conjugated therapeutic agents, including factor or enzyme replacement.22. Has received a single B-cell targeting agent within 3 months prior to first administration of study intervention; or received more than 1 previous B-cell targeting therapy including belimumab within 6 months prior to first administration of study intervention.23. Has received B-cell depleting therapy (e.g., rituximab, obinutuzumab, daratumumab) within 6 months prior to first administration of study intervention.24. Use of anti-tumor necrosis factor (TNF) medication, other biologic medications (e.g., tocilizumab, alefacept, efalizumab, natalizumab, abatacept, anakinra, brodalumab, secukinumab, ixekizumab, or agents whose mechanism of action targets interleukin (IL)- -92- 103693.007823\4927-3677-6616.11, IL-2, IL-6, IL- 17, cytotoxic T-lymphocyte-associated protein (CTLA)-4, or interferon pathway drugs) within the past 90 days, or 5 half-lives prior to screening, whichever is greater.25. Has received a Janus kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib) within 4 months prior to first administration of study intervention.26. Has received eculizumab within 6 months prior to screening.27. Has used oral cyclophosphamide within 3 months or IV cyclophosphamide within 6 months prior to the first administration of study intervention.28. Has received systemic immunomodulatory agents (e.g., leflunomide, MTX, tacrolimus, sirolimus, mizoribine, cyclosporine) other than those described to be allowed in the Inclusion Criteria within 3 months prior to first administration of study intervention. Glucocorticoids are not included in this criterion.29. Has received topical cream / ointment preparations of cyclosporine A, high potency topical GCs (e.g., World Health Organization [WHO] Classification, Group I to III), or other topical immunomodulatory agents (such as tacrolimus, pimecrolimus) within 4 weeks prior to first administration of study intervention covering a body surface area (BSA) of >20%.30. Has received adrenocorticotropic hormone (ACTH) administered by injection within 1 month prior to the first administration of study intervention.31. Has received epidural, IV, IM, intra-articular, intrabursal, or intralesional administration of GCs within 6 weeks prior to the first administration of study intervention.32. Has received pulse steroids (prednisone equivalent >100 mg) within 6 months prior to first administration of study intervention.33. Has received plasmapheresis, immunoadsorption therapy, or intravenous immunoglobulin (IVIg) within 6 months prior to first administration of study intervention.34. Has received a live vaccine within 4 weeks before the first administration of study intervention or longer as either indicated on the package insert of the relevant vaccine or according to local regulations (or within 12 months prior to first administration of study intervention for BCG) or has a known need to receive a live vaccine during the study or within at least 8 weeks after the last administration of study intervention in this study.-93- 103693.007823\4927-3677-6616.135. Has received an investigational antibody or biologic therapy (other than those listed elsewhere in this section) within 6 months prior to the first administration of study intervention or received any other investigational therapy, including investigational medical device or new investigational agent within 3 months or 5 half-lives (whichever is longer) prior to first administration of study intervention or is currently enrolled or plan to enroll in another study using an investigational intervention or procedure.36. Use of complementary therapies, including traditional / Chinese medicines, herbs, ointments, or procedures (e.g., acupuncture), that have the potential to activate (e.g., echinacea) or inhibit (e.g., Tripterygium wilfordii Hook F) the immune system is prohibited within 6 weeks of first administration of study intervention. In addition, use of complementary therapies, including traditional / Chinese medicines and herbs, that have the potential to interact with antithrombotic agents (e.g., St. John’s Wort) is prohibited within 6 weeks of first administration of study intervention in those taking antithrombotic agents. Any questions or concerns with the use of these therapies should be discussed with the study sponsor and / or medical monitor.37. Has taken any disallowed therapies, Concomitant Therapy, whose timelines conflict with the planned first administration of study intervention.
[0281] Infections or predisposition to infections38. Has a severe infection including opportunistic infections (e.g., pneumonia, tuberculosis, biliary tract infection, diverticulitis, Clostridioides difficile infection, cytomegalovirus, pneumocystosis, aspergillosis) requiring parenteral antiinfectives, and / or hospitalization, and / or is assessed as serious / clinically significant by the investigator, within 8 weeks prior to screening. The patient may be rescreened after the 8-week exclusionary period has passed.39. Has a chronic infection (e.g., bronchiectasis, chronic osteomyelitis, chronic pyelonephritis) or requires chronic treatment with anti-infectives (e.g., antibiotics, antivirals).40. Has a history of active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening.-94- 103693.007823\4927-3677-6616.141. Has a history of an infected joint prosthesis, or has ever received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.42. Tests positive for hepatitis B virus (HBV) infection.43. Is seropositive for antibodies to hepatitis C virus (HCV), unless they satisfy 1 of the following conditions:• Has a history of successful treatment, defined as being negative for HCV ribonucleic acid (RNA) at least 24 weeks after completing antiviral treatment and has a negative HCV RNA test result at screening,OR• While seropositive, has a negative HCV RNA test result at least 24 weeks prior to screening and a negative HCV RNA test at the screening.44. History of being human immunodeficiency virus (HIV)l or HIV2 antibodypositive or tests positive for HIV at screening.45. COVID-19 infection:During the 6 weeks prior to baseline, have had ANY of the following (Regardless of vaccination status)(a) confirmed severe acute respiratory syndrome coronavirus SARS-CoV-2 (COVID-19) infection (test positive), OR(b) suspected SARS-CoV-2 infection (clinical features without documented test results), OR(c) close contact with a person with known or suspected SARS-CoV-2 infection Exception: may be included with a documented negative result for a validated SARS- CoV-2 test:- obtained at least 2 weeks after conditions (a), (b), (c) above (timed from resolution of key clinical features if present, e.g., fever, cough, dyspnea) AND- with absence of ALL conditions (a), (b), (c) above during the period between the negative test result and the baseline study visitNOTES on COVID-related exclusion:-95- 103693.007823\4927-3677-6616.1• The field of COVID-related testing (for presence of and immunity to the SARS-CoV- 2 virus) is rapidly evolving. Additional testing may be performed as part of screening and / or during the study if deemed necessary by the investigator and in accordance with current regulations / guidance from authorities / standards of care.Precaution: for those who may carry a higher risk for severe COVID- 19 illness, follow guidance from local health authorities when weighing the potential benefits and risks of enrolling in the study and during participation in the study.
[0282] General46. Lives in an institution on court or authority order.47. Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.48. Has any condition for which, in the opinion of the investigator or the sponsor or sponsor’s representative, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol- specified assessments.49. Is unwilling or unable to undergo multiple venipunctures because of poor tolerability or lack of easy venous access.50. Donated whole blood (volume >450 mL) or blood plasma within 30 days of screening.51. Has an infection (e.g., sinusitis, bronchitis, uncomplicated urinary tract infection) and is receiving oral anti-infectives within 2 weeks prior to first administration of study intervention.Efficacy AssessmentsBritish Isles Lupus Assessment Group
[0283] The BILAG index scores participants based on the need for alterations or intensification of therapy (Hay EM (1993), Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus, Q J Med, 1993;86:447-458; Isenberg DA (2005), Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus-96- 103693.007823\4927-3677-6616.1Assessment Group’s disease activity index for patients with systemic lupus erythematosus, Rheumatology, 2005;44:902-906). The assessing physician would evaluate 97 items divided into 9 organ systems. The physician considers presence of each item in the past 4 weeks and answers 0=not present, 1 improving, 2=same, 3=worse, or 4=new. Each organ / system was classified programmatically or by data reviewers as BILAG A, B, C, D, or E based upon criteria specific to the organ system (Isenberg 2005). The BILAG index was designed to give practicing physicians a tool to help in decision-making based on amount of activity in each organ / system. The baseline measurement for the BILAG is defined as the closest measurement taken during the study and prior to administration of study intervention at Week 0.• BILAG improvement is defined as (1) all BILAG A scores at baseline improved to either B, C, or D and (2) all BILAG B scores at baseline improved to C or D and (3) no worsening in disease activity defined as no new BILAG A scores and <1 new BILAG B score.• Major clinical response in BILAG is defined as BILAG C score or better in all organ systems.• No worsening in BILAG disease activity is defined as no new BILAG A scores and <1 new BILAG B score.
[0284] BILAG flare: Defined as at least 1 new BILAG A or at least 2 new BILAG B meeting at least one of the following criteria:o Not present at baselineo The occurrence of a new / worse manifestation in a different component of an organ system that is already presento At least 1 A or 2 B scores in an organ system which improves to B / C / D for at least 2 sequential study visits followed by new / worse disease activity
[0285] Adjudicated flare: Adjudication for a flare is performed by sponsor (or designee) clinicians with expertise in lupus disease features and clinical assessment tools. All flares will be adjudicated regardless of whether it is the participant’s first flare or an additional flare occurring in either the same or a different organ system.SLE Disease Activity Index 2000-97- 103693.007823\4927-3677-6616.1
[0286] The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients at the time of the visit or in the previous 30 days; the index is weighted according to the feature.Features are scored by the assessing physician if present at the time of the visit or within the last 30 days, with more severe features having higher scores, and then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105 (Touma Z (2010), Gladman DD, Urowitz MB, SLEDAI-2K for a 30-day window, Lupus. 2010;19(1):49-51; Touma Z (2011), Urowitz M, Ibanez D, Gladman D, SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation, Lupus. 2011;20(1):67-70.). The baseline measurement for the SLEDAI-2K is defined as the closest measurement taken prior to the initiation of the Week 0 study intervention administration. SLEDAI improvement is defined as a reduction from baseline in total SLEDAI-2K score. No worsening of total SLEDAI-2K from baseline is defined as a change <0 in SLEDAI-2K score and meaningful improvement is best defined as a reduction in SLEDAI-2K of 4 or more.Physician ’s Global Assessment of Disease Activity
[0287] The PGA independent of participants’ assessment is recorded on a VAS with responses for disease activity ranging from 0-3 and verbal anchors “None” (0), “Mild” (1), “Moderate” (2) and “Severe” (3) (Petri M (1991), Genovese M, Engle E, Hochberg M.Definition, incidence, and clinical description of flare in systemic lupus erythematosus, A prospective cohort study, Arthritis Rheum, 1991;34:937-944; Petri M (1992), Hellmann D, Hochberg M, Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol, 1992;19(l):53-59.). The baseline measurement for the PGA is defined as the closest measurement taken prior to the initiation of the Week 0 administration.• No worsening in PGA is defined as no significant deterioration (<10% increase from baseline) using a VAS (Furie RA (2009), Petri MA, Wallace DJ, et al, Novel evidencebased systemic lupus erythematosus responder index, Arthritis Rheum, 2009;61(9):1143- 1151).Joint Count Assessments
[0288] Assessment of active joints will be performed at scheduled visits. To be considered an active joint, an affected joint must be painful as reported by the subject and must demonstrate-98- 103693.007823\4927-3677-6616.1tenderness and at least one additional sign of inflammation (e.g., observed swelling such as edema or effusion) on physical examination as determined by the joint assessor. Each of 64 joints will be evaluated for symptoms of pain, tenderness and 62 joints for swelling or effusion (hips are excluded).Cutaneous Lupus Erythematosus Disease Area and Severity Index
[0289] Cutaneous lupus disease activity and severity would be measured by the CLASI. The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus patients with or without systemic involvement. The CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage caused by the disease (CLASI Activity and CLASI Damage scores). Activity is scored by the investigator based on erythema, scale / hyperkeratosis, mucous membrane involvement, acute hair loss, and non-scarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The scores are calculated by simple addition based on the extent of the symptoms (Albrecht J (2005), Taylor L, Berlin JA, et al, The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus, J Invest Dermatol. 2005;125(5):889-894).
[0290] CLASI scores range from 0-70 for activity and 0-56 for damage, with higher scores indicating worse disease activity.Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index
[0291] The SLICC / ACR damage index is a validated, reliable instrument to measure organ damage after the diagnosis of lupus. The SLICC / ACR damage index evaluates 12 systems which are assessed by 41 items for damage, which is defined as non-reversible change that is not related to active inflammation and that has occurred since the onset of lupus and present for at least 6 months. Items are scored based upon evidence of damage with a maximum possible score of 47. Scores can only increase with time. If evidence of damage is noted for an item, it is given a score of 1 (Gladman D (1996), Ginzler E, Goldsmith C, et al, The development and initial validation of the Systemic Lupus International Collaborating Clinics / American College of-99- 103693.007823\4927-3677-6616.1Rheumatology Damage Index for systemic lupus erythematosus, Arthritis Rheum, 1996;39(3):363-369).Efficacy Composite Scores
[0292] SLE Responder Index-4 Composite Response: The SRI-4 response is defined as a composite endpoint requiring at least a 4 point reduction in SLEDAI-2K score, no worsening (<10 mm increase) from baseline in the PGA of disease activity score, and no new BILAG A and no more than 1 new BILAG B scores (Furie 2009). SRI-5, SRI-6, SRI-7, and SRI-8 response are defined similarly, except the SLEDAI-2K improvement from baseline is to be at least 5, 6, 7, or 8 points, respectively. The SRI-4 composite response is the proportion of subjects who achieve a SLEDAI-2K SRI-4 response and do not meet the TF criteria.
[0293] Lupus Multivariable Outcomes Score: The LuMOS is a multivariable response score that aggregates changes in variables including the SLEDAI-2K, C4 levels, anti-double-stranded DNA titers, and BILAG scores for organ system manifestations.
[0294] Lupus Low Disease Activity State: The LLDAS is defined as meeting the following criteria:- SLEDAI-2K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis), and no reported fever, hemolytic anemia, or gastrointestinal activity)- No new disease activity compared with the previous assessment- PGA ≤1 on a 0-3 VAS- A current prednisone (or equivalent) dose of ≤7.5 mg daily- Well-tolerated standard maintenance doses of permitted immunosuppressive drugs
[0295] BILAG Composite Lupus Assessment: A participant is a BICLA responder if the following criteria are met:- Reduction of all baseline BILAG-2004 A to B / C / D and baseline BILAG-2004 B to C / D and no BILAG-2004 worsening in other organ systems, as defined by >1 new BILAG-2004 A or >2 new BILAG-2004 B.-100- 103693.007823\4927-3677-6616.1- No worsening from baseline in SLEDAI-2K as defined as an increase from baseline of >0 points in SLEDAI-2K. Increase from baseline corresponds to the change from baseline.- No worsening from baseline in participants’ lupus disease activity defined by an increase >0.30 points on a 3-point PGA VAS.- No discontinuation of study intervention (according to eCRF form “Discontinuation of Study Intervention”) or use of rescue medication beyond the protocol-allowed threshold before assessment.
[0296] If any of the conditions cannot be evaluated at Week 52 (e.g., due to missing values) the participant is defined as a BICLA nonresponder.Patient-reported Outcomes
[0297] The PRO instruments were provided in the local language in accordance with local guidelines, and can generally be completed in 30 to 40 minutes.
[0298] The PRO instrument must be available for regulators and for IRB / ERC submissions, therefore the PRO instrument or screen shots need to be attached to the protocol or provided in a companion manual with the instruments that will be submitted with the protocol.
[0299] The PRO and AE data were reconciled with one another.
[0300] Visually impaired / blind participants might complete the PRO using the Subject Transcription Mode functionality within the PRO instruments with assistance by appropriately trained site personnel. The PRO instrument would capture any subject transcription mode activities within the audit trail system.
[0301] Pain Numeric Rating Scale: The Pain NRS is a segmented numeric version of the VAS for participant self-administration, in which a participant is asked to select a whole number (0-10 integers) that best reflects the worst intensity of his / her pain in the past 7 days. The 11-point numeric scale ranges from 'O' representing “no pain” to TO' representing “severe pain” (Daut RL (1983), Cleeland CS, Flanery RC, Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain, 1983;17(2):197-210; Cleeland CS (1994), Ryan KM, Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med-101- 103693.007823\4927-3677-6616.1Singapore, 1994;23(2): 129-138.; Naegeli AN (2015), Tomaszewski EL, Al Sawah S.Psychometric validation of the Brief Pain Inventory-Short Form in patients with systemic lupus erythematosus in the United States, Lupus, 2015;24(13):1377-1383.).
[0302] Lupus Symptoms: Participants would be asked to report the worst severity of their joint pain, joint stiffness, skin rash, and swelling in legs and / or feet over the past 7 days on a 0 to 10 NRS, with one anchor indicating “No [specific symptom]” and the other anchor, “Severe [specific symptom]”. The items are scored individually, with higher scores reflecting greater symptom severity.
[0303] Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue Scale [Version 4]): The FACIT-Fatigue (Version 4), is a self-administered, 13 item questionnaire that includes items on tiredness, weakness, and difficulty conducting usual activities due to fatigue. The recall period for all the items is the past 7 days. Responses to all items are rated on a 5-point Likert response scale ranging from 0 “not at all” to 4 “very much”. The FACIT-Fatigue can generally be completed in 5 minutes (Celia D (2002), Lai J, Chang C, Peterman A, Slavin M, Fatigue in cancer patients compared with fatigue in the general United States population, Cancer, 2002;94(2):528-538; Yellen SB (1997), Celia DF, Webster K, Blendowski C, Kaplan E, Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system, J Pain Sympt Manage, 1997;13 (2):63-74.). A study using a combination of approaches, including both anchor-based estimates derived from statistically significant cross-sectional and longitudinal differences and distribution-based estimates concluded that the minimal clinically important difference in patients with SLE for the FACIT-Fatigue is between 3 and 4 points (Lai J-S (2011), Beaumont JL, Ogale S, Brunetta P, Celia D, Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial, J Rheumatol, 2011;38(4):672-679). This range is similar to that which has been reported in other disease areas (Celia 2002; Celia D (2005), Yount S, Sorensen M, Chartash E, Sengupta N, Grober J, Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis, J Rheumatol, 2005;32(5):811-819; Patrick DL (2003), Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, Assessing the clinical significance of healthrelated quality of life (HrQOL) improvements in-102- 103693.007823\4927-3677-6616.1anaemic cancer patients receiving epoetin alfa, European Journal of Cancer, 2003;39(3):335-345).
[0304] Patient Global Impression of Severity: The PGIS is a 1-item questionnaire based on the clinical global impression scale developed by Guy (Guy W (1976), Ed. ECDEU assessment manual for psychopharmacology, Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration;1976:217-222), designed to assess a patient’s impression of the severity of their health condition. The PGIS asks the patient to select the one response, ranging from 1 - ‘No Symptoms’ to 5 -‘Very Severe’, that best describes the overall severity of their lupus (Guy 1976). The PGIS will also serve as an anchor measure to explore what might constitute clinically meaningful thresholds for change for other PRO measures included in the study.
[0305] Patient Global Impression of Change: The PGIC is a patient-reported measure of perceived change in their health condition following a study intervention. The PGIC assesses the extent to which a person’s health condition has improved or worsened since the start of their treatment using a scale ranging from l=Very much improved to 7=Very much worse (4=No change). The instructions ask the participant to select the one response that best describes the overall change in their SLE since treatment was initiated (Guy 1976).
[0306] The PGIC also serves as an anchor measure to explore clinically meaningful change thresholds for the other PRO measures included in the study.
[0307] The Lupus Quality of Life (LupusQoL): The LupusQoL is a participant selfadministered, 34-item questionnaire measuring HRQoL in participants with SLE. The recall period for all items is the past 4-weeks. The LupusQoL includes 8 domains (physical health, emotional health, body image, pain, planning, fatigue, intimate relationships, and burden to others). Responses to all items are rated on a 5-point Likert response scale ranging from “All the time”, “Most of the time”, “A good bit of the time”, “Occasionally”, to “Never” (McElhone K (2007), Abbott J, Shelmerdine J, et al, Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus, Arthritis Rheum, 2007;57(6):972-979). In a prospective, longitudinal, observational study using a combination of anchor- and distribution based approaches, the LupusQoL domain minimal -103- 103693.007823\4927-3677-6616.1clinically important differences (MCID) for deterioration ranged from -22.4 to -28.7, and for improvement from 3.5 to 7.3 (McElhone K (2016), Abbott J, Sutton C, et al, Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus, Arthritis Care and Research, 2016;68(10):1505-1513). The MCID for improvement in the Physical Health domain was determined to be an increase of 4 points.
[0308] Short Form-36 Version 2 Standard (4- week Recall): The SF-36 version 2 is a selfadministered, 36-item questionnaire measuring HRQoL. The recall period for all items is the past 4 weeks. The SF-36 version 2 Standard includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary (PCS) and a mental component summary (MCS). Responses to all items are rated on a 3-, 5- or 6-point Likert scale (Quality Metric Inc (2011). User’s Manual for the SF-36v2 Health Survey. 3rd edition; 2011: https: / / www.optum.com / solutions / life-sciences / answer-research / patient- insights / sf-health-surveys / sf-36v2-healthsurvey. html. ).Study ResultsPrimary Endpoint
[0309] The primary endpoint, SLEDAI-2K Responder Index (SRI)-4 at Week 24, was found to be statistically significant at a pre-specified Type 1 error rate of 0.10 (2-sided) in the nipocalimab 15 mg / kg group (p=0.081). Furthermore, the proportion of participants in the 15 mg / kg nipocalimab group achieving an SRI-4 composite response was numerically greater than the 5 mg / kg nipocalimab group (Table IB).Table IB, Primary Endpoint Analysis, FAS*-104- 103693.007823\4927-3677-6616.1Summary of secondary and selected prespecified exploratory endpoints
[0310] At Week 52, a higher proportion of participants from the 5 mg / kg IV q2w and 15 mg / kg IV q2w vs Placebo IV q2w arm achieved SRI-4 composite response (nominal P=0.054 and P=0.02 respectively), SRI-5 composite response (nominal P=0.007 and P=0.001 respectively) and SRI-6 composite response (nominal P=0.007 and P=0.002 respectively) (FIGs.2A-2C). In particular, compared to the placebo group, higher proportion of participants in the 15 mg / kg IV q2w group achieved SRI-4 response at Week 52 (52.6% vs 39.7%; Δ13.9; FIG. 25).
[0311] Higher proportion of participants from 15 mg / kg IV q2w vs Placebo arm achieved >4-point improvement from baseline in SLEDAI-2Keand >50% reduction in CLASI-activitydscore, with nominal p value <0.1 for 15 mg / kg IV q2w nipocalimab vs Placebo at Week 24.
[0312] In addition, at Week 24, a higher proportion of participants achieved LLDASfand SRI-4 compositive response + taper in 15 mg / kg IV q2w nipocalimab groups compared to placebo, with nominal p value <0.1 for 15 mg / kg IV q2w nipocalimab vs. Placebo, demonstrating the steroid sparing effect of 15 mg / kg IV q2w nipocalimab (Table 2).-105- 103693.007823\4927-3677-6616.1
[0313] Moreover, as shown in FIG. 3, numerically higher proportion of participants from Nipocalimab 15 mg / kg group vs placebo achieved <7.5 mg / day Oral GCs Over time (Based on mF AS). A statistical analysis was performed for Week 24 (Taper + selected endpoints) based on average response rate with imputed data (FIGs. 4A-4D). Number of subjects in placebo, 5 mg / kg group, and 15 mg / kg group for 1) SRI-44+Taper is 33, 36, and 32, respectively; 2) BICLA+Taper is 33, 36, and 32, respectively; 3) CLASI-50+Taper is 21, 23, and 16, respectively (CLASI-50: >50% reduction in the CLASI activity score from baseline), and 4) JOINT-50+Taper is 32, 33, and 28, respectively (JOINT-50: >50% reduction in active joint counts from baseline). Statistical analysis for Week 24 (SRI4 + selected endpoints) was also performed for IFN-high subgroup (67% of overall patients, FIG. 4E) and modified aAB-high subgroup (78% of overall patients, FIG. 4F). In addition, higher proportion of participants from Nipocalimab 5 mg / kg and 15 mg / kg groups vs placebo achieved LLDAS at week 52 (based on mF AS) (FIG. 5).Table 2. Summary of Key Secondary and Selected Exploratory Efficacy Endpoints, Primary Estimand-106- 103693.007823\4927-3677-6616.1-107- 103693.007823\4927-3677-6616.1-108- 103693.007823\4927-3677-6616.1Patient subgroup analysis
[0314] Preplanned exploratory analysis was conducted in patient subgroups hypothesized to demonstrate enhanced responses to nipocalimab in the study (Table 3).
[0315] Subjects presenting with high IFN gene signatures score at baseline were identified and accounted for ~66% of the study participants (termed IFN-High subgroup).• Subjects in the IFN-high subgroup demonstrated numerically higher SRI-4 composite responses in both the 5 mg / kg and 15 mg / kg nipocalimab groups compared to the placebo and compared to the overall population at week 52 (FIG. 6).- Unstratified response: A= 13.9%- IFN-High subgroup: A=23.8%- IFN-Low subgroup: A=1.4%wherein, A=15 mg / kg-Placebo, calculated with PE, mFAS, MI.• In addition, a numerically higher proportion of participants in the IFN-high subgroup achieved SRI-4 composite response + taper in both the 5 mg / kg and 15 mg / kg nipocalimab groups compared to placebo and compared to the overall population at week 24 (FIG. 7).- Unstratified response: A=35.6%- IFN-High subgroup: A=42.8%- IFN-Low subgroup: A=20%
[0316] IFN gene signatures score were determined using a POISE 10-gene set disclosed in U. S. Patent No. 12,009,079, which is incorporated herein by reference. In brief, gene expression data from healthy individuals and SLE patients were used to compute the IFN POISE Enrichment score using GSVA (Hanzelmann, S., Castelo, R., & Guinney, J. (2013). **GSVA: gene set variation analysis for microarray and RNA-seq data.** *BMC Bioinformatics*, 14, 7.[DOI: 10.1186 / 1471-2105-14-7](https: / / doi.org / 10.1186 / 1471-2105-14-7)). The score distribution was bimodal, with the lower distribution including both healthy individuals and SLE patients, while the higher distribution consisted solely of SLE patients.-109- 103693.007823\4927-3677-6616.1
[0317] To determine the cutoff between these distributions, the ' cutoff package (Version: 0.1.0) (Choisy, M. (2015). **cutoff: Identify a cutoff value from bimodal data (Version 0.1.0).** Retrieved from [GitHub Repository](https: / / github.com / choisy / cutoff) was used. This package estimates a finite mixture model through the Expectation-Maximization algorithm; here, two normal distributions were assumed. The algorithm determined the optimal cutoff at -0.33, which also represented the maximum healthy value. The parameters for the ' cutoff function were set to nb = 50, distr = 2, and typel = 0.05.
[0318] Subjects demonstrating high autoantibody (aAB) burden were identified and evaluated for enhanced subgroup response. Autoantibodies were measured at baseline from serum samples using the semiquantitative assays for anti-Ro60 (evaluated with QUANTA Flash Ro60), anti-Ro52 (evaluated with QUANTA Flash Ro52), anti-Smith (anti-Sm) (evaluated with QUANTA Flash Sm), anti-La (evaluated with QUANTA Flash SSB), and anti-dsDNA (evaluated with QUANTA Lite). The data were log2-transformed, and missing values were imputed using the 'mice' package in R (van Buuren & Groothuis-Oudshoorn, 2011).Subsequently, values were standardized using the preprocessing function from the ' caret' package (Kuhn, 2018), employing the range method for normalization. A distance matrix among patients was computed using the 'daisy' method from the 'cluster' package (Maechler et al., 2021), which is suitable for mixed-type data. Patients were clustered using the Consensus Clustering algorithm from the 'M3C' package (Feng et al., 2021). The optimal number of clusters, denoted as K, was assessed from 2 to 5, with K = 5 identified as the best choice for downstream analysis. Cluster 5 (termed aAB-High) exhibited a high autoantibody profile, with increased baseline levels of the IFN signature, total IgG, and circulating immune complexes comprising for 15% of the participants in Phase 2 study, (van Buuren, S., & Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*, 45(3), 1-67. doi:10.18637 / jss.v045.i03; Kuhn, M. (2018). caret:Classification and Regression Training. *R package version 7.0-1*. Retrieved from https: / / CRAN. R-project.org / package=caret; Maechler, M., Rousseeuw, P. J., Struyf, A., Hubert, M., & Hornik, K. (2021). cluster: Cluster Analysis Basics and Extensions. *R package version 2.1.8*. Retrieved from https: / / cran.r-proj ect.org / packag e=cluster; Feng, X., Choudhary, A., &-110- 103693.007823\4927-3677-6616.1Hou, C. (2021). M3C: Multi-dimensional Consensus Clustering inR. *R package version 1.28*. Retrieved from https: / / CRAN. R-project.org / package=M3C).• Subjects in the aAB-high subgroup demonstrated numerically higher SRI-4 composite responses in both 5 mg / kg and 15 mg / kg nipocalimab groups compared to the placebo and compared to the overall population at week 52 (FIG. 8).- Unstratified response: A=13.9- aAB-High subgroup: A=64.7%• An enrichment strategy was also used to identify the aAB-high group without use of clustering algorithms. Subjects could be enriched for those in the aAB-high subgroup by baseline stratification using seropositivity for both anti-Ro60+(i.e., >20 CU evaluated with QUANTA Flash Ro60) anti-Ro52+(i.e., >20 CU evaluated with QUANTA Flash Ro52) but seronegative for anti -La' (i.e., <20 CU evaluated with QUANTA Flash SSB) (Termed Enriched aAB-High). As shown in FIG. 9, the Enriched aAB-High subgroup demonstrates greater response with nipocalimab at week 52.- Unstratified response: A=13.9- Enriched aAB-High subgroup: A=47.9%• A further stratification method was used to subgroup subjects having at least one of the following at screening into a modified aAB-high group:- Positive anti-dsDNA antibodies (i.e., >75 lU / mL evaluated with QUANTA Lite test system).- Positive anti-Smith antibodies (i.e., >20 CU evaluated with QUANTA Flash® Sm Werfen).- ANA (i.e., >1:80 on ZEUS IFA test system) and at least one of the following:■ Positive anti-Ro60 (i.e., >20 CU evaluated with QUANTA Flash Ro60) and / or positive anti-Ro52 (i.e., >20 CU evaluated with QUANTA Flash Ro52).■ Positive anti-RNP (i.e., >120 AU / ml using AtheNA ANA-II Plus test system).■ Historical evidence of positive anti-dsDNA antibodies.-111- 103693.007823\4927-3677-6616.1As shown in FIG. 21, the modified aAB-High subgroup demonstrates greater response with nipocalimab at week 52.- Unstratified response: A=13.9- Modified aAB-High subgroup: A=22.3%Table 3. Summary of Key Exploratory Patient SubgroupsSubjects who achieved a composite SRI-4 response at indicated timepoints based on Logistic Regression; Primary Estimand; Modified Full Analysis Set-112- 103693.007823\4927-3677-6616.1
[0319] In addition, as shown in FIG. 26, 1) among all patients, higher proportion of patients in nipocalimab 15 mg / kg IV q2w group achieved LLDAS response at Week 52 compared to placebo group (37.5% vs 20.5%; Al 7); 2) among modified aAB-high patients, higher proportion of patients in nipocalimab 15 mg / kg IV q2w group achieved LLDAS response at Week 52 compared to placebo group (38.9% vs 18.0%; A20.9); 3) among aAB-high patients, higher proportion of patients in nipocalimab 15 mg / kg IV q2w group achieved LLDAS response at Week 52 compared to placebo group (53.5% vs 11.1%; A42.4); 4) among IFN-high patients, higher proportion of patients in nipocalimab 15 mg / kg IV q2w group achieved LLDAS response at Week 52 compared to placebo group (41.5% vs 16.7%, A24.8).
[0320] Dose-dependent reductions in total IgG, CIC, and anti-dsDNA IgG autoantibodies levels were observed through Week 52 with nipocalimab treatment (FIGs. 27-29). Of those participants with positive anti-dsDNA at baseline, 1 / 22 (Placebo), 1 / 8 (5 mg / kg) and 1 / 14 (15 mg / kg) converted to negative. In participants with low C3 at baseline, increases in C3 were observed from Week 32 through Week 52 in the nipocalimab 15 mg / kg group (FIG. 30). C3 normalized at Week 52 in 0 / 20 (Placebo), 0 / 9 (5 mg / kg) and 8 / 17 (15 mg / kg).Key Safety Results
[0321] Overall, nipocalimab was well-tolerated by participants both 5 mg / kg and 15 mg / kg treatment groups with no major safety signals.
[0322] The number of participants with one or more TEAE reported were 76.0% (n=57) of participants in the placebo group, 89.6% (n=69) in the nipocalimab 5 mg / kg group and 82.9% (n=63) in the nipocalimab 15 mg / kg group. Rates of TEAEs do not appear to be dose-dependent overall.-113- 103693.007823\4927-3677-6616.1
[0323] The most common AE by System Organ Class (SOC) was the Infections and Infestations SOC reported in 56.0% (n=42), 58.4% (n=45) and 60.5% (n=46) in the placebo, 5 mg / kg, and 15 mg / kg groups respectively. The most commonly reported TEAE based by preferred term was nasopharyngitis with 12.0% (n=9) of placebo, 13.0% (n=10) of 5 mg / kg and 13.2% (n=10) of 15 mg / kg participants experiencing the TEAE.
[0324] A total of 24 SAEs (in 22 unique subjects) were reported through Week 58. There were reported in 6 (8.0%), 6 (7.8%) and 10 (13.2%) in the placebo, nipocalimab 5 mg / kg, and 15 mg / kg groups, respectively. Three suspected unexpected serious adverse reaction (SUSAR) reported in two subjects, one from each nipocalimab treatment group. Two deaths reported in 2 subjects from each nipocalimab treatment group due to septic shock. Both events were assessed by the PI as not related to the study intervention.
[0325] A total of 11 adverse events of special interest (AESI) of severe infection or infection that required IV anti-infective reported in 4.0% (n=3), 3.9% (n=3) and 6.6% (n=5) of the placebo, 5 mg / kg and 15 mg / kg groups respectively. Among all 11 reported AESIs, two (one UTI and one CMV infection) were mild in severity and not SAEs both reported in the 15 mg / kg group. No AESI of hypoalbuminemia reported. Through Week 58, 0 / 74 participants from placebo, 2 / 74 and 17 / 75 from 5mg / kg and 15mg / kg treatment group, respectively, reported minimum IgG of <3g / L. None of the participants in either nipocalimab treatment group with minimum IgG<3g / L reported any SAEs through Week 58.
[0326] Mild Increase of cholesterol, LDL and HDL without impacting cholesterol / HDL ratio observed. Changes in albumin and total cholesterol were not clinically significant.Key Pharmacodynamic (PD) Biomarker Results• Nipocalimab reduced serum total IgG in a rapid, deep, sustained and dose-dependent manner, consistent with the mechanism and observations in previous studies, a first POC for the FcRn mechanism in this disease.• At week 24, lower IgG lowering (55.5% median reduction from baseline) was observed in the 15 mg / kg group compared to observations in previous studies.• Nipocalimab reduced anti-dsDNAk, one of SLE specific pathogenic autoantibodies, in a rapid, sustained and dose-dependent manner.-114- 103693.007823\4927-3677-6616.1Example 2
[0327] This is a phase 3 study of the efficacy and safety of nipocalimab in moderate to severe system erythematosus lupus (SLE). Specifically, this example describes a phase 3, randomized, double-blind, placebo-controlled, parallel, multicenter, interventional study in participants with moderate to severe SLE.
[0328] This phase 3 study contains two identical studies (Study A and Study B). A target of 275 participants will be enrolled in each study for a total of 550 participants. Participants in each study will be assigned to one of two groups (Nipocalimab and placebo) in a 3:2 ratio.Participants will be stratified according to SLEDAI-2K score, IFN signature, oral GC dose and region. The studies include a mandatory oral GC tapering at Weeks 8-28 for participants receiving >5 mg prednisone or equivalent at baseline. FIG. 10 is a schematic overview of Study A and Study B.Table 4. Objectives and Endpoints-115- 103693.007823\4927-3677-6616.1-116- 103693.007823\4927-3677-6616.1-117- 103693.007823\4927-3677-6616.1Table 5. Inclusion Criteria-118- 103693.007823\4927-3677-6616.1-119- 103693.007823\4927-3677-6616.1-120- 103693.007823\4927-3677-6616.1Table 6. Exclusion Criteria-121- 103693.007823\4927-3677-6616.1-122- 103693.007823\4927-3677-6616.1-123- 103693.007823\4927-3677-6616.1-124- 103693.007823\4927-3677-6616.1-125- 103693.007823\4927-3677-6616.1-126- 103693.007823\4927-3677-6616.1Example 3
[0329] This is an alternate phase 3 study of the efficacy and safety of nipocalimab in moderate to severe system erythematosus lupus (SLE). Specifically, this example describes a phase 3, randomized, double-blind, placebo-controlled, multicenter study of nipocalimab in adults with moderate to severe SLE.Objectives And EndpointsDefinitions
[0330] Sustained reduction in oral glucocorticoid (GC) dose at Week 52 is defined as achieving <5 mg / day oral prednisone (or equivalent) AND no increase of that dose from Week 32 through Week 52.-127- 103693.007823\4927-3677-6616.1
[0331] IFN high is defined as an elevated peripheral Type 1 IFN gene signature above the established range of normal at baseline.
[0332] Autoantibody high is defined as positive for serum anti-Ro / SSA (Ro60 and Ro52) and negative for serum anti-La / SSB at baseline.Table 7. Objectives and Endpoints-128- 103693.007823\4927-3677-6616.1-129- 103693.007823\4927-3677-6616.1-130- 103693.007823\4927-3677-6616.1Study DesignOverall Design
[0333] The Phase 3 clinical development program for nipocalimab in SLE includes 2 identical Phase 3 studies (Study A and Study B) conducted in parallel under a single protocol with separate databases. Both Phase 3 studies are 52-week multicenter, randomized, doubleblind, placebo-controlled, and parallel-group studies to evaluate the safety and efficacy of-131- 103693.007823\4927-3677-6616.1nipocalimab in participants aged 18 to 75 years (inclusive) with moderate to severe SLE and who are on protocol-permitted standard of care therapy.
[0334] Eligible participants will be randomized (1:1 ratio) to Study A or Study B within 6 weeks of screening, followed by randomization to 1 of 2 study intervention groups (nipocalimab 460 mg SC weekly or placebo SC weekly) in a 3:2 ratio. Study visits are weekly through Week 4, and every 4 weeks thereafter through Week 52. Participants who complete the double-blind treatment through Week 52 may continue into a 104- week open-label long-term extension (LTE) if criteria are met. Eligibility criteria for the open- label LTE are as follows: (1) Completion of the double-blind period (including all activities listed for Week 52 in the main study SoA) (participants who discontinued the study and / or permanently discontinued study intervention prior to Week 52 are NOT eligible); and (2) Per investigator, the potential benefit of nipocalimab treatment outweighs the potential risks for the participant, considering blinded study intervention during the double-blind period.
[0335] In the open-label LTE, study visits are weekly through Week 56, followed by visit intervals of 8, 12, or 16 weeks through Week 156.
[0336] Stratification variables within Study A and Study B, and within each study intervention group are baseline SLEDAI-2K clinical score (<10; >10), baseline oral glucocorticoid (“GC”) dose (<5; >5 mg / day prednisone [or equivalent]), and geographic region (Eastern Europe, North America, Latin America, Asia-Pacific, and ROW).
[0337] Adjudication of eligibility will be conducted by the sponsor (or delegate) during screening for all participants. Approval of eligibility by the sponsor (or delegate) is required before a participant is randomized.
[0338] The total duration of each study is up to 168 weeks and consists of 4 study periods: a <6-week screening period, a 52-week double-blind treatment period, a 104- week open-label LTE, and a 6-week follow-up period. At the Week 52 visit of the double-blind period, participants who complete the double-blind treatment through Week 52 may continue into a 104-week open-label LTE if criteria are met. All participants will be followed for 6 weeks after the last study intervention administration, either after their last study intervention administration in-132- 103693.007823\4927-3677-6616.1the double-blind period (for participants not enrolling in the open-label LTE) or after their last study intervention administration in the open-label LTE.
[0339] Study intervention is administered subcutaneously on a weekly basis. From Week 0 through Week 4 of the double-blind period and from Week 52 to Week 56 of the open-label LTE, participants will self-administer on-site, under supervision of the investigator or designated site staff. If criteria are met, with appropriate training and per investigator discretion, participants can opt to self-administer study intervention off-site (e.g., home) after the Week 4 visit of the double- blind period and after the Week 56 visit of the open-label LTE. Participants who self-administer (on- or off-site) are required to complete a dosing diary for each week. If study intervention is administered by site staff, the same instructions on the dosing diary are to be followed, and the site staff should utilize the dosing diary for the administration.
[0340] Participants treated with <5 mg / day prednisone (or equivalent) at baseline shall remain at the baseline dose through Week 52. Starting from Week 8, participants treated with >5 mg / day prednisone (or equivalent) oral GCs at baseline will be tapered to 5 mg / day prednisone (or equivalent) by Week 32 and maintain the dose to Week 52 to minimize confounding treatment effects of GCs on major efficacy endpoints. From Week 52 (first visit of the open-label LTE), further decreases of the GC dose are permitted based on investigator judgment (maintaining control of disease activity to minimize the risk of triggering a flare or precipitating adrenal insufficiency).
[0341] Efficacy, pharmacokinetic (PK), immunogenicity, biomarkers, and safety will be assessed. The analyses will be performed separately for each study.
[0342] All participants will have a safety follow-up visit 6 weeks after the last study intervention administration, either after their last study intervention administration in the doubleblind period (for participants not enrolling in the open-label LTE) or after their last study intervention administration in the open-label LTE.
[0343] The end of each of the 2 studies is considered as the last visit for the last participant in the respective study.-133- 103693.007823\4927-3677-6616.1Blinding, Control, Study Phase / Periods, Intervention Groups
[0344] A placebo control will be used to establish the frequency and magnitude of changes in clinical endpoints that may occur in the absence of active intervention. Randomization will be used to minimize bias in the assignment of participants to intervention groups to increase the likelihood that known and unknown participant attributes (e.g., demographic and baseline characteristics) are evenly balanced across intervention groups, and to enhance the validity of statistical comparisons across intervention groups. Blinded intervention will be used to reduce potential bias during data collection and evaluation of clinical endpoints.Number Of Participants
[0345] The 2 studies will include a total of 600 participants (300 in Study A and 300 in Study B).Study Arms and Duration
[0346] The total duration of each study is up to 168 weeks and consists of 4 study periods: a <6-week screening period, a 52-week double-blind treatment period, a 104- week open-label LTE, and a 6-week follow-up period.During double-blind period:
[0347] Group 1: Participants will receive nipocalimab 460 mg SC weekly, in addition to standard of care, from Week 0 through Week 51.
[0348] Group 2: Participants will receive placebo SC weekly, in addition to standard of care, from Week 0 through Week 51.During open-label LTE:
[0349] Participants will receive nipocalimab 460 mg SC weekly, in addition to standard of care, from Week 52 through Week 155.Efficacy Evaluations-134- 103693.007823\4927-3677-6616.1
[0350] ClinROs and PROs of efficacy include the following:Table 8Safety Evaluations
[0351] Key safety assessments include AEs, SAEs, AESI, laboratory parameters, ECGs, pregnancy testing, physical examination, vital signs, injection-site reactions, hypersensitivity reactions, and TB evaluations.Study Population
[0352] Screening for eligible participants will be performed within 42 days (6 weeks) before randomization. The sponsor and / or designee will confirm the eligibility of each participant prior to randomization.
[0353] The inclusion and exclusion criteria for enrolling participants in this study are described below. If there is a question about these criteria, the investigator must consult with the appropriate sponsor representative and resolve any issues before enrolling a participant in the study.Inclusion Criteria
[0354] Each potential participant must satisfy all of the following criteria to be enrolled in the study:Table 9. Inclusion Criteria-135- 103693.007823\4927-3677-6616.1-136- 103693.007823\4927-3677-6616.1Exclusion Criteria
[0355] Any potential participant who meets any of the following criteria will be excluded from participating in the study:Table 10. Exclusion Criteria-137- 103693.007823\4927-3677-6616.1-138- 103693.007823\4927-3677-6616.1-139- 103693.007823\4927-3677-6616.1-140- 103693.007823\4927-3677-6616.1-141- 103693.007823\4927-3677-6616.1
[0356] Investigators must ensure that all study enrollment criteria have been met at screening. If a participant's clinical status changes (including any available laboratory results or receipt of additional medical records) after screening but before the first dose of study intervention is given such that the participant no longer meets all eligibility criteria, then the participant must be excluded from participation in the study.Study Intervention and Concomitant Therapy
[0357] Nipocalimab will be manufactured and provided under the responsibility of the sponsor.
[0358] Placebo will be manufactured and provided under the responsibility of the sponsor. The placebo is composed of 20% (w / w) PEG4K, 10 mM Histidine, pH6.0.Table 11. Description of Interventions-142- 103693.007823\4927-3677-6616.1Concomitant Medications Prior to Randomization
[0359] Table 12 outlines permitted concomitant medications for SLE and stabilization requirements prior to randomization. During screening, the investigator should assess if the participant is demonstrating an inadequate response to the protocol-permitted standard of care treatment, or an acute flare that might warrant escalation of treatment.Table 12. Permitted SLE Concomitant Medications at Randomization
[0360] Table 13 outlines permitted concomitant medications during the study, including LTE. Any initiation or dose changes must be documented in concomitant medications for anti--143- 103693.007823\4927-3677-6616.1malarials, oral GCs, and nonbiologic immunomodulators. Notable changes in other permitted medications should be recorded.Table 13. Permitted Concomitant Therapies-144- 103693.007823\4927-3677-6616.1Prohibited Medications
[0361] The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in which prohibited therapies are administered. Use of additional immunosuppressants or immunomodulators will trigger TF rules.
[0362] Use of additional immunosuppressants or immunomodulators, other than those explicitly permitted, are prohibited including, but not limited to, the following:Other Fc-conjugated therapeutic agents, including factor or enzyme replacement therapy, not specifically included in other criteria.B-cell-depleting therapy or B-cell- or lymphocyte-targeted therapies used to treat autoimmune disease (including but not limited to obinutuzumab, belimumab, rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], B-145- 103693.007823\4927-3677-6616.1lymphocyte stimulator-receptor fusion protein [e.g., atacicept], anti-B-cell activating factor [e.g., tabalumab]).Anti-interferon medication (e.g., anifrolumab).Anti-TNF medication (e.g., infliximab, golimumab, certolizumab pegol, etanercept, CT- P13, and adalimumab).T-cell inhibitors (e.g., alefacept, abatacept).Complement inhibitors (e.g., eculizumab).Inhibitors of interleukins, including anti-IL-1 (e.g., canakinumab, anakinra), anti-IL-6 (e.g., tocilizumab), and anti-IL-17 (e.g., brodalumab, secukinumab, and ixekizumab). IL-2 inhibitors or exogenous IL-2 therapy.Other biologies.Prednisone (or equivalent) for >40 mg / day for more than 10 consecutive days.Epidural, IV, IM, intra-articular or intrabursal GCs, except for protocol-permitted increase of GC dose. Cyclosporine A or its derivatives (oral or topical ointment / cream preparations) except for ophthalmic use.Use of cytotoxic drugs is prohibited, including but not limited to, cyclophosphamide, chlorambucil, nitrogen mustard, or other alkylating agents.Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus, voclosporin, or sirolimus).Other systemic immunomodulatory agents (e.g., mizoribine, leflunomide.JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib).Toll-like receptor inhibitors.Thalidomide or lenalidomide.Dapsone.ACTH by injection.Plasmapheresis, immunoadsorption therapy, or IVIG.Topical preparations of any of the therapies noted here, unless specifically allowed, are prohibited.Live vaccines.SLICC / ACR Damage Index-146- 103693.007823\4927-3677-6616.1
[0363] The SLICC / ACR damage index is a validated, reliable instrument to measure organ damage after the diagnosis of lupus. The SLICC / ACR damage index evaluates 12 systems which are assessed by 41 items for damage, which is defined as nonreversible change that is not related to active inflammation and that has occurred since the onset of lupus and present for >6 months. Items are scored based upon evidence of damage with a maximum possible score of 47. Scores can only increase with time. If evidence of damage is noted for an item, it is given a score of 1.Joint Assessments
[0364] On physical examination, the joint assessor will assess for tenderness, swelling, and effusion. Each of 64 joints will be evaluated for tenderness and 62 joints will be evaluated for swelling and effusion (hips are excluded). To be considered an active joint, an affected joint must demonstrate tenderness and at least 1 additional sign of inflammation (e.g., observed swelling such as edema or effusion) on physical examination as determined by the joint assessor.CLASI
[0365] Cutaneous Lupus Erythematosus Disease Area and Severity Index is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus patients with or without systemic involvement. CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage caused by the disease (CLASI Activity and CLASI Damage scores). Activity is scored by the investigator based on erythema, scale / hyperkeratosis, mucous membrane involvement, acute hair loss, and nonscarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The scores are calculated by simple addition based on the extent of the symptoms.
[0366] CLASI scores range from 0 to 70 for activity and 0 to 56 for damage, with higher scores indicating worse disease activity.PGA of Disease Activity
[0367] The PGA, independent of participants’ assessment, is recorded on a VAS with responses for disease activity ranging from 0 to 3 and verbal anchors “None” (0), “Mild” (1),-147- 103693.007823\4927-3677-6616.1“Moderate” (2) and “Severe” (3). The baseline measurement for the PGA is defined as the closest measurement taken prior to initiation of study intervention administration at Week 0.
[0368] No worsening in PGA is defined as no significant deterioration (<10% increase from baseline) using a VAS.SLEDAI-2K
[0369] SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in patients with SLE at the time of the visit; the index is weighted according to the feature. Features are scored by the assessor if present at the time of the visit or within the last 30 days, with more severe features having higher scores, then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105. The baseline measurement for the SLEDAI-2Kis defined as the closest study measurement taken prior to initiation of study intervention administration at Week 0.
[0370] SLEDAI improvement is defined as a reduction from baseline in total SLEDAI-2K score. No worsening of total SLEDAI-2K from baseline is defined as a change <0 in SLEDAI-2Kscore and meaningful improvement is best defined as a reduction in SLEDAI-2K of 4 or more.BILAG-2004
[0371] The BILAG-2004 index scores participants based on the need for alterations or intensification of therapy. The assessing physician will evaluate 97 items divided into 9 organ systems. The physician considers presence of each item in the past 4 weeks and answers 0=not present, 1 improving, 2=same, 3=worse, or 4=new. Each organ / system is classified programmatically or by data reviewers as BILAG-2004 A, B, C, D, or E based upon criteria specific to the organ system (Isenberg 2005). The BILAG-2004 index was designed to give practicing physicians a tool to help in decision-making based on amount of activity in each organ / system. The baseline measurement for the BILAG-2004 is defined as the closest measurement taken during the study and prior to administration of study intervention at Week 0.-148- 103693.007823\4927-3677-6616.1BILAG-2004 improvement is defined as (1) all BILAG-2004 A scores at baseline improved to either B, C, or D and (2) all BILAG-2004 B scores at baseline improved to C or D and (3) no worsening in disease activity defined as no new BILAG-2004 A scores and <1 new BILAG-2004 B score.Major clinical response in BILAG-2004 is defined as BILAG-2004 C score or better in all organ systems.No worsening in BILAG-2004 disease activity is defined as no new BILAG-2004 A scores and <1 new BILAG-2004 B score.
[0372] BILAG flare: Defined as at least 1 new BILAG-2004 A or at least 2 new BILAG-2004 B meeting at least 1 of the following criteria:Not present at baselineThe occurrence of a new / worse manifestation in a different component of an organ system that is already presentAt least 1 A or 2 B scores in an organ system which improves to B / C / D for >2 sequential study visits followed by new / worse disease activity
[0373] Adjudicated flare: All flares will be adjudicated regardless of whether it is the participant’s first flare or an additional flare occurring in either the same or a different organ system.Efficacy Composite ScoresSRI-4 Composite Response
[0374] The SRI-4 composite response is defined as a composite endpoint requiring >4-point reduction in SLEDAI-2Kscore, no worsening (<10% increase) from baseline in the PGA of disease activity score, and no new BILAG-2004 A and no more than 1 new BILAG-2004 B scores. SRI-5, SRI-6, SRI-7, and SRI-8 composite responses are defined similarly, except the SLEDAI-2K improvement from baseline is to be at least 5, 6, 7, or 8 points, respectively. The SRI-4 composite response is the proportion of participants who achieve a SRI-4 composite response and do not meet the TF criteria.-149- 103693.007823\4927-3677-6616.1Lupus Low Disease Activity State
[0375] The LLDAS is defined as meeting the following criteria:SLEDAI-2K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis), and no reported fever, hemolytic anemia, or gastrointestinal activityNo new disease activity compared with the previous assessment PGA <1 on a VAS scale of 0 to 3A current prednisone (or equivalent) dose of ≤7.5 mg dailyWell-tolerated standard maintenance doses of permitted immunosuppressive drugsBILAG Composite Lupus Assessment
[0376] A participant is a BICLA responder if the following criteria are met:Reduction of all baseline BILAG-2004 A to B / C / D and baseline BILAG-2004 B to C / D and no BILAG-2004 worsening in other organ systems, as defined by≥1 new BILAG- 2004 A or >2 new BILAG-2004 B.No worsening from baseline in SLEDAI-2K as defined as an increase from baseline of >0 points in SLEDAI-2K. Increase from baseline corresponds to the change from baseline. No worsening from baseline in participants’ lupus disease activity defined by an increase >0.30 points on a 3-point PGA VAS.No discontinuation of study intervention (according to eCRF form “Discontinuation of Study Intervention”) or use of rescue medication beyond the protocol-allowed threshold before assessment.
[0377] If any of the conditions cannot be evaluated at Week 52 (e.g., due to missing values) the participant is defined as a BICLA nonresponder.DORIS
[0378] The on-treatment DORIS defines clinical SLE remission as determined by clinical SLEDAI-2K=0, BILAG-2004 D or E for all systems, or clinical European consensus lupus outcome measure (ECLAM) 0, including routine laboratory assessments and PGA. A distinction is made between remission off and on therapy. Remission can be categorized as Clinical-150- 103693.007823\4927-3677-6616.1Remission or Complete Remission (requiring negative serologies) and separately as Clinical Remission on treatment and Complete Remission on treatment. A modified definition of DORIS Clinical Remission on treatment is used in this study and is defined as meeting all the following conditions:SLEDAI-2K score = 0 (excluding anti-dsDNA, C3, and C4 components)PGA score <0.5 cm on 10 cm, 0 to 3 VAS scalePrednisone (or equivalent) dose <5 mg / dayAntimalarial, immunosuppressant, or study intervention use is permittedPatient-reported Outcomes
[0379] The PRO instruments will be provided in the most prevalent local language(s) in accordance with site feasibility recommendations and will be completed by participants using the sponsor-provided site device.
[0380] The PRO instrument will be available for regulators and for IRB / IEC submissions. PRO and AE data will not be reconciled with one another.FACIT-Fatigue Scale
[0381] The participant-completed FACIT-Fatigue (Version 4) is a 13-item questionnaire that includes items on tiredness, weakness, and difficulty conducting usual activities due to fatigue. The recall period for all the items is the past 7 days. Responses to all items are rated on a 5-point Likert response scale ranging from 0 “not at all” to 4 “very much.” The FACIT-Fatigue can generally be completed in 5 minutes. A study using a combination of approaches, including both anchor-based estimates derived from statistically significant cross-sectional and longitudinal differences and distribution-based estimates concluded that the minimal clinically important difference in patients with SLE for the FACIT-Fatigue is between 3 and 4 points. This range is similar to that which has been reported in other disease areas.PGIS-Fatigue-151- 103693.007823\4927-3677-6616.1
[0382] The PGIS-Fatigue is a single-item questionnaire designed to assess a patient’s impression of the severity of lupus-related fatigue. The questionnaire based on the clinical global impression scale. The PGIS-Fatigue asks the patient to select 1 response, ranging from “No fatigue” to “Very severe fatigue,” that best describes the overall severity of their lupus-related fatigue over the past 7 days.PGIC-Fatigue
[0383] The PGIC-Fatigue is a single- item questionnaire designed to assess a patient’s perception of change in their lupus-related fatigue following the study intervention. The questionnaire is based on the clinical global impression scale. The PGIC-Fatigue assesses the extent to which the participant perceives their lupus-related fatigue has improved or worsened since their first study visit using a scale ranging from “very much improved” to “very much worse.” The PGIC-Fatigue asks the participant to select 1 response that best describes the overall change in their lupus-related fatigue compared with their first study visit.Lupus Symptoms
[0384] Participants will be asked to report the worst severity of their joint pain, joint stiffness, skin rash, and swelling in legs and / or feet over the past 7 days on a 0 to 10 NRS, with 1 anchor indicating “No [specific symptom]” and the other anchor, “Severe [specific symptom]”. The items are scored individually, with higher scores reflecting greater symptom severity.PGIS-Joint Pain
[0385] The PGIS-Joint Pain is a single- item questionnaire designed to assess a patient’s impression of the severity of lupus-related joint pain. The questionnaire is based on the clinical global impression scale. The PGIS-Joint Pain asks the patient to select 1 response, ranging from “No pain in your joints” to “Very severe pain in your joints,” that best describes the overall severity of their lupus-related joint pain over the past 7 days.PGIC-Joint Pain-152- 103693.007823\4927-3677-6616.1
[0386] The PGIC-Joint Pain is a single-item questionnaire designed to assess a patient’s perception of change in their lupus-related joint pain following the study intervention. The questionnaire is based on the clinical global impression scale. The PGIC-Joint Pain assesses the extent to which the participant perceives their lupus-related joint pain has improved or worsened since their first stud visit using a scale ranging from “very much improved” to “very much worse.” The PGIC-Joint Pain asks the participant to select 1 response that best describes the overall change in their lupus-related joint pain compared with their first study visit.SF-36
[0387] The participant-completed Short Form-36 (Version 2 Standard) is a 36-item questionnaire measuring HRQOL. The recall period for all items is the past 4 weeks. The SF-36 version 2 Standard includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a PCS and an MCS. Responses to all items are rated on a 3-, 5- or 6-point Likert scale.PGIS-SLE
[0388] The PGIS-SLE is a single- item questionnaire designed to assess a patient’s impression of the severity of their lupus. The questionnaire is based on the clinical global impression scale. The PGIS-SLE asks to select 1 response, ranging from “No symptoms” to “Very severe,” that best describes the overall severity of their lupus at this time.PGIC-SLE
[0389] The PGIC-SLE is a single-item questionnaire designed to assess a patient’s perception of change in their lupus following the study intervention. The questionnaire is based on the clinical global impression scale. The PGIC-SLE assesses the extent to which the participant perceives their lupus has improved or worsened since their first study visit using a scale ranging from “very much improved” to “very much worse.” The PGIC-SLE asks to select 1 response that best describes the overall change in their lupus compared with their first study visit.-153- 103693.007823\4927-3677-6616.1Lupus QoL
[0390] The participant-completed Lupus Quality of Life measure is a 34-item questionnaire measuring HRQOL in participants with SLE. The recall period for all items is the past 4 weeks. The Lupus QoL includes 8 domains (physical health, emotional health, body image, pain, planning, fatigue, intimate relationships, and burden to others). Responses to all items are rated on a 5-point Likert response scale ranging from “All the time,” “Most of the time,” “A good bit of the time,” “Occasionally,” to “Never.”EQ-5D-5LThe EQ-5D-5L is a self-administered, generic health status measure, consisting of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), each with 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems), providing a descriptive health state profile which can be linked to a country-specific value set to provide a single summary index value (sometimes referred to as utility score). The EQ-VAS asks respondents to rate their own health on a scale from 0 (“worst imaginable health”) to 100 (“best imaginable health”), recording the respondent’s overall health- related quality of life. The EQ-5D-5L has a recall period of ‘today’ and can generally be completed in 2 to 3 minutes.Justification for Dose
[0391] The nipocalimab 460 mg SC weekly dose regimen selected for this Phase 3 study was based on PK, PD, clinical efficacy, and safety data from the Phase 2 Study (Example 1) in participants with SLE as well as PK, PD, and safety data from multiple Phase 1 studies. Results from PK-PD and exposure-response modeling were used to inform the SC dose selection.
[0392] Two nipocalimab IV dose regimens (5 mg / kg IV q2w and 15 mg / kg IV q2w) were evaluated in the SLE Phase 2 Study (Example 1). The primary endpoint, proportion of participants who achieved SRI-4 composite response at Week 24, was met in the nipocalimab 15 mg / kg IV q2w treatment group without a plateau in efficacy by Week 52 and was safe and well-154- 103693.007823\4927-3677-6616.1tolerated. Based on the Phase 2 results, it was decided to evaluate a SC dose regimen in the SLE Phase 3 studies that would provide IgG lowering similar to the nipocalimab 15 mg / kg IV q2w dose regimen.
[0393] Two nipocalimab IV dose regimens (5 mg / kg IV q2w and 15 mg / kg IV q2w) were evaluated in the SLE Phase 2 study (Example 1). The primary endpoint (proportion of participants achieving SRI-4 composite response at Week 24) was met in the nipocalimab 15 mg / kg IV q2w treatment group at Week 24 without a plateau in efficacy by Week 52 and was safe and well tolerated. Based on the Phase 2 results, it was decided to evaluate a SC dose regimen in the SLE Phase 3 studies that will provide similar IgG lowering as the 15 mg / kg IV q2w dose regimen.
[0394] PK / PD modeling and simulation was performed using pooled data from Phase 1 healthy participants to characterize the PK (and bioavailability) and PD (effects on IgG) to inform the IV / SC switch. Results showed that, despite lower area under the curve (AUC) and higher interindividual variability associated with PK metrics following administration of the SC doses compared to the IV doses, this did not translate to higher variability in IgG reduction. Model-based simulations showed that transitioning from a less frequent dosing interval (i.e., IV dosing every other week) to a more frequent dosing interval (i.e., SC dosing every week) will reduce the peak to trough fluctuation in IgG, with similar median average % IgG lowering.
[0395] Then, the PK-RO and IgG models developed in healthy participants were evaluated and updated using data from Phase 2 SLE patients (Example 1). In general, serum nipocalimab concentrations showed greater variability and baseline IgG was significantly higher in SLE patients compared to healthy participants, but the updated models adequately characterized the PK-PD relationship in SLE patients. Simulation analysis using the PK-IgG model updated using the Phase 2 data predicted that the steady state IgG % reduction from baseline was comparable between the 460 mg SC qw and 15 mg / kg IV q2w doses, with median (90% PI) average IgG lowering of 72% (52%-86%) and 64% (44%-80%), respectively (Figure 22 and Table 14).Table 14: Median (90% PI) of Predicted Changes in IgG With Administration of Nipocalimab at 15 mg / kg IV q2w and 460 mg SC qw-155- 103693.007823\4927-3677-6616.1
[0396] As mentioned above, based on the IV and SC IgG simulations, there is a minimal difference expected for average % IgG lowering for the 2 routes of administration with less fluctuation expected for the SC qw regimen, thus non-inferior efficacy is expected from the nipocalimab 460 mg SC qw dose regimen compared to the previously studied 15 mg / kg IV q2w dose regimen.
[0397] To confirm that the 460 mg SC qw could achieve similar average IgG reduction as the IV dose regimen, a Phase 1 study was conducted to evaluate the safety, tolerability, PK and PD of the PFS-AI in healthy participants. Results showed that the 460 mg qw dose administered via PFS-AI achieved 72% (IQR: 71%-73%) median reduction from baseline in pre-dose IgG at Week 4 (steady state) in healthy participants.
[0398] Exposure-response analyses were conducted to link the average % IgG reduction after the last dose and the secondary endpoint of SRI-4 composite response at Week 52 from the SLE Phase 2 study (Example 1, Figure 23). The results demonstrate a sigmoidal exposureresponse relationship between this endpoint (primary endpoint in this Phase 3 study) and the IgG biomarker, adding credence to IgG as a biomarker for efficacy in SLE which provides support to the choice of the 460 mg SC qw dose.
[0399] Based on the identified exposure-response relationship, the SRI-4 composite response at Week 52 was predicted based on PK-PD model-predicted average IgG reduction. The 15 mg / kg IV q2w and 460 mg SC qw regimens resulted in SRI-4 composite response rates-156- 103693.007823\4927-3677-6616.1at Week 52 of 59% (95% CI: 48%-70%) and 59% (95% CI: 48%-71%), respectively. Thus, the 460 mg SC weekly dose regimen is expected to show non-inferior efficacy for the SRI-4 response compared to the 15 mg / kg IV q2w regimen, further supporting the switch to the 460 mg SC weekly dose regimen in this Phase 3 study.
[0400] A longitudinal PK-PD model was developed to describe total cholesterol, LDL, and albumin data from multiple Phase 1 studies and validated with data from the SLE Phase 2 study (Example 1). Model-based simulations predicted similar profiles for lipids and albumin with the nipocalimab 15 mg / kg IV q2w and the 460 mg SC qw regimens (Figure 24). Thus, no clinically meaningful impact of SC administration of nipocalimab on cholesterol, LDL, or albumin are expected.
[0401] In summary, the totality of the data from the SLE Phase 2 study (Example 1) as well as the collective modeling analyses based on both Phase 1 data in healthy participants and Phase 2 (Example 1) data in participants with SLE support the nipocalimab regimen of 460 mg SC weekly for the Phase 3 studies administered using a PFS-AI. Model-based simulations predict similar average IgG reduction and efficacy profiles will be achieved for 460 mg SC weekly and 15 mg / kg IV q2w dose regimens..
[0402] Two nipocalimab IV dose regimens (5 mg / kg IV q2w and 15 mg / kg IV q2w) were evaluated in the SLE Phase 2 Study (Example 1). The primary endpoint, proportion of participants who achieved SRI-4 composite response at Week 24, was met in the nipocalimab 15 mg / kg IV q2w treatment group without a plateau in efficacy by Week 52 and was safe and well tolerated. Based on the Phase 2 results, it was decided to evaluate a SC dose regimen in the SLE Phase 3 studies that would provide IgG lowering similar to the nipocalimab 15 mg / kg IV q2w dose regimen.
[0403] PK-PD modeling and simulation was performed using pooled data from Phase 1 healthy participants to characterize the PK (and bioavailability) and PD (effects on IgG) to inform the IV / SC switch. The model was then evaluated and updated using participant data from the Phase 2 Study (Example 1). Model simulations showed that steady state percent IgG reduction from baseline was comparable between 460 mg SC weekly and 15 mg / kg IV q2w doses, with median (90% prediction interval) average IgG lowering of 72% (52% to 86%) and -157- 103693.007823\4927-3677-6616.164% (44% to 80%), respectively, and that weekly administration reduced the peak to trough fluctuation in IgG compared with every other week administration with similar median average percent IgG lowering. In addition, exposure-response analysis was performed to link the average percent IgG reduction after the last dose and the secondary endpoint of SRI-4 composite response at Week 52 from the SLE Phase 2 study (Example 1). Model simulations showed that SRI-4 composite response at Week 52 was comparable between 460 mg SC weekly and 15 mg / kg IV q2w doses, with median (95% CI) response rates of59% (48% to 71%) and 59% (48% to 70%), respectively.
[0404] A longitudinal PK-PD model was also developed to describe total cholesterol, LDL, and albumin data from multiple Phase 1 studies and validated with data from the SLE Phase 2 Study (Example 1). Model-based simulations predicted similar profiles for lipids and albumin with 460 mg SC weekly and 15 mg / kg IV q2w regimens. Thus, no clinically meaningful impact of SC administration of nipocalimab on cholesterol, LDL, or albumin are expected.
[0405] In summary, the totality of the data from the SLE Phase 2 study (Example 1) as well as the collective modeling analyses based on both Phase 1 data in healthy participants and Phase 2 (Example 1) data in participants with SLE support the nipocalimab regimen of 460 mg SC weekly for the Phase 3 studies administered using a PFS-AI. Model-based simulations predict similar average IgG reduction and efficacy profiles will be achieved for 460 mg SC weekly and 15 mg / kg IV q2w dose regimens.-158- 103693.007823\4927-3677-6616.1
Claims
What is claimed is:
1. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn agent to the subject.
2. The method of claim 1, wherein the anti-FcRn agent is administered every week, every two weeks, every three weeks, or monthly.
3. The method of claim 1 or 2, wherein the anti-FcRn agent is nipocalimab, rozanolixizumab, batoclimab, IMVT-1402, efgartigimod, SYNT001, SYNT002, ABY-039, or DX-2507.
4. The method of any one of the preceding claims, wherein the anti-FcRn agent is administered at a dose from about 5 mg / kg to about 45 mg / kg, about 5 mg / kg to about 15 mg / kg, about 15 mg / kg to about 45 mg / kg, or about 30 mg / kg to about 45 mg / kg based on the weight of the subject.
5. The method of any one of the preceding claims, wherein the anti-FcRn agent is administered at a dose of about 5 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 45 mg / kg based on the weight of the subject.
6. The method of any one of the preceding claims, wherein the anti-FcRn agent is administered intravenously or subcutaneously.
7. The method of any one of the preceding claims, wherein the anti-FcRn agent is an anti-FcRn antibody comprising:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8.-159- 103693.007823\4927-3677-6616.
18. The method of claim 7, wherein (a) the light chain of the anti-FcRn antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9; and (b) the heavy chain of the anti-FcRn antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10.
9. The method of claim 7 or claim 8, wherein (a) the light chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 1; and (b) the heavy chain of the anti-FcRn antibody comprises the amino acid sequence of SEQ ID NO: 2.
10. The method of any one of the preceding claims, wherein the anti-FcRn agent is nipocalimab.
11. The method of any one of the preceding claims, wherein nipocalimab is administered every two weeks intravenously at 10-30 mg / kg based on the weight of the subject.
12. The method of any one of the preceding claims, wherein nipocalimab is administered every two weeks intravenously at 15 mg / kg based on the weight of the subject.
13. The method of any one of claims 1-9, wherein nipocalimab is administered every week subcutaneously at 200-1000 mg.
14. The method of any one of claims 1-9 or 13, wherein nipocalimab is administered every week subcutaneously at 400-600 mg.
15. The method of any one of claims 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 460 mg or 518 mg.
16. The method of any one of claims 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 460 mg.
17. The method of any one of claims 1-9, 13, or 14, wherein nipocalimab is administered every week subcutaneously at 518 mg.
18. The method of any one of claims 1-9 or 13-17, wherein nipocalimab is administered via an auto injector.-160- 103693.007823\4927-3677-6616.
119. The method of any one of the preceding claims, wherein the subject has a SLEDAI-2K score over 4, 5, or 6 before initiation of said administering.
20. The method of any one of the preceding claims, wherein the subject has a BILAG-2004 index score equal to or over 1 BILAG A score before initiation of said administering.
21. The method of any one of the preceding claims, wherein the subject has a BILAG-2004 index score equal to or over 2 BILAG B score before initiation of said administering.
22. The method of any one of the preceding claims, wherein the subject has a CLASI activity score equal to or over 6 before initiation of said administering.
23. The method of any one of the preceding claims, wherein the subject has at least 4 active joints before initiation of said administering.
24. The method of any one of the preceding claims, wherein the subject is seropositive for antinuclear antibodies (ANA) before initiation of said administering.
25. The method of claims 22 or 23, wherein the subject is seropositive for antinuclear antibodies (ANA) before initiation of said administering.
26. The method of any one of the preceding claims, wherein the subject is seropositive for anti-dsDNA antibodies before initiation of said administering.
27. The method of any one of the preceding claims, wherein the subject is seropositive for antiSmith antibodies before initiation of said administering.
28. The method of any one of the preceding claims, wherein the subject is seropositive for antinuclear antibodies (ANA) and at least one of: 1) is seropositive for anti-RO52 and / or anti-RO60 antibodies; 2) is seropositive for anti-La antibodies; 3) is seropositive for anti-RNP antibodies; and 4) has historical evidence of seropositive anti-dsDNA antibodies, before initiation of said administering.
29. The method of any one of the preceding claims, wherein the subject meets at least one of the following criteria before initiation of said administering:-161- 103693.007823\4927-3677-6616.1a) seropositive for anti-dsDNA antibodies;b) seropositive for anti-Smith antibodies; orc) seropositive for antinuclear antibodies (ANA);and at least one of:i) seropositive for anti-RO52 and / or anti-RO60 antibodies;ii) seropositive for anti-RNP antibodies; oriii) subject has historical evidence of seropositivity for anti-dsDNA antibodies.
30. The method of any one of the preceding claims, wherein the subject is seropositive for antinuclear antibodies (ANA) and has low C3 and / or C4 levels, before initiation of said administering.
31. The method of any one of the preceding claims, wherein the subject is seropositive for anti-RO52 antibodies and anti-RO60 antibodies, and is seronegative for anti-La antibodies, before initiation of said administering.
32. The method of any one of the preceding claims, wherein the subject meets at least one of the following criteria before initiation of said administering:a) seropositive for anti-dsDNA antibodies, seropositive for anti -RO 52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies;b) seropositive for anti-Smith antibodies, seropositive for anti-RO52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies; orc) seropositive for ANA, seropositive for anti-RO52 antibodies, seropositive for anti-RO60 antibodies, and seronegative for anti-La antibodies.
33. The method of any one of the preceding claims, wherein the subject has a positive type I interferon (IFN-I) gene signature score, before initiation of said administering.-162- 103693.007823\4927-3677-6616.
134. The method of claim 33, wherein the subject has a positive IFN-I gene signature score when a combined expression value of the genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L in a biological sample from the subject is equal to or higher than a threshold value.
35. The method of claim 33, wherein the biological sample is a blood sample or a tissue sample.
36. The method of claim 34 or claim 35, wherein the gene expression is assayed using quantitative Polymerase Chain Reaction (qPCR), RNA sequencing, or microarray.
37. The method of any one of claims 34-36, wherein gene expression is measured at the mRNA level.
38. The method of any one of claims 34-37, wherein the combined expression value is a sum of normalized threshold cycle (CT) values (SUMΔCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L.
39. The method of claim 38, wherein the threshold value is SUMΔCT of genes DHX58, EIF2AK2,HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.
40. The method of claim 38 or 39, wherein the threshold value is SUMΔCT of 57.474.
41. The method of any one of claims 34-37, wherein the combined expression value is a sum of log2 fold changes of normalized differential expression between the biological sample and a biological sample obtained from one or more healthy subjects of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L ((SUMlog2(2-ddCT)).
42. The method of claim 41, wherein the threshold value is SUMlog2(2^-ddCT) of genes DHX58, EIF2AK2, HERC5, IFI44, IFI44L, IFI6, IRF7, PARP9, PLSCR1 and SAMD9L of one or more healthy subjects.
43. The method of claim 41 or claim 42, wherein the threshold value is SUMlog2(2^-ddCT) of 8.725.-163- 103693.007823\4927-3677-6616.
144. The method of any one of claims 34-37, wherein the combined expression value is a POISE Score of Formula I:POISE Score = 70- 143.7251664- SUMlog2(2A’ddCT)| (Formula I)45. The method of claim 42, wherein the threshold value is the POISE Score of between 30 and 40.
46. The method of claim 42 or claim 43, wherein the threshold value is the POISE score of 35.
47. The method of claim 33, wherein the subject has a positive IFN-I gene signature score based on immune profile test of a blood sample from the subject, before initiation of said administering.
48. The method of claim 47, wherein the subject has a positive IFN-I gene signature score based on immune profile test when a combined expression value of the genes HERC5, IF127, IFIT1, and RSAD2 is equal to or higher than a threshold value.
49. The method of claim 38, wherein the threshold value is based on the expression value of the genes HERC5, IFI27, IFIT1, and RSAD2 of one or more healthy subjects.
50. The method of any one of the preceding claims, wherein the subject receives glucocorticoid at a first dose before initiation of said administering, and the method provides a clinical benefit as indicated by the subject receives glucocorticoid at a second dose that is lower than the first dose within 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52 weeks or more weeks of initiation of said administering.
51. The method of claim 50, wherein the first dose is 10 mg per day or higher.
52. The method of claim 50, wherein the second dose is 5 mg per day or lower.
53. The method of claim 50, wherein the first dose is 20 mg per day or lower.
54. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by a decrease in SLE Disease Activity Index 2K (SLEDAI-2K) in the-164- 103693.007823\4927-3677-6616.1subject by more than 4, 5, 6, 7, 8 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
55. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by the subject achieving SLEDAI-2K Responder Index (SRI)-4 within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
56. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by a decrease in CLASI-activity score in the subject by more than 40%, 50%, 60%, 70%, 80% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
57. The method of claim 56, wherein the subject has a CLASI-activity score of >=6, 8, 10, 12 at baseline.
58. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by a reduction in active joint counts in the subject by more than 50%, 60%, 70% from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
59. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by the subject achieving Lupus Low Disease Activity State (LLDAS) within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
60. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by an improvement in Bodily Pain Score SF-36 score in the subject by more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
61. The method of any one of the preceding claims, wherein the method provides a clinical benefit in the subject as measured by an improvement of 1-3 points in Lupus Symptoms from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
62. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by an increase in FACIT Fatigue score in the subject by more than 3, 4, 5, 6-165- 103693.007823\4927-3677-6616.1or points from baseline within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
63. The method of any one of the preceding claims, wherein the method provides a clinical benefit as measured by the subject achieving no moderate or severe British Isles Lupus Activity Group (BILAG) flare within 12, 24, 30, 36, 42, 48 or 52 weeks of initiation of said administering.
64. The method of any one of the preceding claims, wherein the subject has a reduction in autoantibodies in the blood.
65. The method of any one of the preceding claims, wherein the method does not significantly decrease level of albumin in the subject compared with baseline.
66. The method of any one of the preceding claims, wherein the method does not significantly increase the level of serum total cholesterol in the subject compared with baseline.
67. A method of treating Systemic lupus erythematosus in a subject in need thereof, the method comprising administering an anti-FcRn antibody to the subject, wherein the anti-FcRn antibody comprises:(a) a light chain, which comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 5; and(b) a heavy chain, which comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 8;and wherein the anti-FcRn antibody is administered every week subcutaneously at 460 mg or 518 mg.
68. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 460 mg.-166- 103693.007823\4927-3677-6616.
169. A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering nipocalimab to the subject, wherein the nipocalimab is administered every week subcutaneously at 518 mg.
70. A pharmaceutical product, comprising:a therapeutic agent, comprising from about 400 mg to about 600 mg of nipocalimab; and a subcutaneous injection device, comprising:a container configured to contain the therapeutic agent;a discharge nozzle sized to deliver the therapeutic agent to a subject subcutaneously; anda driver configured to drive the therapeutic agent from the container and out of the discharge nozzle.
71. The pharmaceutical product of claim 70, wherein the therapeutic agent has a volume from about 1.4 mL to 2.5 mL.
72. The pharmaceutical product of claim 70, wherein the therapeutic agent has a volume of about 2.09mL ± 0.25mL.
73. The pharmaceutical product of any one of claims 70-72, wherein the subcutaneous injection device is an autoinjector.
74. The pharmaceutical product of any one of claims 70-73, wherein the driver has a drive force that drives the therapeutic agent out of the discharge nozzle and into air at a rate from 0.09mL / second to 0.3mL / second.
75. The pharmaceutical product of any one of claims 70-74, wherein the subcutaneous injection device comprises a skin-contacting surface that contacts skin of the subject during an injection, and the discharge nozzle is a needle that (i) extends beyond the skin-contacting by about 6.5mm + 1mm when the drug is delivered to the subject, and / or (ii) has a needle gage from 23G to 27G, or both (i) and (ii).
76. The pharmaceutical product of any one of claims 70-75, wherein the pharmaceutical product is disposed in the container.-167- 103693.007823\4927-3677-6616.
177. The pharmaceutical product of any one of claims 70-76, wherein the therapeutic agent comprises 200 mg / mL to 250 mg / mL nipocalimab.
78. The pharmaceutical product of any one of claims 70-76, wherein the therapeutic agent comprises from about 400 mg to about 500 mg of nipocalimab.
79. The pharmaceutical product of any one of claims 70-78, wherein the therapeutic agent comprises about 460 mg of nipocalimab.-168- 103693.007823\4927-3677-6616.1
